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DNA damage is hypothesized to be a driver of aging. In support of this, DNA damage and 
genetic mutations, resulting from replication of that damage, both increase in the nuclear genome 
as organisms age. Furthermore, long-lived species are relatively resistant to genotoxic stress. 
Conversely, organisms with DNA repair-deficient or genome instability disorders have 
decreased lifespans and age rapidly, which supports this theory. One main source of endogenous 
DNA damage is reactive oxygen species (ROS) generated by mitochondria. While it is true that 
ROS can damage other macromolecules in the cell, DNA is the only one that is repaired rather 
than replaced, illustrating the dire consequences of DNA damage. If repair is not 100% complete 
over a lifetime, it stands to reason that this unrepaired damage could be a major contributor to 
aging. 
Ercc1-/Δ mice are deficient in multiple DNA repair pathways and therefore suffer more 
DNA damage than normal mice. As a consequence, they age prematurely, modeling a human 
progeroid syndrome. This makes them a useful in vivo system for studying the contribution of 
DNA damage to aging. For this reason, we challenged the mice with a chemotherapeutic 
crosslinking agent to determine if DNA damage promotes aging, with an environmental 
contaminant and a diet of polyunsaturated fatty acids to see if these promote DNA damage and 
aging. We found that a particular class of lesions, DNA interstrand crosslinks, accelerate 
aging-associated changes through a cytostatic, rather than cytotoxic mechanism. We also 
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 v 
exposed the mice to a specialized antioxidant to test the hypothesis that mitochondrial-derived 
reactive oxygen species are the cause of endogenous DNA damage that promotes aging. 
Collectively, these studies identified genes, environmental influences and therapeutics that 
impact lifespan and healthspan. In total, the studies strongly support the hypothesis that DNA 
damage can promote degenerative changes associated with aging. These studies have public 
health significance as they reveal multiple novel strategies to decrease the DNA damage burden, 
therefore presenting potential opportunities to improve quality of life in old age. 
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1.0  INTRODUCTION 
Chapter 1, Sections 1.1-1.5, are adapted from a published review in DNA Repair with copyright 
permission from Elsevier.  
Gregg, S.Q.1,2, Robinson, A.R.1,3, and Niedernhofer, L.J.1.4 (2011). Physiological 
consequences of defects in ERCC1-XPF DNA repair endonuclease. DNA Repair 10 (7): 
781-791. 
 
1University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Hillman Cancer Canter 2.6, 
Pittsburgh, PA 15213, USA. 
2Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, S362 
Biomedical Science Towers, 3500 Terrace Street, Pittsburgh, PA 15261, USA  
3Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, 130 
DeSoto Street, Pittsburgh, PA 15261, USA. 
4Department of Microbiology and Molecular Genetics, University of Pittsburgh School of 
Medicine, 523 Bridgeside Point II, 450 Technology Drive, Pittsburgh, PA 15219, USA. 
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1.1 FUNCTIONS OF ERCC1-XPF NUCLEASE 
The ERCC1–XPF/ERCC4 complex is a structure-specific endonuclease involved in the repair of 
damaged DNA. ERCC1–XPF performs a critical incision step in nucleotide excision repair 
(NER), and is also involved in the repair of DNA interstrand crosslinks (ICLs) and some 
double-strand breaks (DSBs) (Ahmad et al., 2008; Busch et al., 1997; Kuraoka et al., 2000; Petit 
and Sancar, 1999; Sargent et al., 1997a; Schlake et al., 1993; Sekelsky et al., 1995). A fraction 
of ERCC1–XPF is localized at telomeres, where it is implicated in recombination of telomeric 
sequences and loss of telomeric overhangs at deprotected chromosome ends (Munoz et al., 2005; 
Zhu et al., 2003). Deficiency of either ERCC1 or XPF/ERCC4 in humans results in a variety of 
conditions, which include the skin cancer-prone disease xeroderma pigmentosum (XP), a 
progeroid syndrome of accelerated aging, or cerebro-oculo-facio-skeletal syndrome (COFS) 
(Jaspers et al., 2007; Niedernhofer et al., 2006). These diseases are extremely rare in the general 
population and therefore mice with low levels of either ERCC1 or XPF have been generated and 
studied extensively. These murine models clearly illustrate the importance of DNA repair in 
preventing aging-related tissue degeneration (Diderich et al., 2011). The purpose of this chapter 
is to provide an overview on the phenotypes of patients with mutations in ERCC1 or XPF, and 
the mouse models used to study the diseases that result from decreased levels of ERCC1–XPF. 
1.1.1 Nucleotide excision repair 
Ultraviolet light damages DNA, resulting in a myriad of lesions, most predominantly 
cyclobutane pyrimidine dimers (CPDs) and (6-4) photoproducts (de Laat et al., 1999). NER is 
the only mechanism by which these photodimers can be removed from DNA in human cells, and 
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ERCC1–XPF functions as the nuclease that incises the damaged strand 5′ to the adduct 
(Bardwell et al., 1994; Park et al., 1995; Sijbers et al., 1996a; Tapias et al., 2004). This incision 
creates a 3′ end that is used as a primer by the replication machinery to replace the excised 
nucleotides. XPF contains the catalytic activity with its conserved nuclease domain, and ERCC1 
is required for binding to DNA (Enzlin and Scharer, 2002; Fagbemi et al., 2011; Li et al., 1994; 
Tripsianes et al., 2005; Tsodikov et al., 2005; Tsodikov et al., 2007). Defects in the proteins 
required for NER can result in xeroderma pigmentosum (XP), trichothiodystrophy (TTD), and 
Cockayne syndrome (CS), highlighting the importance of DNA repair in preventing UV-induced 
skin cancer and developmental abnormalities. XP is a disease characterized by extreme 
photosensitivity and a 10,000-fold increased risk of cutaneous and ocular neoplasms (Kraemer et 
al., 1994). Cells from all of the XP complementation groups (XP-A to XP-G, and XP-V) are 
hypersensitive to UV radiation (Itoh et al., 2000; Mayne and Lehmann, 1982; Niedernhofer et 
al., 2006; Sijbers et al., 1996a; Weeda et al., 1997b). ERCC1–XPF-deficient cells are distinct 
from other XP patient-derived cells because of their extreme sensitivity to chemicals that induce 
DNA ICLs (Busch et al., 1997; De Silva et al., 2000; Hoy et al., 1985; Niedernhofer et al., 
2004). Another critical piece of evidence indicating that ERCC1–XPF has functions distinct 
from NER is that ERCC1 and XPF knockout mice exhibit a much more severe phenotype than 
XPA null mice, which are completely deficient in NER (Busch et al., 1997; de Vries et al., 1995; 
McWhir et al., 1993; Nakane et al., 1995; Tian et al., 2004). 
1.1.2 Intrastrand crosslink repair 
The mechanism of DNA ICL repair in mammalian cells is not as well defined as NER. In 
replicating cells, crosslinking agents lead to DSBs created by an endonuclease(s) near the site of 
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stalled replication machinery (Raschle et al., 2008). In the absence of ERCC1–XPF, replication-
dependent crosslink-induced DSBs occur, indicating that ERCC1–XPF cannot be solely 
responsible for creating these DSBs (Niedernhofer et al., 2004). There is clear evidence that 
ERCC1–XPF participates in the same mechanism of ICL repair as the Fanconi anemia proteins. 
In the absence of ERCC1–XPF, FANCD2 is still monoubiquitylated by FANCL, but 
translocation of FANCD2 to chromatin is impaired (Bhagwat et al., 2009). In addition, when 
FANCD2 is depleted, replication-dependent incisions of ICLs are dramatically reduced 
(Knipscheer et al., 2009). 
Recently it was demonstrated that XPF binds SLX4, a related endonuclease, and this 
interaction is critical for ICL repair (Andersen et al., 2009; Fekairi et al., 2009; Munoz et al., 
2009a; Svendsen et al., 2009). Fanconi anemia patients, mice deficient in ERCC1-XPF, and 
Slx4(Btbd12)−/− mice share many spontaneous developmental and degenerative phenotypes, 
supporting roles for all of these proteins in a common pathway and illustrating the dramatic 
consequences of failure to repair endogenous ICLs (Auerbach, 2009; Crossan et al., 2011). 
Recent reports describe the discovery of biallelic mutations in SLX4 in two patients who 
exhibited clinical features of Fanconi anemia (Kim et al., 2011; Stoepker et al., 2011). Based on 
evidence that reintroduction of wild-type SLX4 into the patients’ cells rescued sensitivity to 
crosslinking agents, SLX4 is considered a new complementation group of Fanconi anemia: 
FANCP. 
1.1.3 Double-strand break repair 
Orthologs of ERCC1–XPF in lower eukaryotes such as Arabidopsis thaliana, Drosophila 
melanogaster, and Saccharomyces cerevisiae play a vital role in the repair of DSBs and meiosis 
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(Baker et al., 1978; Fishman-Lobell and Haber, 1992; Hefner et al., 2003; Ivanov and Haber, 
1995). The two primary mechanisms of DSB repair are non-homologous end-joining (NHEJ) 
and homologous recombination (HR). Work in budding yeast has contributed tremendously to 
defining the role of ERCC1–XPF in DSB repair in mammalian cells. Mutation of rad10 or rad1, 
the orthologs of ERCC1 and XPF in S. cerevisiae, suppresses HR between sequence repeats 
(Klein, 1988; Prado and Aguilera, 1995; Schiestl and Prakash, 1990). The function of the Rad10-
Rad1 nuclease in HR is to remove non-homologous 3′ termini of single-stranded overhangs of 
broken ends to facilitate single-strand annealing, an error-prone sub-pathway of HR (Fishman-
Lobell and Haber, 1992; Ivanov and Haber, 1995; Paques and Haber, 1997; Prado and Aguilera, 
1995). Like single-strand annealing, there is an error prone sub-pathway of NHEJ that utilizes 
short stretches of homology to join two broken DNA ends, termed micro-homology mediated 
end-joining. Rad10-Rad1 also participates in this end-joining pathway in yeast (Ma et al., 2003). 
Yeast Mre11 and Rad1 proteins define a Ku-independent mechanism to repair double-strand 
breaks lacking overlapping end sequences (Ma et al., 2003). Mammalian cells deficient in 
ERCC1–XPF are modestly sensitive to ionizing radiation (IR), a source of DSBs (Ahmad et al., 
2008). Like in yeast, HR and end-joining of DSBs is attenuated in ERCC1-XPF-deficient 
mammalian cells (Adair et al., 2000; Al-Minawi et al., 2008; Niedernhofer et al., 2001; Sargent 
et al., 2000; Sargent et al., 1997b). 
The ERCC1–XPF endonuclease is required for efficient single-strand annealing and gene 
conversion in mammalian cells (Ahmad et al., 2008; Al-Minawi et al., 2008). Therefore, it is 
proposed that ERCC1–XPF nuclease facilitates both HR and NHEJ pathways (single-strand 
annealing and microhomology-mediated end-joining), but only if the broken DNA ends contain 
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3′-overhanging unmatched sequences or ends that cannot be used to prime DNA synthesis 
(Ahmad et al., 2008). 
1.1.4 At telomeres 
ERCC1–XPF deficiency is linked with accelerated aging, and telomere shortening is associated 
with aging, so therefore it was important to understand if the nuclease impacts telomere length or 
function (Satoh et al., 1996). Telomeres in humans with mutations in XPF or Ercc1 knockout 
mice are not shorter than controls (Zhu et al., 2003). Furthermore, there is no difference in sister 
chromatid exchange at telomeres in the absence of ERCC1–XPF (Hagelstrom et al., 2010). 
However, ERCC1 co-localizes with TRF2 at telomeres (Zhu et al., 2003). In a TRF2 dominant 
negative background, ERCC1–XPF deficient cells accumulate telomeric double-minutes. This 
led to the conclusion that ERCC1–XPF cleaves the G-rich, 3′-overhang, rendering chromosomes 
vulnerable to end-to-end fusions (Zhu et al., 2003). Hence the absence of ERCC1–XPF 
apparently does not have a deleterious impact on telomere length or function. Consistent with 
that, correction of XP-F cells or overexpression of XPF in normal human cells leads to telomere 
shortening (Wu et al., 2008). Therefore, accelerated aging associated with ERCC1–XPF 
deficiency is presumed to arise from cellular senescence and cell death and not as a consequence 
of telomere-dependent replicative senescence. 
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1.2 XPF-DEFICIENCY IN HUMANS 
Humans with mutations in XPF can be classified into two groups based on the clinical 
manifestations of their disease (see Table 1.1). The majority of XP-F patients present with mild 
symptoms of XP, which include sun sensitivity, freckling of the skin, and basal or squamous cell 
carcinomas typically occurring after the second decade of life. This is in contrast to many XP-A 
and XP-C patients, in which skin cancer occurs even before 2 years of age (Kraemer et al., 
1987). The second group of XP-F patients exhibit neurological deterioration in addition to their 
XP-like symptoms. There has been one published case of a patient with mutations in XPF with 
dramatically accelerated aging (Niedernhofer et al., 2006). The mutation in XPF, its impact on 
protein expression, function and subcellular localization are all critical determinants in the 
clinical manifestations (Ahmad et al., 2010). Of note, all XP-F patients carry a missense 
mutation in at least one allele, and none of these affect the catalytic domain of the protein (Table 
1.1). This has led to speculation that ERCC1–XPF is essential for human life (Jaspers et al., 
2007). This is supported by the observation that mice homozygous for null alleles of these genes 
are not viable except in select genetic backgrounds (see the end of Section 1.3). 
The first XPF-deficient human patient was reported in 1979, several years before the XPF 
gene was identified and cloned (Arase et al., 1979). The patient, referred to as XP23OS, was 
confirmed as XP-F by genetic complementation analysis, and exhibited mild XP symptoms 
including freckling and photosensitivity. Primary cells from patient XP23OS have only 10% of 
the normal level of NER as measured by UV-induced unscheduled DNA synthesis (UDS), but 
only modest sensitivity to UV as measured by clonogenic survival. The seeming discrepancy can 
be explained by the fact that UDS measures NER that occurs in the first 3 h following UV 
irradiation, whereas in a clonogenic survival assay, cell growth is measured in the 7–10 days  
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Table 1.1: List of patients with verified mutations in XPF or ERCC1 
 
The first 14 patients (XP26BR through XP30MA) are XP-F patients without neurodegeneration. The middle 9 
patients (XP42RO through CO107TA) are XP-F patients with neurodegeneration. The last two patients (XP202DC 
through 165TOR) have a mutation in ERCC1. 
a Age of patient at time of diagnosis and patient’s gender. 
b Unscheduled DNA synthesis as a percentage compared to control cells. 
c Fold increase in UV sensitivity of patient fibroblasts compared to control cells. 
d Presence (+) or absence (−) of neurodegenerative symptoms. 
e Presence (+) or absence (−) of abnormal pigmentation including freckling, blistering, epidermal atrophy and 
keratoses. 
f Presence (+) or absence (−) of skin carcinomas (basal cell and squamous cell carinomas). 
 
following UV irradiation. Thus XP23OS cells must have low levels of NER, but that is adequate 
to prevent cell death and replicative senescence given ample time to repair the genome (Zelle et 
al., 1980). Furthermore, host cell reactivation of reporter expression following UV damage was 
only modestly impaired. These results suggest that although the efficiency of NER was impaired 
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in this patient, the pathway must be intact to explain the relatively mild symptoms in this 45-
year-old patient. In the years that followed, several patients with XP group F were described, 
most of them from Japan, having mild to moderate symptoms, similar to patient XP23OS 
(Fujiwara et al., 1985a; Fujiwara et al., 1985b; Kondo et al., 1989; Nishigori et al., 1986; Norris 
et al., 1988; Thielmann et al., 1991; Yamamura et al., 1989). The majority of XP-F patients had 
UV sensitivity and freckling of the skin, but severe ocular and neurological symptoms were rare 
in XP (see Table 1.1) (Berneburg et al., 2000; Moriwaki et al., 1993). It is important to note that 
there have been reports of additional XP-F patients that are not included in Table 1.1 because the 
mutations have yet to be verified in genomic DNA (Matsumura et al., 1998). 
The human XPF gene was cloned in 1996 with the identification of a human gene 
homologous to yeast Rad1 (Brookman et al., 1996; Sijbers et al., 1996a). This cDNA corrected 
the defect in cells from XP group F patients. Additionally, causative mutations were identified in 
XP-F patients that corresponded to this gene. Following the cloning of XPF, an unusual XP-F 
patient was described displaying progressive late-onset neurologic decline (Sijbers et al., 1998). 
This patient, referred to as XP42RO, had mild ocular photophobia with severe erythema on sun 
exposure. Basal and squamous cell carcinomas were detected in the second decade of life and by 
the fourth decade the patient exhibited profound neurodegenerative symptoms including ataxia 
and cerebral and cerebellar atrophy. The mutation found in XP42RO cells is a C → T transition 
at nucleotide 2377, which results in a change of the conserved arginine residue at 799 to a 
tryptophan. The R799W mutation was identified in at least eight other XP-F patients, six of 
whom had reported neurodegeneration (see Table 1.1). Patient XP126LO harbors the R799W 
mutation, but is without neurologic symptoms to date. One possible explanation is that 
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neurologic symptoms may not appear until the 4th or 5th decade of life, and this patient was 
assessed and diagnosed at 22 years of age. 
More recently, mutations in XPF were linked to a novel progeroid syndrome or disease of 
accelerated aging (called XFE progeroid syndrome). The patient, referred to XP51RO, had 
severe photosensitivity, which led investigators to hypothesize that NER was defective, and 
genetic complementation with XP patient cells revealed that XPF was affected (Niedernhofer et 
al., 2006). In addition to sun sensitivity and the classical symptoms of XP, patient XFE had 
severe symptoms of accelerated aging that affected the neurologic, hepatobiliary, 
musculoskeletal, and hematopoietic systems. Mutation analysis revealed a G → C transversion at 
position 458 which resulted in a non-conservative substitution of arginine at residue 153 to 
proline. The mutation in XPF was unexpected because patient XFE had severe symptoms of 
accelerated aging, unlike most other XP-F patients who had mild XP. R153 is located within a 
conserved helicase motif of XPF which is also a leucine-rich region postulated to be important 
for protein–protein interactions. Primary fibroblasts from patient XP51RO are highly sensitive to 
UV and the crosslinking agent mitomycin C. Patient XP51RO had normal early postnatal 
development, but progeroid symptoms began to appear in early prepubescence. The symptoms 
included an old, wizened appearance, loss of subcutaneous fat, liver dysfunction, vision and 
hearing loss, renal insufficiency, muscle wasting, osteopenia, kyphosis and cerebral atrophy. 
These symptoms of accelerated aging are strikingly similar to those seen in Ercc1−/− and Xpfm/m 
mice (see Figure 1.1). 
Very recently, a patient with features similar to XP51RO was identified in the UK. The 
patient has the facial appearance of CS, sun-sensitivity, microcephaly, neurological problems and 
developmental delay, together with pancytopenia and renal failure. Cellular studies revealed low 
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UDS and assignment to the XP-F group (D. Pilz, D. McGibbon, R. Sarkany, M. Stefanini and A 
Lehmann, personal communication). XP-F patients with early onset and more severe symptoms 
 
 
Figure 1.1: Images and symptoms of ERCC1-deficient mice and symptoms of patient XP51RO 
(A) Representative images of Ercc1-/- (left; 3 weeks of age) and Ercc1-/Δ (right; 18 weeks of age) mice. (B) Table 
listing the symptoms of aging observed in Ercc1-/- mice, Ercc1-/Δ mice, and patient XP51RO who had a progeroid 
syndrome (or disease of accelerated aging) due to a homozygous mutation in XPF. Symptoms are compared to 
normal human aging. (+) Indicates presence and (-) indicates absence of the symptom. References are listed in the 
right hand column. Also indicated are whether or not the same symptoms are associated with old age in humans and 
(+) or (-) indicates presence of absence in the Ercc1-/- mice, Ercc1-/Δ mice, or progeroid patient XP51RO. 
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appear to have mutations that lead to mislocalization of ERCC1–XPF to the cytoplasm, thereby 
decreasing the cellular capacity for efficient repair of nuclear DNA (Ahmad et al., 2010). 
1.3 ERCC1 MUTATIONS IN HUMANS 
ERCC1 was the first human DNA repair gene cloned (Westerveld et al., 1984). For decades, 
however, no patients were identified with ERCC1 mutations; hence the gene does not have the 
standard XP nomenclature (XP-x) like other NER factors associated with xeroderma 
pigmentosum. Recently, a single patient was discovered who had mutations in ERCC1 resulting 
in severe pre- and postnatal developmental defects (Jaspers et al., 2007). The patient, referred to 
as 165TOR, had severe skeletal defects at birth, including microcephaly, arthrogryposis and 
rocker-bottom feet. These abnormalities were seen in conjunction with neurological alterations 
including cerebellar hypoplasia and blunted cortical gyri. The clinical diagnosis was cerebro-
oculo-facio-skeletal syndrome, or COFS syndrome. COFS syndrome was first reported by 
Lowry in 1971, and further characterized in the Manitoba aboriginal population by Pena and 
Shokeir in 1974 (Lowry et al., 1971; Pena and Shokeir, 1974). COFS syndrome is a rare 
autosomal recessive disorder in which patients undergo rapid neurologic decline. Symptoms 
include but are not limited to microcephaly and brain atrophy with calcifications, cataracts, optic 
atrophy, progressive joint contractures, and severe postnatal growth failure (Graham et al., 
2001). Patients with COFS syndrome are reported to have mutations in genes encoding DNA 
repair proteins ERCC6/CSB, ERCC5/XPG and ERCC2/XPD (Meira et al., 2000; Nouspikel et 
al., 1997). 
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Two mutations were found in the coding region of ERCC1 in patient 165TOR. The 
maternal allele harbors a C → T transition that converts Gln158 into an amber translational stop 
codon. The result is a truncated polypeptide that lacks the entire C-terminal domain, essential for 
binding XPF (de Laat et al., 1998). The paternal allele has a C → G transversion, resulting in the 
conversion of Phe231 to leucine. This amino acid falls within the C-terminal tandem helix–
hairpin–helix domain of ERCC1, critical for binding XPF, and is conserved in invertebrates and 
mammals (de Laat et al., 1998). ERCC1 mRNA levels were normal in this patient, although the 
protein levels of ERCC1 and XPF in the nucleus were reduced 4–5-fold. The truncated protein 
was not detectable by immunoblot. Accordingly, fibroblasts from patient 165TOR had 15% of 
the normal level of NER, representing a modest defect, suggesting that the missense mutation 
affects stability of ERCC1–XPF and/or its nuclear localization, but not enzymatic activity. 
Unexpectedly, the expression of ERCC1–XPF in 165TOR cells is reduced but 
comparable to a patient with mild XP-F. Several hypotheses have been proposed to explain this 
incongruity, the simplest being that ERCC1 and XPF play distinct roles in vivo. Evidence against 
this hypothesis includes the fact that Ercc1−/− and Xpfm/m mice have apparently identical 
phenotypes (McWhir et al., 1993; Tian et al., 2004). Additionally, ERCC1 and XPF are required 
to stabilize one another in vivo (de Laat et al., 1998; Sijbers et al., 1996b). It is important to note 
that COFS is also caused by mutations in the TFIIH subunit XPD and the NER endonuclease 
XPG that stabilizes TFIIH (Graham et al., 2001; Hamel et al., 1996; Thorel et al., 2004; 
Zafeiriou et al., 2001). ERCC1–XPF and the other members of the NER machinery have been 
demonstrated to play a role in regulating transcription that has been suggested to be independent 
of their role in DNA repair (Le May et al., 2010). Therefore, the clinical severity of patient 
165TOR may be due to a transcription-coupled nucleotide excision repair defect during 
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development. It is also possible that 165TOR was genetically replete of functional ERCC1–XPF 
during development, but selective pressure led to partial reversion of the cellular phenotype 
postnatally. Reversion with mosaicism has been reported in many genome instability disorders 
including Fanconi anemia, Werner and Bloom syndromes, and observed for ERCC1–XPF 
deficient cells chronically exposed to crosslinking agents (Auerbach, 2009; Bosma et al., 2003; 
Ellis et al., 2001; Hirschhorn, 2003). In addition, there are undoubtedly modifier genes that 
affect the severity of symptoms caused by mutations in ERCC1 or XPF as illustrated by the fact 
that Ercc1−/− mice are not viable in inbred C57Bl/6 or FVB/n backgrounds, but are born with 
Mendelian frequency in an f1 mixed background (Niedernhofer et al., 2006). Finally, little is 
known about regulation of ERCC1–XPF expression, which could be tissue-specific and 
therefore, contribute to heterogeneous phenotypes. Identifying modifier genes, identifying 
regulators of nuclease expression, and modeling additional patient mutations in mice will be 
essential for deciphering genotype:phenotype correlations. A second patient with mutations in 
ERCC1 was briefly described recently (Imoto et al., 2007). The patient had a nonsense mutation 
affecting amino acid 226, which lies early in the helix–hairpin–helix domain necessary for 
binding XPF. The second allele contains a splice-site mutation (IVS6-G → A). The patient 
displayed neurologic symptoms beginning at age 15 years and died by the age of 37. 
Neurodegeneration was progressive and severe, resulting in dementia and cortical atrophy. The 
symptoms are very similar to XPF patients with neurologic involvement (Table 1.1), supporting 
the conclusion that ERCC1 and XPF function exclusively as a complex in vivo. 
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1.4 MOUSE MODELS OF ERCC1-XPF DEFICIENCY 
1.4.1 ERCC1 knockout mice 
To understand the biological significance of ERCC1, the gene was knocked-out in the mouse by 
two independent laboratories (McWhir et al., 1993; Weeda et al., 1997a). The two knockout 
alleles were created by interrupting different exons. McWhir et al. (1993) created the first 
knockout mouse model by disrupting exon 5 of Ercc1, leading to a truncated transcript missing 
the last four exons, which contain the XPF interaction domain (Enzlin and Scharer, 2002; 
McWhir et al., 1993; Sijbers et al., 1996b). The second knockout strain was generated by 
inserting a neomycin resistance cassette into exon 7 of Ercc1 (Weeda et al., 1997a). The result 
was a truncation in the helix–hairpin–helix motif required for interaction with XPF (de Laat et 
al., 1998). Ercc1 mRNA was not detected in these mice (Weeda et al., 1997a). The former strain 
is born with Mendelian frequency; the latter is sub-Mendelian, likely due to differences in the 
genetic background (McWhir et al., 1993; Weeda et al., 1997a). Deletion of ERCC1 is lethal in a 
fully inbred genetic background, indicating that there are modifier genes that influence the 
severity of the phenotype (Niedernhofer et al., 2006). In both knockout strains, postnatal growth 
is severely retarded and the mice die at approximately 3 weeks of age when they weigh only 
about 20% compared to their normal littermates (McWhir et al., 1993; Weeda et al., 1997a). The 
median lifespan of Ercc1−/− mice in an f1 mixed genetic background of 50:50 C57BL/6:FVB/n is 
21 days and the maximum lifespan 28 days (Niedernhofer et al., 2006). The Ercc1−/− mice 
spontaneously develop symptoms characteristic of progressive neurodegeneration, including 
dystonia, trembling and ataxia (Niedernhofer et al., 2006). 
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The hematopoietic system of Ercc1−/− mice develops normally (Prasher et al., 2005). 
However, by the end of life, Ercc1−/− mice are leukopenic and thrombocytopenic, and there is 
extensive adipose transformation of the bone marrow, hallmark features of normal aging in mice 
(Prasher et al., 2005). Proliferation of multi-potent and lineage-committed progenitors from 
Ercc1−/− mice is profoundly impaired (Prasher et al., 2005). Collectively, these data suggest that 
ERCC1-deficient mice undergo rapid turnover of hematopoietic cells leading to premature 
exhaustion of stem cell reserves. In addition, bone marrow progenitors from Ercc1−/− mice are 
exquisitely sensitive to crosslinking agents, similar to murine models of Fanconi anemia (Parmar 
et al., 2009; Prasher et al., 2005). 
The liver of Ercc1−/− mice is prominently affected, with hepatocellular polyploidy, 
aneuploidy and G2 arrest (Chipchase et al., 2003; McWhir et al., 1993; Nunez et al., 2000). The 
structural changes correlate with impaired liver function as demonstrated by significantly 
increased liver enzymes in the serum (McWhir et al., 1993). Ercc1−/− mice develop kyphosis, 
sarcopenia, dystonia and ataxia, indicative of musculoskeletal and nervous system defects 
(Niedernhofer et al., 2006). There is a suppression of the somatotroph, lactotroph and thyrotroph 
hormonal axes in the Ercc1−/− mice, which explains their growth delay and diminutive size 
(Niedernhofer et al., 2006). Many of the degenerative and endocrine abnormalities are similar to 
what occurs with old age in mice (Caruso and Silliman, 2006; Schumacher et al., 2008). To 
further investigate the relationship of DNA repair deficiency to normal aging, genome-wide 
expression changes in Ercc1−/− mice relative to wild-type littermates were compared to changes 
that occur with natural aging (differences in gene expression between old wild-type and young 
wild-type mice). There is a highly significant overlap between these two profiles, whether 
comparing gene-by-gene or over-represented biological pathways (Niedernhofer et al., 2006). 
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This provided some of the early support for the notion that DNA damage may contribute to 
aging. 
1.4.2 XPF mutant mice  
Tian et al. (2004) recreated the XPF mutation in patient XP23OS in the mouse (Tian et al., 
2004). The patient had a single base insertion after nucleotide 1330 leading to a frameshift 
mutation after lysine 455 and a stop codon 38 residues later (Matsumura et al., 1998). This leads 
to truncation of XPF upstream of the catalytic domain and its ERCC1-interaction domain (Enzlin 
and Scharer, 2002). The clinical phenotype of the patient was mild, having reached her 4th 
decade without neurodegeneration or skin cancer (Matsumura et al., 1998). In keeping with this, 
the level and length of the XPF transcript in XP23OS cells are comparable to normal cells, 
illustrating that the patient must have a second normal XPF allele. To further emphasize this, a 
mouse homozygous for the frameshift mutation has undetectable levels of Xpf mRNA and a 
severe phenotype identical to that of ERCC1 null mice (Tian et al., 2004). The Xpfm/m mice 
develop normally and are born with Mendelian frequency. However, postnatal growth is delayed 
such that by two weeks of age the Xpfm/m mice are approximately 25% the size of littermates, and 
die by three weeks of age. Hepatocellular polyploidy was prominent, as in the Ercc1−/− mice 
(Tian et al., 2004). The phenotypic parallels between ERCC1 and XPF null mice strongly 
suggest that the proteins function exclusively as a complex. 
Importantly, ERCC1 and XPF-deficient mice appear to have a normal complement of 
mature and immature B cells (Schrader et al., 2004; Tian et al., 2004; Winter et al., 2003). This 
provides definitive evidence that ERCC1–XPF is not essential for NHEJ, the DSB repair 
pathway required for class switch recombination (CSR) (Kotnis et al., 2009). However, ex vivo 
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CSR is mildly attenuated in splenocytes isolated from Ercc1−/− mice and the mutation pattern in 
the switch region of the immunoglobulin locus is significantly different from that of normal 
littermate mice, suggesting that ERCC1–XPF may contribute to DNA end-processing of DSBs at 
the Ig locus (Schrader et al., 2004). Consistent with this, ERCC1-deficient mice are 
hypersensitive to IR, which induces DNA DSBs (Ahmad et al., 2008). 
1.4.3 Liver corrected Ercc1-/- mice 
To investigate the cause of death in Ercc1−/− mice, Selfridge et al. (2001) crossed the mice with a 
transgenic strain expressing ERCC1 specifically in the liver, using transthyretin (TTR) 
regulatory sequences to control ERCC1 expression (Selfridge et al., 2001). The resulting mice 
(Ercc1−/− + TG) have dramatically improved growth, reaching 58% of normal body weight for 
their age. Furthermore, their lifespan is significantly increased, with a median survival of ∼75 
days. Hepatocellular polyploidy and abnormal liver functions are largely corrected by expression 
of ERCC1 in the liver. Interestingly, by 7 weeks of age, the transgenic mice begin to display 
evidence of renal dysfunction (significantly elevated serum creatinine and proteinuria) and renal 
histopathology (glomerulosclerosis, hyaline casts, renal tubular epithelial anisokaryosis, 
karyomegaly, hyperchromasia, pyknosis and keryorrhexis) (Lawrence et al., 2008; Selfridge et 
al., 2001). These data suggest that Ercc1−/− mice die of liver failure, and that hepatocytes and 
renal cells are the most vulnerable to loss of ERCC1-XPF-dependent DNA repair. 
Since the Ercc1−/− + TG mice live longer than Ercc1−/− mice, they are a practical system 
for identifying other tissues affected by ERCC1-deficiency. Performance of Ercc1−/− + TG mice 
on an opto-kinetic response test to measure visual acuity is impaired by 4 weeks and worsens 
with age (Selfridge et al., 2001). Structural abnormalities of the eye were not detected, indicating 
 19 
that loss of vision is not due to a developmental defect (Selfridge et al., 2001). Also, there is no 
evidence for retinal degeneration typical of CSB mice, another NER-defective mutant strain 
(Lawrence et al., 2008). 
Like Ercc1−/−, symptoms associated with neurodegeneration were observed in Ercc1−/− + 
TG mice. The Ercc1−/− + TG mice displayed dystonia and ataxia indicative of a cerebellar defect. 
While mild atrophy of the neocortex and cerebellum were observed, there were no abnormalities 
or loss of Purkinje cells to explain these phenotypes. Also, there were no signs of degeneration at 
the neuromuscular junctions. Therefore these symptoms were attributed to uremic 
encephalopathy, caused by kidney failure (Lawrence et al., 2008). 
Male and female Ercc1−/− + TG mice were found to be infertile (Hsia et al., 2003). Testes 
of these mice were approximately 50% the normal size at puberty and contained significantly 
fewer spermatocytes. Spermatogenesis is not arrested at a particular stage, as expected for a 
meiotic defect, but instead there is abundant apoptosis in these rapidly dividing cells (Hsia et al., 
2003; Paul et al., 2007). This leads to a 97% reduction in the sperm count (Paul et al., 2007). 
Ovaries from adult Ercc1−/− + TG mice showed a reduced number of oocytes and an absence of 
primary follicles (Hsia et al., 2003). 
1.4.4 Ercc1 mutant mice 
To further probe the DNA repair function of ERCC1 in vivo, a premature stop codon was 
engineered at position 292 of mErcc1 (Weeda et al., 1997a). This results in a C-terminal deletion 
of seven amino acids of the murine protein, including a phenylalanine residue at position 293, 
thought to be essential for binding to XPF (de Laat et al., 1998). Thus, the prediction was that 
this mutation would ablate DNA repair function without compromising the protein stability 
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(Sijbers et al., 1996b). Unlike either of the null alleles, normal levels of the mutant Ercc1 
transcript are detected in the tissues from the mutant mice (Weeda et al., 1997a). Homozygous 
Ercc1*292 (also referred to as Ercc1Δ/Δ) mice live up to six months, which is six-times longer than 
ERCC1 null mice. Similar to the Ercc1−/− mice, the Ercc1*292 mice are infertile and their skin is 
atrophic and lacks subcutaneous fat (Weeda et al., 1997a). The spleen of Ercc1*292 mice contains 
increased ferritin and hemosiderin deposits, indicative of a high turnover of erythrocytes. The 
kidney exhibits dilated renal tubules with hyaline casts. Nuclear polyploidy is common in the 
liver and kidney. Thus, virtually all of the phenotypes of Ercc1−/− mice are recapitulated in this 
longer-lived mutant strain. Primary mouse embryonic fibroblasts (MEFs) from the Ercc1−/− mice 
are modestly more sensitive to the crosslinking agent mitomycin C than MEFs from Ercc1*292 
mice, suggesting that their increased longevity is due to increased DNA repair capacity (Weeda 
et al., 1997a). Despite this, topical application of the tumor initiator, DMBA to Ercc1*292 mice 
leads to acute toxicity rather than carcinogenesis, illustrating a dramatic difference from other 
NER-deficient mice (Weeda et al., 1997a). 
1.4.5 Ercc1 hypomorphic mice 
Combination of one null and one mutant Ercc1 allele yields mice (Ercc1−/*292; Ercc1−/Δ or 
Ercc1d/−) that are born with Mendelian frequency and have an even greater maximal lifespan of 
seven months in an f1 background of 50:50 C57Bl/6J:FVB/n (Dolle et al., 2006). Ercc1−/Δ mice 
are runted compared to their wild-type littermates (de Waard et al., 2010). However, they 
develop normally until sexual maturity, at which point they began to exhibit signs of rapid aging 
(Nevedomskaya et al., 2010). They live 24–30 weeks while progressively developing dystonia, 
tremors, kyphosis and ataxia (de Waard et al., 2010). 
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The Ercc1−/Δ mice were crossed with a transgenic lacZ reporter strain to measure the 
mutation frequency in vivo (Dolle et al., 2006). The mutation frequency is modestly elevated in 
the liver of 5–6 month old Ercc1−/Δ mice compared to normal littermates. Interestingly, the 
mutations are primarily chromosomal rearrangements characteristic of old wild-type mice rather 
than point mutations, characteristic of NER-deficient mice (Dolle et al., 2006). This observation 
extends the parallels between the progeroid Ercc1−/Δ mice and aged normal mice. 
Ercc1−/Δ mice are hypersensitive to IR (Ahmad et al., 2008). Even though these mice are 
hypomorphic for ERCC1–XPF, they were equally as sensitive to IR as DNA-PKcs knockout 
mice (Li et al., 2002). IR causes persistent γH2AX foci in ERCC1-deficient cells and mice, 
supporting a role for ERCC1–XPF in the repair of DSBs. The involvement of ERCC1–XPF in 
DSB repair is presumably a Ku-independent pathway, since Ercc1−/−Ku86−/− mice are not viable 
(Ahmad et al., 2008). Ercc1−/− MEFs have normal levels of spontaneous and mitomycin C-
induced sister chromatid exchanges, illustrating that ERCC1–XPF is not essential for 
homologous recombination (Niedernhofer et al., 2001; Sonoda et al., 1999). In contrast, DSBs 
with 3′ overhangs cause large deletions in Ercc1−/− cells (Ahmad et al., 2008; Niedernhofer et 
al., 2001). These genetic and in vitro data support a role for ERCC1–XPF in processing a subset 
of DSBs (those with 3′ overhangs) and a role in the alternative end-joining pathway of DSB 
repair (McVey and Lee, 2008). 
Ercc1−/−, Ercc1−/− + TG, and Ercc1−/Δ mice all develop progressive dystonia, tremors and 
ataxia, highly suggestive of neurodegeneration (de Waard et al., 2010; Lawrence et al., 2008; 
Niedernhofer et al., 2006). The former strains display cerebellar hypoplasia, similar to the 
ERCC1 patient 165TOR, but this could not be completely dissected from developmental 
abnormalities, due to their young age (Jaspers et al., 2007; Lawrence et al., 2008; Niedernhofer 
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et al., 2006). Evidence for degenerative processes in the central nervous system is quite clear in 
Ercc1−/Δ mice (de Waard et al., 2010). De Waard et al. (2010) found profound astrocytosis and 
microgliosis in the spinal cord of 4 month old Ercc1−/Δ mice, compared to normal littermates and 
1 month old mutant animals. This is accompanied by a significant reduction in the number of 
motor neurons in the ventral horn of the spinal cord and a concomitant denervation of the 
skeletal muscle. There is an approximately 50% reduction in neurons from 4 to 8 weeks of life, 
and then again from 8 to 16 weeks of life in the Ercc1−/Δ mice. It is also evident that the pre-
synaptic motor nerve terminals have degenerated in the aged Ercc1−/Δ mice with characteristics 
similar to those seen in amyotrophic lateral sclerosis and aging motor neurons (de Waard et al., 
2010). 
Genome-wide expression profiling of Ercc1−/Δ mice revealed a highly significant 
correlation with the transcriptome of numerous long-lived models, including Ames and Snell 
dwarf mice and/or calorically restricted mice (Schumacher et al., 2008). In addition, there is a 
significant correlation with the transcriptome of old wild-type mice. This indicates that Ercc1−/Δ 
mice look biologically “old”, but also that the failure to repair DNA damage in these mice 
triggers activation of a stress response that is transcriptionally regulated and promotes longevity. 
Schumacher et al. showed that this same stress response is also triggered by nutritional 
deprivation and is mediated through suppression of growth hormone–insulin-like growth factor 1 
signaling as evidenced by the significant correlation with Ames and Snell dwarf mice. All of 
these mice displayed suppression of the somatotroph axis, oxidative metabolism and peroxisomal 
biogenesis coupled with an upregulation of antioxidants, DNA damage and apoptosis 
(Schumacher et al., 2008). 
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This was further supported by analysis of metabolites in the serum and urine of Ercc1−/Δ 
mice (Nevedomskaya et al., 2010). There is no difference between Ercc1−/Δ mice and normal 
littermates at 8 and 12 weeks of age. However by 16 weeks, there are significant differences, 
which become further amplified by 20 weeks of age. Collectively, these data support the 
conclusion that Ercc1−/Δ mice develop normally into adulthood, but then undergo degenerative 
changes. Several of the metabolic changes mimic those that occur with caloric restriction, 
including increased HDL, decreased LDL and VLDL, and ketosis. However, a number of 
metabolic changes in the Ercc1−/Δ mice are also consistent with degeneration, such as increased 
glucose, citrate and succinate in the urine, indicative of kidney dysfunction, and metabolic 
alkalosis, indicative of liver dysfunction (Nevedomskaya et al., 2010). These observations are 
consistent with the model that DNA damage accumulates in Ercc1−/Δ mice leading to metabolic 
reprogramming in response to stress (Schumacher et al., 2008). This may be beneficial, but in 
the long-run is insufficient to sustain the organism in the face of continued DNA damage 
(Niedernhofer et al., 2006). 
Remarkably, Ercc1−/Δ mice spontaneously develop numerous diseases associated with 
old age in humans. This includes osteoporosis and intervertebral disc degeneration (Vo et al., 
2010). There is progressive attrition of disc extracellular proteoglycans with age, leading to loss 
of disc height and its cushioning function (Roughley, 2004; Roughley et al., 2002). Similar 
changes were observed in discs of 5-month-old Ercc1−/Δ mice and these alterations were 
exacerbated in mice treated with genotoxic chemotherapeutic agents (Vo et al., 2010). These 
observations support the conclusion that DNA damage, if not repaired, can promote common 
aging-related degenerative diseases, even in post-mitotic tissues. 
 24 
1.4.6 Tissue-specific deletion of ERCC1 
Tissue-specific deletion of a gene is a powerful tool for dissecting a complex phenotype, such as 
that of the ERCC1-deficient mice, allowing for dissection of whether a particular symptom or 
pathology is a direct consequence of a deletion of a gene or merely a secondary consequence 
(e.g., is neurodegeneration due to loss of ERCC1 in neurons or uremic encephalopathy due to 
loss of ERCC1 in the kidneys?). Tissue-specific knockout of protein expression occurs if the 
gene of interest (or an exon vital to its function) is flanked (floxed) by recombination signals 
(loxP or FRT) and mice expressing the two copies of the floxed allele are crossed with transgenic 
mice expressing recombinase (CRE or FLP, respectively) under a tissue-specific promoter 
(Tronche et al., 2002). Another important attribute of this approach is that it is possible to 
distinguish developmental from degenerative changes by selecting promoters that are active only 
postnatally. 
A floxed allele of Ercc1 was generated by inserting loxP sites in intron 2 and 5, such that 
Cre recombinase excises exons 3–5 of the Ercc1 locus (Doig et al., 2006). Mice harboring two 
floxed alleles of Ercc1 were crossed with transgenic mice expressing Cre-recombinase under a 
tyrosinase promoter (Selfridge et al., 2010). The goal was to knockout expression of ERCC1 in 
melanocytes to generate a murine melanoma model. Unexpectedly, the mice die by 6 months of 
age due to severe colonic obstruction. Tyrosinase is expressed in all neural crest cell-derived 
lineages, including parasympathetic neurons that innervate the gastrointestinal tract and are 
required for colonic peristalsis. Knocking-out ERCC1 expression in neural crest cells causes p53 
activation and apoptosis of ganglion cells in the mesenteric plexus. Denervation of the bowel 
explains the colonic obstruction and demonstrates that ERCC1–XPF dependent DNA repair is 
critical for protecting neurons from degeneration (Selfridge et al., 2010). This provides strong 
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evidence that the neurological symptoms observed in ERCC1-deficient mice are due, at least in 
part, to loss of functional neurons rather than a defect in supportive glial cells. 
ERCC1 was also knocked-out specifically in the skin to create a model of UV-induced 
skin cancer. Ercc1flox/− mice were crossed with transgenic mice expressing Cre recombinase 
under the keratin 5 (K5) promoter, which is only expressed in the basal layer of the epidermis 
(Doig et al., 2006). To facilitate UV carcinogenesis studies, these mice were produced in an 
albino, hairless background. Deletion of Ercc1 in the skin leads to a 20-fold reduction in the 
minimal erythemal dose in response to UV-B irradiation, leading to dramatic, but transient 
hyperplasia (Doig et al., 2006). Furthermore, the mice develop significantly more skin tumors, 
early, and at a lower dose of UV-B than normal controls. The cumulative dose of UV-B required 
to induce tumors in half of the ERCC1-deficient mice was 37-times lower than normal controls 
in a chronic exposure study (Doig et al., 2006). The mice also developed actinic keratosis and 
squamous cell carcinomas. Thus, this tissue-specific knockout strain offers an accurate and rapid 
(tumors within 8 weeks) model of UV-induced skin cancer, which may be useful in the study of 
XP. Subsequently, these mice have been used to test topical treatments that protect against UV-
induced skin cancer (Lawrence et al., 2009). 
1.4.7 Double mutant mice 
TRF1 and TRF2 are shelterin proteins required to protect telomeres at chromosomal ends 
(Smogorzewska et al., 2000). Overexpression of either protein leads to a dominant negative 
effect exemplified by telomere shortening, loss of telomeric 3′ G-rich overhangs and end-to-end 
fusions (Munoz et al., 2009b; Munoz et al., 2005). Overexpression of TRF2 in the skin of mice 
by putting the cDNA under control of the keratin 5 promoter (K5TRF2), leads to skin atrophy, 
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hyperpigmentation and increased skin cancer in sun-exposed areas. These results demonstrate 
that dysregulation of telomeres promotes UV-induced skin cancer (Munoz et al., 2005). Skin and 
keratinocytes isolated from either K5TRF1 or K5TRF2 mice contain telomeric defects, which 
were rescued by knocking-out Xpf (Munoz et al., 2009b; Munoz et al., 2005). This strongly 
supports the previous observation that the absence of ERCC1–XPF does not negatively impact 
telomere length or function, but instead has an unexpected beneficial effect (Zhu et al., 2003). 
1.5 CONCLUDING REMARKS 
This chapter provides a comprehensive overview of the physiological impact of reduced 
expression or activity of ERCC1–XPF DNA repair endonuclease. There is tremendous 
variability between patients with mutations in ERCC1 or XPF, ranging from mild cutaneous 
symptoms to severe neurodegeneration. ERCC1 patient 165TOR had severe developmental 
abnormalities that are not normally seen in XP-F patients. These differences cannot be fully 
predicted by the patients’ mutations or the level of residual NER (UDS) in patient fibroblasts. 
Clearly, further work is needed to decipher how expression and activity of ERCC1–XPF is 
regulated. This in turn is likely to yield better methods for predicting the physiological 
consequences of a particular mutation (Fan et al., 2008). The studies in mice have been crucial 
for a number of reasons. First, the identical phenotypes of Ercc1−/− and Xpfm/m mice, which are 
null for XPF, provide the strongest possible evidence that ERCC1 and XPF must function 
exclusively as a heterodimer. Second, the unexpected premature aging phenotypes of the ERCC1 
mutant mice led to the discovery of a new rare genetic disease (XFE progeroid syndrome) and 
contributed to the body of evidence that DNA damage is one type of cellular damage that 
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promotes aging-related degenerative changes (e.g., neurodegeneration). Third, it is clear that the 
severity of symptoms associated with ERCC1–XPF deficiency are somehow linked to variable 
levels of expression or activity. This implies that functional single nucleotide polymorphisms in 
either gene may be important for predicting risk of cancer or degenerative diseases. Fourth, 
ERCC1 mutant mice are unique amongst the NER-deficient mutant strains because they 
spontaneously develop neurodegeneration, which may be used to screen therapies for treating 
XP, CS and TTD patients. Finally, tissue-specific ERCC1 knockout strains will be crucial for 
identifying which tissues and cell types are most vulnerable to DNA damage and are responsible 
for triggering systemic stress responses. 
1.6 THEORIES OF AGING 
In the 21st century, there has been a global demographic shift, such that the number of 
individuals over the age of 60 is increasing rapidly in both developed and non-developed nations 
(2001b).  In 1950, there were approximately 205 million persons over the age of 60 worldwide.  
In 2000, this number nearly tripled to 606 million persons age 60+. However, by 2050 that 
number is predicted to reach nearly 2 billion and comprise nearly 20% of the population (2001b; 
Greenberg, 2011). Aging is the number one risk factor for numerous chronic degenerative 
diseases, including cardiovascular disease, arthritis, cataracts, glaucoma, osteoporosis, type 2 
diabetes, and neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease.  
Eighty percent of individuals over the age of 65 have at least one chronic disease, whereas 
greater than 50% have two or more (2011a). In the United States alone, the direct medical costs 
associated with these chronic diseases is estimated to be $582 billion annually (Hoffman and 
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Rice, 1996).  Therefore, in order to improve the quality of life for the elderly by reducing the 
disease burden, and to minimize the economic burden from the medical care of the aged 
population, it is critical to identify the molecular mechanisms that underlie aging. 
The amount of DNA damage and resulting genetic mutations found in the nuclear 
genome increases with age in a variety of tissues in aged organisms (Dolle et al., 2002; Hamilton 
et al., 2001; Mecocci et al., 1999; Wang et al., 2012). Interestingly, multiple mouse models that 
are long-lived are resistant to stressors that cause DNA damage (i.e., UV light and oxidative 
stress) (Murakami, 2006). Conversely, mouse models of DNA repair deficiency or genome 
instability disorders have short lifespans, including strains with mutations in Ercc1, Xpf, Xpd, 
Wrn, Blm, Ku80, and Terc (de Boer et al., 2002; de Waard et al., 2010; Hasty et al., 2003b; 
Kirkwood, 2005; McWhir et al., 1993; Tian et al., 2004; Warner and Sierra, 2003; Weeda et al., 
1997a). In fact, many human progerias, or diseases of accelerated aging, are caused by mutations 
in genes that are required for genomic maintenance (Hasty et al., 2003b; Niedernhofer et al., 
2006). This supports the theory that damage to nuclear DNA contributes to the functional decline 
and loss of an ability to maintain homeostasis that invariably occurs with aging (Kirkwood, 
2005; Warner and Sierra, 2003).  
The main cause of endogenous DNA damage is reactive oxygen species (ROS), the 
majority of which are generated by mitochondria (Balaban et al., 2005; Kirkwood, 2005). This 
led to the theory that free radicals, produced endogenously as part of normal cellular metabolism, 
can cause damage to lipids, DNA and other cellular components (Chakravarti and Chakravarti, 
2007; Cooke et al., 2003; Cui et al., 2012; Mandavilli et al., 2002), thereby promoting aging-
related functional decline of an organism’s tissues (Harman, 1956; Muller et al., 2007). This is 
supported by research showing that mitochondria from aged and post-mitotic cells exhibit loss of 
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membrane potential and accumulate damage to their genome (Jendrach et al., 2005). Some ROS 
produced by mitochondria diffuse throughout the cell, resulting in oxidative damage to cellular 
macromolecules, even in the nucleus (Chakravarti and Chakravarti, 2007; Cooke et al., 2003; 
Cui et al., 2012; Mandavilli et al., 2002). Because DNA is the only cellular macromolecule that 
is repaired instead of replaced, it stands to reason that damage to DNA could be a major 
contributor to aging. 
As discussed above, Ercc1-/Δ mice are a particularly useful model to study the aging 
process and how DNA damage contributes to aging. ERCC1-deficient mice mimic natural aging 
of the hepatobiliary, renal, neurological, musculoskeletal, hematopoietic, and epidermal systems 
over the span of seven months rather than the normal mouse lifespan, which can be up to three 
years (de Waard et al., 2010; Goss et al., 2011; Gregg et al., 2012a; Nevedomskaya et al., 2010; 
Niedernhofer et al., 2006). Therefore, this model accelerates the aging process by >5-fold in a 
mammalian system. Also, the primary defect causing accelerated aging is well-defined in 
Ercc1-/Δ mice: they are defective in the repair of nuclear DNA. This enables testing of 
hypotheses about what exposures in our environmental or diet may induce DNA damage and 
thereby promote aging. Likewise the Ercc1-/Δ mice are amenable to rapid screening of 
therapeutics intended to attenuate DNA damage and therefore, aging (e.g., anti-oxidants).  
Finally, Ercc1-/Δ mice can be used to test whether signaling pathways identified as important 
modifiers of lifespan in other model systems are similarly important for regulating 
lifespan/healthspan in response to DNA damage accumulation (e.g, mTOR, sirtuins, NF-κB 
transcription factor). 
ERCC1-deficient mice are extremely sensitive to crosslinking agents (Niedernhofer et al., 
2006) and their phenotype differs largely from mice deficient solely in NER, Xpa-/- mice (de 
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Vries et al., 1995). Therefore, damage repaired by ERCC1-XPF that is not repaired by the NER 
pathway, is hypothesized to be causing the premature aging phenotype of this mouse model. It 
has been shown that ERCC1-XPF is required for the unhooking of ICLs from one strand of DNA 
during the repair process (Bhagwat et al., 2009). Therefore, the aim of Chapter 2 was to test the 
hypothesis that DNA ICLs promote cellular senescence and aging. If crosslinks are indeed 
driving aging, then reducing endogenous crosslinks should delay aging-associated changes. The 
free radical theory states that cells age because of free radical damage to cells and tissues over 
time (Harman, 1956). Therefore the aim of Chapter 3 was to test the hypothesis that 
mitochondrial-derived ROS promote aging in a DNA repair-deficient mouse model. If crosslinks 
promote aging and reduction of oxidative damage attenuates aging-related symptoms, then the 
next step is to find a source of endogenous crosslinks. The aim of Chapter 4 was to test the 
hypothesis that lipid peroxidation, a potential source of endogenous ICLs, promotes age-related 
decline. Finally, if a reduction of oxidative damage attenuates aging, NF-κB, which is activated 
in response to oxidative stress (Miyamoto, 2011), may be involved in the aging process. 
Therefore, the aim of Chapter 5 was to test the hypothesis that NF-κB drives systemic aging and 
is a therapeutic target for attenuating and/or delaying aging-related degenerative changes. 
In total, the studies provide strong evidence that nuclear DNA damage can promote 
degenerative changes associated with aging. Furthermore, the studies reveal multiple 
unanticipated strategies that can be used to reduce the DNA damage burden and thereby 
potentially improve health in old age. 
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2.1 INTRODUCTION 
DNA interstrand crosslinks (ICL) covalently link both strands of DNA together, rendering them 
inseparable (Dronkert and Kanaar, 2001). Strand separation is essential for DNA replication and 
transcription (Hoeijmakers, 2001; Osawa et al., 2011). Therefore, ICLs are generally accepted to 
be highly cytotoxic, in particular, to rapidly dividing cells. Less than 40 ICLs can kill a cell 
(Grillari et al., 2007), while tens of thousands of single-strand breaks, abasic sites and oxidative 
lesions are tolerated by cells (Ames, 1989; Grillari et al., 2007; Lindahl and Barnes, 2000). This 
forms the conceptual basis for why drugs that induce ICLs are thought to be so effective for 
treating cancer (McHugh et al., 2001). 
Environmental exposures that crosslink DNA can be from industrial exposures, dietary 
sources, inhalation of atmospheric contaminants or due to cancer chemotherapy (2009). The 
unifying feature is that crosslinking agents must be bi-functional, having two reactive groups 
(Dronkert and Kanaar, 2001). They all react with DNA in a two-step fashion, first forming a 
monoadduct by reacting with a nucleobase in one strand of DNA then, if the sequence context is 
appropriate, reacting with a second nucleobase on the opposite strand to form an ICL (Anderson 
and Walker; Hartley et al., 1991). Crosslinking agents, without exception, form multiple types of 
DNA lesions in addition to ICLs, including monoadducts, intrastrand crosslinks and 
DNA:protein crosslinks (Friedberg et al., 2006). This has made it particularly challenging to 
decipher the biological impact of ICL lesions. 
Mechlorethamine (MEC) is a chemotherapeutic agent used to treat multiple myeloma and 
ovarian cancer (2012a). It is a bifunctional nitrogen mustard (Figure 2.1A) that crosslinks 
deoxyguanosine residues at 5′-GNC sequences (Millard et al., 1990; Ojwang et al., 1989; Rink et 
al., 1993). 2-Chloroethylamine (CEA) is a structurally similar monofunctional compound (Wijen 
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et al., 2000) (Figure 2.1B). Both compounds can form monoadducts, however only MEC has the 
ability to further react with protein to form DNA-protein crosslinks (Michaelson-Richie et al., 
2011) or an additional DNA base to form intra- and interstrand crosslinks (Wijen et al., 2000) 
(Figure 2.1C). While the ICLs that are formed only make up 1-5% of the total types of damage 
induced (Dronkert and Kanaar, 2001), they are thought to be responsible for the cytotoxicity to 
cells after chemotherapeutic treatment. Direct comparison of the impact of MEC and CEA on 
cells and organisms offers a unique opportunity to dissect the unique impact of ICLs on cells. 
To accomplish this, we utilized mice and cells that are genetically engineered to be DNA 
repair deficient and therefore hypersensitive to genotoxic agents such as MEC and CEA. 
ERCC1-XPF is a nuclease required for nucleotide excision repair (NER) of monoadducts 
(Sijbers et al., 1996a) as well as the repair of ICLs (Bhagwat et al., 2009; Grillari et al., 2007; 
Niedernhofer et al., 2004).  XPA is a DNA damage recognition protein required only for NER 
(de Vries et al., 1995).  Comparing the impact of MEC and CEA on ERCC1-XPF-deficient and 
Xpa-/- mice offers a second approach for deciphering the specific effect of ICLs on tissues. Any 
response to MEC observed exclusively in ERCC1-XPF deficient mice will be attributable to 
ICLs. 
Another rationale for testing the effect of ICLs on aging is that genetic deletion of Xpa in 
mice ablates NER but results in a very mild phenotype (de Vries et al., 1995; Melis et al., 2008). 
In contrast, mutation in Ercc1, reducing but not knocking-out expression of ERCC1-XPF in 
mice, leads to dramatic accelerated aging (Goss et al., 2011; Gregg et al., 2012a; Niedernhofer et 
al., 2006; Schumacher et al., 2008; Vo et al., 2010). This difference in phenotypes has been 
ascribed to ICL repair deficiency or ICLs in the ERCC1-XPF deficient mice. This suggests that 
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ICLs may drive aging, which has important implications for cancer survivors treated with 
crosslinking agents. 
In this study, Ercc1-/Δ mice, with reduced expression of ERCC1-XPF (Weeda et al., 
1997a), and Xpa-/- mice (Melis et al., 2008), along with wild-type littermates were chronically 
exposed to MEC or CEA and the impact on their health in terms of pre-mortem symptoms and 
post-mortem pathology was measured. Likewise primary fibroblasts from these mice were 
exposed to MEC and CEA to measure the impact on cell viability, growth and function. MEC, 
but not CEA, induced cell senescence in vitro and in vivo. In addition, MEC, but not CEA, 
promoted early onset of aging-related symptoms in all of the mouse strains. Ercc1-/Δ mice were 
more severely affected than wild-type or Xpa-/- mice. Collectively, these data support the 
conclusion that crosslinking agents promote cell senescence and aging. This in turn implies that 
ICLs may be cytostatic rather than frankly cytotoxic and that chemotherapeutic agents such as 
mechlorethamine and cisplatin accelerate the onset of aging-related degenerative changes in 
cancer survivors. 
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2.2 RESULTS 
2.2.1 Exposure paradigm 
To measure the effect of MEC and CEA on cells, early passage, congenic wild-type (WT), 
Ercc1-/- and Xpa-/- MEFs (n = 3 independent cell lines per group) were exposed to 0.1 µM MEC 
(Figure 2.1A) or 0.16 µM CEA (Figure 2.1B) to induce equivalent numbers of DNA adducts 
based on the mustards’ ability to alkylate DNA in rat 9L gliosarcoma cells (Tokuda and Bodell, 
1987). Using this approach, differences in outcomes could be ascribed to ICLs, which are unique 
to MEC (Figure 2.1C). The cells were treated at passages 3, 4 and 5 and the impact on cell 
proliferation was measured (Fig. 1d).  Apoptosis, cellular senescence (senescence-associated β-
galactosidase) and DNA damage (γH2AX) were measured at passage 4 (Figure 2.1D). Similarly, 
DNA repair-deficient mice and their WT littermates (n ≥ 5 mice per genotype per treatment 
group) were treated once a week for six weeks with 8 µg/kg of either MEC or CEA, beginning at 
8 weeks of age (Figure 2.1E). We previously reported that ERCC1-deficient mice have a 100-
fold increased sensitivity to the crosslinking agent, mitomycin C (Niedernhofer et al., 2006), 
therefore, this dose of MEC was chosen as it is approximately 100-fold lower than the dose that 
affects the health of WT mice (Heston, 1950). The mice were monitored daily for the onset of 
symptoms until the age of 20 weeks, at which time they were sacrificed and tissues were 
collected for pathologic analysis. Alternatively, to assess in vivo senescence, Ercc1-/Δ mice were 
crossed with p16-luciferase reporter (p16Luc-reporter) mice and treated once a week for four weeks 
with 8 µg/kg of either MEC or CEA. They were imaged weekly to measure p16 expression, a 
marker of senescence until 15 weeks of age, at which time they were sacrifice (Figure 2.1F). 
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Figure 2.1: Chemical structures and exposure paradigms 
Chemical structures of (A) mechlorethamine (MEC), (B) 2-chloroethylamine (CEA) and (C) a MEC DNA crosslink. 
(D) In vitro treatment schematic of wild-type (WT), Ercc1-/- and Xpa-/- primary mouse embryonic fibroblasts 
(MEFs). Cells were treated for one hour with 0.1µM MEC and 0.16 µM CEA, calculated to induce the same number 
of monoadducts lesions, such that the difference in outcomes could be ascribed to ICLs. Cells were counted, 
reseeded at equal density and treated with MEC and CEA at passage 3, 4 and 5 to assess cellular proliferation. At 
passage 4, MEFs were either fixed and stained, or analyzed by flow cytometry to assess DNA damage, senescence 
and apoptosis. (E) In vivo treatment schematic of WT, Ercc1-/Δ and Xpa-/- mice. Subcutaneous injections of MEC 
and CEA were administered once a week for six weeks starting at 8 weeks of age. Animals were monitored daily 
and tissues were collected at 20 weeks of age when the mice were moribund. (F) p16Luc-reporterErcc1-/Δ mice were 
injected with MEC once a week for four weeks, starting at 10 weeks of age. Mice were injected with luciferin and 
imaged prior to sacrifice and tissue collection at 15 weeks of age. 
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2.2.2 MEC, but not CEA, promotes senescence in vitro 
Proliferation of WT, Ercc1-/- and Xpa-/- primary MEFs untreated or exposed to MEC or CEA was 
measured by counting the cells at each passage and re-seeding at equal density. The growth of all 
of the cell lines exposed to CEA was equivalent (Figure 2.2A), indicating that at this dose, CEA 
did not induce enough DNA damage to cause replicative senescence even if the damage was not 
repaired (i.e., in Ercc1-/- or Xpa-/- cells). Likewise MEC, did not affect the proliferation of Xpa-/- 
cells compared to WT, corroborating the CEA data. However, MEC did cause a significant drop 
in proliferation of Ercc1-/- cells compared to all over genotypes and treatments (p ≤ 0.01, Student 
Newman-Keuls (SNK) test), suggesting that ICLs, when not repaired, inhibit proliferation. 
Next, DNA damage was measured at passage 4 in untreated, MEC- or CEA-treated 
MEFs by counting the fraction of nuclei containing γH2AX foci by immunofluorescence 
staining. Thirty-three percent of untreated Ercc1-/- cells contained γH2AX foci (Figure 2.2B). 
This was significantly more than CEA-treated WT (p ≤ 0.01, SNK test), Ercc1-/- (p ≤ 0.05, SNK 
test) and Xpa-/- (p ≤ 0.001, SNK test) cells, containing 8%, 13% and 4%, respectively, as well as 
the 5% of MEC-treated Xpa-/- cells (p ≤ 0.01, SNK test). In addition, Ercc1-/- cells treated with 
MEC contained the highest percentage of γH2AX, with 61% of cells staining positive. This was 
significantly different from Ercc1-/- MEFs treated with CEA as well as untreated, which 
contained 13% and 33% cells positive for γH2AX foci, respectively (p ≤ 0.001, SNK test).  
Furthermore, MEC-treated Ercc1-/- MEFs were also significantly different from all treatment 
groups of WT and Xpa-/- cells, which ranged from 4-18% cells positive for γH2AX foci (p ≤ 
0.001, SNK test). Indicating that treatment with MEC significantly increases that amount of 
cellular DNA damage. 
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To test whether the observed decreased cellular proliferation of Ercc1-/- MEFs treated 
with MEC was due to cell death, the fraction of apoptotic cells was measured. Adherent and 
non-adherent cells were stained for Annexin-V and quantitated by flow cytometry. The fraction 
of apoptotic cells in Ercc1-/- MEFs treated with MEC was approximately 13% and did not 
significantly differ between treatment groups or cell types (Figure 2.2C). Interestingly, however, 
when the cells were treated with a 10-fold higher dose of CEA or MEC there was an increase in 
apoptosis in all cell types treated with CEA compared to MEC as measured by immunodetection 
of cleaved caspase-3 (Figure 2.2D). 
Senescence-associated β-galactosidase (SA β-gal) staining of p4 MEFs was used to 
measure the fraction of senescent cells. In untreated WT samples, 10% of the cells in culture 
were senescent (Figure 2.2E). After treatment with CEA, the level in WT cells remained the 
same. However, MEC induced a 2-fold increase in the amount of senescence detected in WT 
cells. In contrast, approximately 30% of Xpa-/- cells were found to be senescent regardless of 
treatment. At p4 15% of the untreated Ercc1-/- MEFs were senescent. Upon treatment with CEA, 
one quarter of the cells senesced.  However, in the absence of ICL repair, MEC was a potent 
inducer of senescence. 70% of MEC-treated Ercc1-/- cells were SA β-gal-positive compared to 
25% in the CEA-treated ERCC1-deficient MEFs. This was significantly greater than all other 
treatments and genotypes (p ≤ 0.001, SNK test). Interestingly, growth, DNA damage, apoptosis 
and senescence data of cells treated with CEA is comparable to data from untreated cells (Gregg 
et al., 2012b), which indicates that CEA is the baseline for which to measure MEC-induced 
phenotypes. These data indicate that CEA promotes cell death through apoptosis, while MEC 
promotes cellular senescence. 
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Figure 2.2: MEC, but not CEA, promotes senescence in vitro 
(A) Cellular proliferation assay to measure growth in MEFs after treatment with 0.1µM MEC and 0.16µM CEA. 
Cells were counted and an equal number of cells were plated at each passage. Red triangles represent WT, green 
triangles represent Ercc1-/-, blue squares represent Xpa-/- MEFs, light color indicates untreated cells, medium color 
indicates cells treated with CEA, and dark color indicates cells treated with MEC. (B) DNA damage of MEFs 
treated at p3 with 0.1µM MEC and 0.16µM CEA and allowed to recover one passage was assessed by γH2AX 
staining. Cells containing γH2AX foci were counted and compared back to total cell number. Values indicate the 
mean ± S.E.M. ‘†’, p ≤ 0.05; ‘§§’, p ≤ 0.01; ‘***’, p ≤ 0.001; Student Newman-Keuls test. (C) Adherent and 
non-adherent MEFs treated for 1 hour with 0.1µM MEC and 0.16µM CEA at p3 were allowed to recover to p4 and 
were stained for flow cytometry with Annexin V and propidium iodide to look for apoptosis. Values indicate the 
mean ± S.E.M. (D) Immunoblot for cleaved caspase-3 to measure apoptosis on p4 cells treated with 1µM MEC and 
1.6µM CEA at p3 and allowed to recover. Β-actin was used as a loading control. (E) p3 MEFs were treated with 
0.1µM MEC and 0.16µM CEA were allowed to recover to p4. Cells were fixed and stained for 
senescence-associated β-galactosidase (SA β-gal). The percentage of cells stained positive were counted and 
compared back to the total cell number.  Values indicate the mean ± S.E.M. ‘***’, p ≤ 0.001; Student 
Newman-Keuls test. 
10-fold  
higher 
dose 
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2.2.3 Chronic exposure of Ercc1-/Δ mice to MEC, but not CEA, accelerates the onset of 
symptoms and pathologies associated with aging 
WT, Ercc1-/Δ and Xpa-/- mice were administered 8 µg/kg MEC or CEA via subcutaneous 
injection, once a week for six weeks (Figure 2.1E). This dose was not acutely toxic, as the 
weight of the animals was not affected throughout the treatment course (Figure 2.3).  Ercc1-/Δ 
mice spontaneously develop progeroid symptoms (de Waard et al., 2010). Hence we asked if the 
onset of these symptoms from untreated mice was affected by chronic exposure to CEA or MEC. 
While the onset of progeroid symptoms were the same between untreated and CEA-treated 
Ercc1-/Δ mice, multiple symptoms of ERCC1-deficient mice treated with MEC were significantly 
accelerated (Table 2.1, p ≤ 0.05, SNK test).  The onset of ataxia, priapism and urinary 
incontinence, all symptoms associated with neurodegeneration, were accelerated, as well as 
sarcopenia (loss of muscle mass in the hind-limbs). These data suggest that inducing ICLs can 
accelerate the aging symptoms in this mouse model. 
Tissue sections from liver, kidney and brain (cerebellum) of WT Ercc1-/Δ and Xpa-/- mice 
chronically exposed to CEA and MEC were compared. At 20 weeks of age, when the tissues 
were harvested, only the Ercc1-/Δ mice were moribund. The sections were stained with 
hematoxylin and eosin and examined for aging-related degenerative changes. The liver of WT 
and Xpa-/- mice treated with CEA revealed normal hepatocellular architecture (Figure 2.4A). In 
comparison, liver sections from MEC-treated WT and Xpa-/- mice, as well as CEA-treated 
Ercc1-/Δ mice, showed evidence of early ballooning degeneration of hepatocytes, indicative of 
steatosis (Ding et al., 2010; Lackner et al., 2008). All images were taken at 20x magnification, 
demonstrating extremely large nuclei in the hepatocytes of Ercc1-/Δ mice compared to other 
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strains. However, the Ercc1-/Δ mice treated with MEC compared to CEA had dramatically more 
ballooning hepatocyte degeneration, as well as increased necrosis (Figure 2.4A). 
 
 
 
Figure 2.3: Weights of WT, Ercc1-/Δ and Xpa-/- mice treated with MEC and CEA 
Weights in grams of CEA- (medium red) and MEC treated (dark red) WT mice; CEA- (medium green) and MEC-
treated (dark green) Ercc1-/Δ mice; MEC-treated (blue) Xpa-/- mice starting at five weeks of age, three weeks before 
injections started. 
 
 
Table 2.1: Chronic exposure of Ercc1-/Δ mice to a crosslinking agent accelerates the onset of 
symptoms associated with aging 
Symptoms 
Ercc1
-/Δ 
Untreated 
Ercc1
-/Δ + 
CEA 
Ercc1
-/Δ + 
MEC 
n = 
(UT, CEA, MEC) 
Dystonia 8.6 12.5 10.7 5, 4, 6 
Trembling 8.2 10.7 9.7 6, 6, 6 
Kyphosis 11.9 13.4 13.8 6, 5, 6 
Ataxia* 14.4 15.8 11.5 6, 6, 6 
Hind limb wasting* 15.4 15.3 12.3 4, 4, 6 
Priapism** 25.7 > 24.0 20.0 2, 2, 3 
Incontinence** >25.0 > 24.0 20.3 2, 2, 3 
Significantly accelerated symptoms due to treatment of mice with MEC; ‘*’, p < 0.05; ‘**’, p < 
0.01; Student Newman-Keuls test. 
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H&E-stained kidney sections from CEA-treated WT, MEC-treated WT and CEA-treated 
Xpa-/- revealed normal renal pathology (Figure 2.4B). In comparison, kidney samples from 
MEC-treated Xpa-/- and both treatment groups of Ercc1-/Δ mice had enlarged tubular cells. In 
addition, both CEA- and MEC-treated Ercc1-/Δ mice showed increased proteinaceous hyaline 
cast formation in the renal tubules, as well as glomerulosclerosis compared to WT and Xpa-/- 
mice. However, MEC treatment of Ercc1-/Δ mice resulted in more severe glomerulosclerosis than 
CEA treatment (Figure 2.4B). Additionally, kidney functional tests revealed an elevation of urea 
nitrogen in MEC-treated Ercc1-/Δ mice, above the normal limit found in the WT blood serum 
(Figure 2.4C). This increase was significantly different from Ercc1-/Δ mice treated with CEA (p < 
0.05, Student’s t-test). Indicating that treatment with a crosslinking agent can deleteriously affect 
kidney function. 
Finally, H&E stained brains were analyzed for cerebellar changes. Analysis of WT and 
Xpa-/- cerebella revealed no change in neuropathology upon treatment with MEC or CEA (Figure 
2.4D). A decrease in the number of Purkinje cells was noted upon investigation of the Ercc1-/Δ 
brains. In order to quantify this change, nucleated Purkinje cells were counted and the ratio of 
Purkinje cell number to linear Purkinje cell layer was analyzed (Axelrad et al., 2008). There was 
no measurable difference in Purkinje cell count between untreated, CEA-treated and MEC-
treated WT and Xpa-/- mice (Figure 2.4E). However, there was a significant decrease of 
cerebellar Purkinje cells in untreated Ercc1-/Δ mice compared to all treatment groups of WT and 
Xpa-/- mice (p < 0.01, SNK test). There was no difference in the number of cells in CEA-treated 
Ercc1-/Δ mice compared to untreated. In addition, Ercc1-/Δ mice treated with MEC had a further 
reduction in Purkinje cell number compared to untreated and CEA-treated Ercc1-/Δ mice (Figure 
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2.4E; p < 0.05, SNK test). This supports the acceleration of neurodegenerative changes seen in 
these mice prior to sacrifice (Table 2.1) and indicates that ICLs promote neurodegeneration. 
 
 
Figure 2.4: Chronic exposure of Ercc1-/Δ mice to MEC accelerates the onset of symptoms and pathologies 
associated with aging 
(A) Liver and (B) kidney were stained with hematoxylin and eosin (H&E) and imaged by brightfield microscopy at 
20x magnification. (C) Blood urea nitrogen (BUN) levels were measured in the WT and Ercc1-/Δ mice treated with 
MEC or CEA. ’*’, p < 0.05 Student’s t-test. (D) Cerebella were stained with H&E and imaged by brightfield 
microscopy at 40x magnification to visualize Purkinje cells (PC). (E) To quantify PC loss, untreated, CEA- and 
MEC-treated WT, Ercc1-/Δ and Xpa-/- PCs were counted in at least ten cerebellar images for three mice per 
treatment. The cell counts were normalized to the linear PC layer. ‘*’, p ≤ 0.05 for differences between the treatment 
groups of Ercc1-/Δ mice; ‘#’, p ≤ 0.01 comparing the Ercc1-/Δ to WT  and Xpa-/- mice of all treatment groups; Student 
Newman-Keuls test. 
2.2.4 CEA promotes apoptosis in the liver and kidney 
To investigate the mechanism by which MEC induced aging-related pathology, liver and kidney 
sections from the exposed animals were subjected to TUNEL assay to measure apoptosis (Figure 
2.5A and B). Interestingly, none of the MEC-treated liver or kidney samples from WT, Ercc1-/Δ 
or Xpa-/- mice stained TUNEL-positive (Figure 2.5A). In the liver sections from CEA-treated 
mice, there were similar levels of TUNEL-positive cells between genotypes. Analysis of the 
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kidneys revealed TUNEL-positive staining in renal tubules from Ercc1-/Δ and Xpa-/- mice (Figure 
2.5B). This supports the in vitro data, which showed that high doses of CEA in culture can cause 
increased apoptotic changes (Figure 2.2D). This indicates that cell death is not driving the 
aging-related degenerative phenotype of the Ercc1-/Δ mice that is accelerated by induction of 
ICLs. 
 
Figure 2.5: CEA, but not MEC, increases apoptosis 
TUNEL staining (green) to detect apoptosis in (A) liver (40x objective) and (B) kidney (20x objective) from WT, 
Ercc1-/Δ and Xpa-/- mice treated with 8 µg/kg MEC and CEA. Nuclei were counterstained with DAPI (blue). 
 
2.2.5 Ercc1-/Δ mice show tissue-specific senescence after treatment with MEC 
Cells expressing p16 were recently demonstrated to drive aging (Baker et al., 2011). Hence a p16 
reporter was used to measure expression of this senescence marker in Ercc1-/Δ mice treated with 
MEC. Ercc1-/Δ mutant mice containing a p16-Luciferase reporter (p16Luc-reporter) were chronically 
exposed to MEC for four weeks. They were monitored weekly for p16 expression and sacrificed 
at 15 weeks (Figure 2.1F). p16Luc-reporterErcc1-/Δ mice (n = 4) did not show evidence of  p16 
expression at 14 weeks of age, when some progeroid symptoms are already evident (Table 2.1). 
However, by 20 weeks of age, p16 expression is evident in the lung and bladder regions of the 
mice (Figure 2.6A). In contrast, the 15 week-old MEC-treated p16Luc-reporterErcc1-/Δ mice, 
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displayed increased levels of luciferase signal in the lung, pancreas and bladder regions 
compared to untreated mice of similar age (Figure 2.6B). The MEC-treated animals revealed an 
acceleration of the onset of senescence by almost four weeks. This is in accord with the 
acceleration of the aging-related symptoms, ataxia, sarcopenia, priapism and incontinence, which 
were apparent more than 3 weeks earlier than those of control mice (Table 2.1). 
At 15 weeks, the animals were also sacrificed to further investigate the senescence 
pattern in the organs of MEC-treated p16Luc-reporterErcc1-/Δ mice. The luciferase reporter levels in 
the lungs, bladder and pancreas were similar to, if not higher than, tissues imaged from untreated 
18 week-old p16Luc-reporterErcc1-/Δ mice (Figure 2.7). This also supports the accelerated onset of 
the progeroid phenotype in MEC-treated Ercc1-/Δ mice (Table 2.1). Unfortunately, because of 
differential uptake of luciferin by tissues and because hemoglobin absorbs visible light which 
can mask the luciferase signal, “dark” organs, such as the liver and kidneys, were nearly 
impossible to analyze by this method (Berger et al., 2008; Carlsen et al., 2002). 
 
 
Figure 2.6: Treatment with MEC revealed tissue-specific senescence in Ercc1-/Δ mice 
(A) Untreated p16Luc-reporterErcc1-/Δ mice at 14, 17 and 20 weeks of age, represent the natural progression of 
senescence in ERCC1-deficient mice (n ≥ 3 at each timepoint). (B) p16Luc-reporterErcc1-/Δ mice were administered 
subcutaneous injections of 8 ug/mg MEC for 4 weeks (n = 3). At 15 weeks of age, the mice were injected with 
luciferin and imaged. 
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Figure 2.7: Post-mortem tissue-specific senescence in Ercc1-/Δ mice treated with MEC 
Mice were injected with luciferin and tissues harvested 15 minutes later to image organs. (A) Representative image 
of organs from an untreated p16Luc-reporterErcc1-/Δ mouse at 18 weeks of age. The lungs, bladder and pancreas 
luminesce. (B) Representative image of organs from a MEC-treated p16Luc-reporterErcc1-/Δ mouse at15 weeks of age. 
Luminesce is apparent in the lungs, bladder and pancreas. 
2.2.6 MEC treatment of Ercc1-/Δ mice increases neurodegeneration 
To investigate the acceleration of the neurodegenerative phenotype of the Ercc1-/Δ mice by 
treatment with MEC, cerebellar sections were stained by TUNEL assay to label apoptotic cells 
(Figure 2.8A). There was no evidence of increased apoptosis in the brains of WT or Xpa-/- mice 
regardless of the treatment.  However, TUNEL-positive neurons were present in the cerebella of 
Ercc1-/Δ mice.  As seen in the liver and kidney (Figure 2.5A and B), there was increased 
apoptosis in the CEA-treated Ercc1-/Δ mice compared to MEC treatment (Figure 2.8A).  
To further investigate the neurodegenerative symptoms that were accelerated by MEC 
treatment (Table 2.1), the cerebella from the MEC- and CEA-treated mice were stained with 
Fluoro-Jade® B, a fluorescein derivative that preferentially binds to degenerating neurons. WT, 
 47 
Ercc1-/Δ and Xpa-/- mice treated with MEC did not reveal FluoroJade®-positive neurons (Figure 
2.8B).  However, CEA-treated cerebellar sections of all three genotypes showed increased 
staining, indicative of neurodegeneration. In fact, Xpa-/- mice treated with CEA had the highest 
level of degenerating neurons, as measured by Fluoro-Jade® B (Figure 2.8B). This could 
indicate that the timepoint of 20 weeks old, when we sacrificed the mice to look at 
histopathologic changes is too late to visualize the accelerated neurodegenerative phenotype. The 
symptoms assessed when they were alive presented themselves almost four weeks earlier than 
those of untreated and CEA-treated Ercc1-/Δ mice (Table 2.1). Therefore an earlier timepoint may 
be necessary to investigate the neurodegenerative changes induced by DNA ICLs. 
Finally, the Ercc1-/Δ brain sections were also stained with a glial fibrillary acidic protein 
(GFAP) antibody to identify gliosis, another marker of neurodeneration (Figure 2.8C). There was 
staining in the cerebellum of CEA-treated Ercc1-/Δ mice. The staining was increased in the 
Ercc1-/Δ mice treated with MEC. 
 
Figure 2.8: MEC treatment of Ercc1-/Δ mice increases neurodegeneration 
(A) TUNEL staining (green) of cerebellar sections (40x magnification) from MEC and CEA treated WT, Ercc1-/Δ 
and Xpa-/- mice. Nuclei were counterstained with DAPI (blue). (B) Cerebellar sections of mice treated with CEA as 
stained by Fluoro-Jade B®, a stain that preferentially binds to degenerating neurons (40x magnification). (C) 
Immunohistochemical detection of glial fibrillary acidic protein (GFAP) antibody in cerebella from Ercc1-/Δ mice 
after treatment with MEC and CEA (40x magnification). Nuclei were counterstained with hematoxylin. 
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2.3 DISCUSSION 
Accumulation of DNA damage is one contributor to aging. Because of the fact that mutations in 
DNA repair genes result in premature aging of tissues, DNA damage is implicated as a 
contributor to the aging process (Hasty et al., 2003b). However, the type of nuclear damage and 
mechanism by which this occurs is unknown. Herein, we utilize two murine models of human 
diseases, one of xeroderma pigmentosum and the other of XFE progeroid syndrome, to analyze 
the response to DNA damage and assess their effect on the aging process. 
 Furthermore, because early clinical chemotherapy trials were started in the late 1970s and 
early 1980s, long-term toxicity has since been assessed in cancer survivors (Maccormick, 2006). 
These patients have suffered from a number of health problems that are typically associated with 
advanced age, including neurodegenerative, musculoskeletal and osteoporotic symptoms, as well 
as skin changes and fatigue. Therefore, chemotherapies have been identified as a possible source 
of premature aging in long-term cancer survivors (Grillari et al., 2007; Maccormick, 2006). 
Consequently, identifying the causes of aging and strategies to ameliorate the diseases, while 
preserving tissue homeostasis, is a pressing healthcare issue, not only for cancer survivors, but 
the population as a whole. 
 Mechlorethamine was the first chemotherapeutic agent to be developed at Yale 
University during World War II and is still in use today to treat multiple myeloma and ovarian 
cancer (2012a; Christakis, 2011; Gilman, 1963). Despite previous studies indicating that DNA 
interstrand crosslinks are cytotoxic to tumor cells (Geleziunas et al., 1991; Hansson et al., 1987; 
Ross et al., 1978), little is known about the mechanism by which ICLs induce premature aging 
side effects seen in chemotherapeutic patients. Herein we describe the method by which the 
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DNA interstrand crosslink-inducing nitrogen mustard, mechlorethamine, contributes to age-
related degeneration. 
 Interestingly, our in vitro data indicate that MEC, but not CEA, treatment of ICL 
repair-deficient MEFs results in severe growth arrest (Figure 2.2A). This dramatic reduction in 
proliferating cells is not a result of cell death, but rather a result of high levels of senescence in 
cells unable to repair the DNA interstrand crosslinks (Figure 2.2B-E). In fact, cells deficient in 
the nucleotide excision repair pathway alone (i.e., Xpa-/-), which are able to repair ICLs and do 
not exhibit signs of premature aging, show no difference between treatment with MEC compared 
to CEA (Figure 2.2). 
 We further demonstrate that MEC-induced DNA interstrand crosslinks accelerate the 
aging phenotype of our progeroid mice (Table 2.1). Because ERCC1 deficiency leads to 
exquisite sensitization to DNA ICLs (Niedernhofer et al., 2006), we were able to treat mice with 
a low dose of MEC to investigate the effects this crosslinking agent has on the aging phenotype 
of these mice. Specifically there were significant changes in ataxia, priapism and incontinence, 
signs of neurodegeneration, as well as hind-limb wasting, a musculoskeletal symptom. These 
data fit with the aging symptoms seen in long-term cancer survivors (Grillari et al., 2007; 
Maccormick, 2006). We also demonstrate that after treatment with MEC the liver, kidney and 
brain of ICL repair-deficient mice show signs of impaired function (Figure 2.4). In addition we 
establish that this in vivo accelerated aging occurs as a result of senescence and not apoptosis 
(Figure 2.5 and Figure 2.6). These data strongly support the conclusion that DNA interstrand 
crosslinks promote aging through a cytostatic, rather than a cytotoxic method. 
 In conclusion, individual cells undergo senescence after treatment with MEC, both in 
vitro and in vivo. We found no evidence of increased apoptosis or cytotoxicity, as was previously 
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described (Grillari et al., 2007). We did however, find evidence that 2-chloroethylamine, a 
monoadducting chemical, can induce apoptosis in vitro and in vivo (Figure 2.2, Figure 2.5 and 
Figure 2.8), perhaps through an error-prone mutagenic DNA repair pathway (Wijen et al., 2000). 
Additionally, the MEC-treated cells and tissues exhibited a high level of senescence (Figure 2.2 
and Figure 2.6), which may induce the senescence-associated secretory phenotype (SASP) 
(Rodier et al., 2009). This signaling further propagates senescence in surrounding cells leading to 
tissue dysfunction and organismal aging. Therefore, strategies must be developed to diminish the 
aging-related side effects that long-term cancer survivors experience by preventing senescence in 
otherwise healthy tissue. 
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2.4 METHODS 
2.4.1 Cell Culture 
Mouse embryonic fibroblasts (MEFs) were isolated at pre-natal day 15 from heterozygous 
C57Bl/6 mice bred to yield wild-type (WT), Ercc1-/-, and Xpa-/- as previously described (Ahmad 
et al., 2008; Niedernhofer et al., 2006). Cells were cultured in a 1:1 mixture of Dulbecco’s 
modified Eagle medium and Ham’s F-10 supplemented with 10% fetal bovine serum, 1% non-
essential amino acids and 1% penicillin and streptomycin.  MEFs were incubated in MEC (0.1 
μM) and CEA (0.16 μM) for 1h in serum-free medium, with a minimum recovery period of 24h.  
To assay proliferation, 250,000 cells were plated and quantified using an automated cell counter 
(Millipore, Billerica, MA) as previously described (Ahmad et al., 2008). Experiments were 
repeated using three independent cell lines. 
2.4.2 Detection of apoptotic cells by flow cytometry 
WT, Ercc1-/-, and Xpa-/- MEFs treated with MEC or CEA (as described above) and trypsinized at 
confluence.  1 million cells from each treatment group were washed in PBS and stained for 
apoptosis markers FITC Annexin V and Propidium Iodide (BD Pharmingen, Franklin Lakes, NJ) 
according to manufacturer’s instructions. Apoptotic cells were measured on a Beckman Coulter 
(Cytomation) CyAN 9-Color High Speed Analyzer (Beckman Coulter, Inc., Brea, CA) and 
quatified using Summit v.4.3 software. 
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2.4.3 In vitro detection of senescent cells 
Nitrogen mustard-treated cells were plated on glass coverslips and fixed in 2% paraformaldehyde 
+ 0.25% glutaraldehyde in PBS for 10 minutes. Senescence-associated β-galactosidase (SA 
β-gal) staining was performed as previously described (Debacq-Chainiaux et al., 2009; Dimri et 
al., 1995). Nuclei were counterstained with DAPI, and senescent cells were imaged using an 
Olympus BX51 fluorescent microscope (Olympus America Inc., Center Valley, PA) at 40X 
magnification. Mean percentages of SA β-gal positive cells were graphed ± S.E.M. 
2.4.4 In vitro immunohistochemistry 
MEC- or CEA-treated MEFs were grown on glass coverslips to 50-60% confluency.  Cells were 
fixed in 2% paraformmaldehyde + 0.25% glutaraldehyde in PBS and permeabilized with 0.2% 
Triton X-100 solution. Immunofluorescence was performed for γH2AX following 45min block 
in 2% bovine serum albumin (BSA).  Primary antibody for γH2AX (clone JBW 301, Millipore, 
Billerica, MA) was applied overnight at 4°C at a 1:500 dilution. Secondary antibody was applied 
for 1h at room temperature. Nuclei were counterstained with DAPI, and fluorescent images were 
taken using an Olympus BX51 fluorescence microscope at 20X magnification. Mean percentages 
of cells containing γH2AX foci were plotted ± S.E.M. 
2.4.5 Immunoblotting 
MEC- or CEA-treated WT, Ercc1-/-, and Xpa-/- MEFs were trypsinized, pelleted and resuspended 
in ice cold NETT buffer (100mM NaCl, 50mM Tris pH 7.5, 5mM EDTA pH 8.0, 0.5% Triton-
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X) containing Protease Inhibitor Cocktail Set III (Calbiochem, Gibbstown, NJ). 50µg samples 
were boiled for 10min in 4X loading buffer (0.25mol/L Tris-HCl (pH 8.5), 8% SDS, 1.6mmol/L 
EDTA, 0.1mol/L DTT, 0.04% bromophenol blue, 40% glycerol) and separated via SDS-PAGE 
on a 4-20% Mini-PROTEAN gradient gel (Bio-Rad, Hercules, CA).  Protein was transferred to a 
nitrocellulose membrane.  Primary antibody for cleaved caspase-3 (clone 9664, Cell Signaling 
Technology, Beverly, MA) was applied overnight at 4°C at a 1:1000 dilution. This was followed 
by a 1:1000 dilution of HRP-conjugated goat anti-rabbit IgG (Promega, Madison, WI) for 1h at 
room temperature.  Blots were developed and imaged using Alpha Innotech Red gel imaging 
system. 
2.4.6 Mice 
Ercc1-/Δ mice were generated in an f1 hybrid background by crossing Ercc1+/- and Ercc1+/Δ from 
inbred C57Bl/6 and FVB/n backgrounds, respectively. The mice were genotyped by PCR as 
previously described (Ahmad et al., 2008).  p16Luc-reporterErcc1-/Δ were generated by crossing 
p16Luc-reporter with Ercc1+/- C57Bl/6 mice. These were then bred with Ercc1+/Δ FVB/n mice to 
generate p16Luc-reporterErcc1-/Δ mice in an f1 hybrid background. The mice were genotyped by 
PCR using the following primers to amplify the WT and p16Luc-reporter alleles using the forward 
primer: 5'-CTA TGG CGG GCT GTG GAG and 2 reverse primers: 5'-CAC GGT AGG CTG 
CGA AAT G and 5'-TGG GAC ACT CCT TGC CTA CC. The resulting PCR products were 312 
bp for the WT allele and 543 bp for the p16Luc-reporter allele. 
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2.4.7 Treatment of mice with nitrogen mustards 
WT, Ercc1-/Δ, and Xpa-/- were injected subcutaneously with 8 µg/kg of either MEC or CEA 
dissolved in sunflower seed oil from Helianthus annuus (Sigma-Aldrich, St. Louis, MO).  Mice 
were treated once a week for six weeks starting at eight weeks of age. They were monitored 
daily, with weights taken once a week and symptom development noted twice a week.  Tissues 
were collected at 20 weeks of age for analysis. 
2.4.8 Histochemistry 
Liver, kidney and brain were fixed overnight in 10% formalin, embedded in paraffin and 
sectioned using a microtome by standard procedures. Hematoxylin and eosin (H&E) was done 
according to standard procedures. Liver, kidney and brain sections were also permeablized with 
0.1% Triton X-100 + 0.1% sodium citrate and stained using an In Situ Cell Death Detection Kit, 
Fluorescein (Roche Applied Science, Indianapolis, IN) according to manufacturer’s instructions 
to label apoptotic cells. Nuclei were counter-stained with DAPI. Apoptotic-positive cells were 
imaged on an Olympus BX51 fluorescent 4 microscope (Olympus America Inc., Center Valley, 
PA). 
2.4.9 In vivo senescence detection 
p16Luc-reporter and p16Luc-reporterErcc1-/Δ mice were injected with MEC starting at 10 weeks of age 
and lasting four weeks. Mice were injected with 300 mg/kg of Luciferin (Gold Biotechnologies, 
St. Louis, MO) 15min prior to imaging.  Animals were anesthetized with isoflurane and 
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luciferase intensity was measured using an IVIS 200 imaging system (Caliper Life Sciences, 
Hopkinton, MA). Mice were imaged weekly for onset of premature senescence and sacrificed 
one week after the completion of injections. 
2.4.10 Purkinje cell counts 
H&E stained cerebellar sections were imaged on an Olympus BX51 fluorescence microscope 
(Olympus America Inc., Center Valley, PA) at 40x magnification. Purkinje cells were counted as 
previously described (Axelrad et al., 2008). Briefly, nucleated Purkinje cells were counted and 
normalized to linear Purkinje cell layer which was measured using SPOT software (v.4.6, 
Diagnostic Instruments, Inc., Sterling Heights, MI). This ratio was obtained from at least 10 non-
overlapping random fields of view from three mice per treatment group. 
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3.1 INTRODUCTION 
Aging is accompanied by a universal and progressive decline in the function of tissues, leading 
to a decreased ability to maintain homeostasis under stress; therefore, a dramatically increased 
risk of morbidity and mortality (Kirkwood, 2005). These inevitable changes are thought to arise 
as a direct or indirect consequence of cellular damage, which accumulates over time. One of the 
main sources of endogenous damage is reactive oxygen species (ROS), which form the basis of 
the free radical theory of aging (Harman, 1956).  Within cells, mitochondria are the main source 
of ROS, and some ROS can diffuse throughout the cell, resulting in oxidative damage to lipids, 
proteins, RNA and DNA (Chakravarti and Chakravarti, 2007; Cooke et al., 2003; Cui et al., 
2012; Mandavilli et al., 2002). DNA lesions caused by ROS include oxidized bases, abasic sites, 
single-strand breaks and lipid peroxidation-induced adducts including interstrand crosslinks 
(Maynard et al., 2009; Niedernhofer et al., 2003). Thus, mitochondrial dysfunction, which leads 
to an increase in ROS production, has been hypothesized to be central to the aging process (Cui 
et al., 2012). Though there is extensive evidence to support ROS as a driver of aging in lower 
eukaryotes, it remains highly controversial in mammals (Muller et al., 2007). Critically 
evaluating whether mitochondrial-generated ROS play a causal role in aging is, therefore, 
important for devising strategies to prevent or delay age-related degenerative diseases. 
ERCC1-XPF is a structure-specific endonuclease required for nucleotide excision repair, 
interstrand crosslink repair and the repair of some double-strand breaks in the nuclear genome 
(Ahmad et al., 2008; Niedernhofer et al., 2004; Sijbers et al., 1996a). In humans, reduced 
expression of ERCC1-XPF causes a severe progeroid syndrome or disease of accelerated aging. 
This affects the endocrine, epidermal, hematopoietic, hepatobiliary, musculoskeletal, neurologic 
and renal systems (Niedernhofer et al., 2006). Ercc1-/Δ mice model this progeroid syndrome and 
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spontaneously develop progressive degenerative changes that mimic those seen in aged humans 
(de Waard et al., 2010; Goss et al., 2011; Gregg et al., 2012a; Vo et al., 2010). The mice are 
asymptomatic during development, only showing aging-related symptoms after reaching 
adulthood (2 months of age) and have a maximum lifespan of 7 months (de Waard et al., 2010). 
These mice, therefore, offer a sensitive model for investigating endogenous sources of damage 
that may drive aging.  
To investigate the hypothesis that mitochondrial-derived ROS play a causal role in aging, 
Ercc1-/Δ mice were chronically treated with the mitochondrial-targeted ROS scavenger XJB-5-
131 (XJB).  Treatment with XJB was intended to reduce ROS before they could damage the 
nuclear genome. XJB has previously been shown to prolong survival in rat models of ischemia, a 
type of inflammatory oxidative stress (Macias et al., 2007). XJB caused a significant reduction in 
oxidative DNA damage and a significant delay in the onset of aging symptoms and pathologies 
in the Ercc1-/Δ mice. This provides strong experimental evidence that oxidative damage caused 
by mitochondrial-derived ROS drives aging and that targeted anti-oxidants can be used 
therapeutically to attenuate damage and extend healthspan. 
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3.2 RESULTS 
3.2.1 XJB-5-131 concentrates in mitochondria 
4-Hydroxy-2,2,6,6,-tetramethyl piperidine-1-oxyl (TEMPOL) is a stable nitroxide radical that 
acts as a superoxide dismutase mimetic (Goldstein et al., 2003; Krishna et al., 1996), which 
converts superoxide radical anion to oxygen and hydrogen peroxide. The intermediate 
hydroxylamine, which is also generated from nitroxide radical and biological reductants can act 
itself as a scavenger of ROS, in particular of the highly reactive hydroxyl radical, and cycle back 
and forth between nitroxide, nitroxonium cation, and hydroxylamine forms (Charloux et al., 
1995; Fink et al., 2007; Mitchell et al., 2000). TEMPOL was conjugated to a fragment of the 
antibiotic gramicidin S, to create XJB-5-131 (XJB) (Figure 3.1A) (Goldstein et al., 2003; Wipf et 
al., 2005). The gramicidin S fragment is intended to target the radical scavenger to the 
mitochondrial membrane (Frantz and Wipf, 2010; Jiang et al., 2007; Kagan et al., 2009). To test 
if this was the case, a fluorescently-labeled version of XJB was synthesized by conjugation to the 
dye, BODIPY-FL. This agent was added to monolayers of primary mouse embryonic fibroblasts, 
and the fluorescent signal was monitored every 3 min using confocal, live cell imaging. 
Beginning at 1.5 h post-addition of BODIPY-FL-XJB-5-131 to the culture media, a peri-nuclear 
punctuate pattern of fluorescence signal was observed (Figure 3.1B).  The BODIPY-FL signal 
co-localized with MitoTracker®, indicating that XJB was concentrated in the mitochondria.  
Three hours after addition of BODIPY-FL-XJB-5-131, the signal was unchanged, suggesting 
that XJB stably associates with mitochondria. 
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Figure 3.1: XJB-5-131 is a nitroxide radical scavenger conjugated to a mitochondrial-targeting 
moiety derived from gramicidin S 
(A) Structure of XJB-5-131. (B) XJB-5-131 was covalently labeled with BODIPY-FL (green) to enable tracking its 
subcellular localization. It was added to primary mouse embryonic fibroblasts grown on MatTek glass bottom plates 
with MitoTracker® (red) to identify mitochondria. The cells were monitored by live cell imaging for 3 h. Shown is 
an image from 1.5 h post-addition of the fluorescently tagged XJB to the culture medium. 
 
3.2.2 XJB-5-131 extends the healthspan of Ercc1-/Δ mice 
To determine if the mitochondrial-targeted radical scavenger ameliorates signs of premature 
aging in Ercc1-/Δ mice, the animals were treated with 2 mg/kg XJB, three times per week, by 
intraperitoneal injection, starting at five weeks of age (Figure 3.2A). Alternatively, control 
Ercc1-/Δ mice were treated with vehicle only (sunflower seed oil). Importantly, there was no 
difference in the weights of the animals between the two treatment groups throughout the study, 
indicating that there is no toxicity associated with chronic treatment with XJB (Figure 3.3). The 
animals were monitored daily for the onset of their progeroid symptoms, by an investigator 
blinded as to treatment groups. The mice treated with XJB exhibited a significant delay in the 
onset of aging-related symptoms, in particular those associated with neurodegeneration (dystonia 
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and ataxia), as well as kyphosis, lethargy (or reduced spontaneous activity) and hind-limb muscle 
wasting (Table 3.1 and Figure 3.2B). The majority of the mice were treated in a pair-wise 
fashion, in which littermate Ercc1-/Δ mice housed together were treated with XJB or vehicle only, 
to remove genetic and environmental variables. The ages at onset of symptoms were compared 
between these eight littermate pairs to determine the percent of symptoms delayed in the XJB 
treatment group, as a measure of healthspan. Sixty-six percent of symptoms assessed in live 
animals were significantly delayed in the Ercc1-/Δ mice treated with XJB compared to their 
littermates treated with vehicle only (Table 3.1). 
 
Figure 3.2: Progeroid DNA repair-deficient mice treated with XJB are healthier than littermate 
animals treated with vehicle only 
(A) Treatment scheme for Ercc1-/Δ mice. Littermate pairs were injected with either vehicle (sunflower seed oil) or 2 
mg/kg XJB in a blinded fashion, three times per week, intraperitoneally starting at five weeks and lasting until 20 
weeks of age. (B) Photographs of a 20 week-old Ercc1-/Δ littermate pair treated with either XJB or vehicle only. 
Shown are examples of hind-limb wasting (1) and ataxia (2) in mice treated with vehicle only. 
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Figure 3.3: Weights of Ercc1-/Δ mice 
Weights in grams of untreated (green), vehicle- (red), and XJB-treated (blue) Ercc1-/Δ mice starting at five weeks of 
age, when treatment began, and lasting until 22 weeks of age, when the last mice were sacrificed. 
 
 
 
Table 3.1: XJB delays the onset of age-related degeneration 
 
AErcc1-/Δ + Vehicle: n = 8; 5 males, 3 females; 
BErcc1-/Δ + XJB: n = 10; 6 males, 4 females; 
CSymptoms that are significantly delayed after treatment with XJB; p ≤ 0.05, one-tailed Student’s t-test. 
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3.2.3 XJB delays the onset of multiple age-related degenerative symptoms 
The mice in both treatment groups were euthanized at 20 weeks of age in order to compare 
histopathology between them. At this age, the livers of Ercc1-/Δ mice display significant levels of 
necrosis, apoptosis and ballooning degeneration of hepatocytes (Ding et al., 2010; Lackner et al., 
2008). Both necrosis and ballooning degeneration were reduced in the liver of Ercc1-/Δ mice 
treated with XJB compared to those treated with vehicle only (Figure 3.4A).  
Apoptosis and hyaline cast formation occurs in the renal tubules as a result of advanced 
age (Gregg et al., 2012a; Silva, 2005). In the kidneys of Ercc1-/Δ mice, by 20 weeks of age, there 
was evidence of extensive loss of renal tubule epithelial cells and hyaline casts (Figure 3.4B). In 
mice chronically treated with XJB, tissue architecture was preserved and casts were reduced 
(Figure 3.4B).  
The brains of XJB-treated mice were stained with an antibody against glial fibrillary 
acidic protein (GFAP), a marker of neurodegeneration (Qin and Crews, 2012).  GFAP staining in 
the cerebellum of Ercc1-/Δ mice was greatly reduced in XJB-treated animals compared to those 
that received vehicle only (Figure 3.4C). This data is consistent with the delay of 
neurodegenerative symptoms, ataxia and dystonia, in animals treated with XJB (Table 3.1). 
XJB treatment also delayed the loss of pancreatic islets in Ercc1-/Δ mice (Figure 3.4D). 
Furthermore, microcomputed tomography of the spine revealed that osteoporotic changes were 
reduced in Ercc1-/Δ mice treated with XJB versus vehicle only (Figure 3.4E). This correlated 
with a significant increase in the thickness of the trabecular bone (Figure 3.5) and a significant 
delay in onset of kyphosis (Table 3.1). 
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Figure 3.4: Delay in onset of age-related degenerative diseases in Ercc1-/Δ tissues after treatment with XJB 
(A) Liver and (B) kidney sections from vehicle- or XJB-treated Ercc1-/Δ mice were stained with H&E to visualize 
histopathologic changes. (C) An antibody against glial fibrillary acidic protein (GFAP, brown) was used to visualize 
neurodegeneration in the cerebellum of vehicle- or XJB-treated Ercc1-/Δ mice. Nuclei were counter-stained with 
hematoxylin. (D) H&E stained pancreas sections to visualize beta-islet cells. (E) µCT analysis of vertebrae from 
Ercc1-/Δ mice treated with vehicle or XJB to detect osteoporotic pore formation. 
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Figure 3.5: Osteoporotic changes in Ercc1-/Δ mice 
Trabecular thickness of the vertebrae of Ercc1-/Δ mice treated with either vehicle or XJB. ‘*’, p = 0.04, one-tailed 
Student’s t-test. The values represent the mean ± standard error of the mean obtained from three mice per group. 
3.2.4 XJB reduces oxidative DNA damage 
Accelerated aging in DNA repair-deficient Ercc1-/Δ mice presumably arises as a consequence of 
failure to repair DNA damage (Wang et al., 2012). Accordingly, oxidative DNA damage should 
be reduced in XJB-treated mice with delayed aging phenotypes. To test this hypothesis, we 
measured cyclopurine adducts, which are spontaneous, endogenous oxidative lesions normally 
repaired by nucleotide excision repair (Brooks et al., 2000; Romieu et al., 1999). Cyclopurines 
are formed when a hydroxyl radical attacks guanine or adenine residues. XJB-5-131 scavenges 
hydroxyl radicals (Brooks, 2007; Charloux et al., 1995). Both diastereomers of 
cyclodeoxyadenine (cdA) and cyclodeoxyguanine (cdG) were measured in nuclear DNA isolated 
from livers of Ercc1-/Δ mice chronically treated with XJB or vehicle only. The level of all four 
oxidative lesions ranged on the order of 1-2 per 106 nucleosides in liver of mice treated with the 
vehicle only (Figure 3.6). The level of all four cyclopurine adducts was significantly lower (at 
least 3-fold) in mice treated with XJB. This demonstrates a strong correlation between DNA 
damage levels and the onset of aging-related degenerative changes. It also demonstrates that a 
mitochondrial-targeted radical scavenger can significantly reduce oxidative DNA damage in the 
nucleus. 
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Figure 3.6: Amelioration of oxidative DNA damage in the liver of ERCC1-deficient mice treated with XJB 
The levels of the (5′R)- and (5′S)-diastereomers of 8,5′-cyclo-2′-deoxyguanosine (cdG) and 
8,5′-cyclo-2′deoxyadenosine (cdA) in nuclear DNA isolated from the livers of 20 week-old vehicle- and XJB-treated 
Ercc1-/Δ mice. ‘*’, p < 0.05; ‘**’, p < 0.01. The p-values were calculated using two-tailed Student’s t-test. The 
values represent the mean ± standard error of results obtained from DNA of three mice per group. 
 
3.2.5 XJB attenuates cellular senescence and apoptosis 
Loss of functional cells either through senescence or apoptosis promotes aging (Baker et al., 
2011). Therefore, we next asked if XJB attenuates cellular senescence and/or apoptosis in tissues 
where histopathology was improved (Figure 3.4). Senescence-associated β-galactosidase 
activity, a marker of cell senescence, was dramatically reduced in the liver of Ercc1-/Δ mice 
chronically treated with XJB, compared to littermate mutant mice that received vehicle only 
(Figure 3.7A). Liver, kidney and cerebellar sections were also stained with an antibody that 
recognizes cleaved caspase-3 to measure apoptosis (Figure 3.7B-D). In the liver, no apoptotic 
signal was detected in any animals (Figure 3.7B). In the kidney, there was intense staining of the 
collecting ducts in the inner medulla / pyramid area indicative of apoptotic cells in Ercc1-/Δ mice 
treated with vehicle only (Figure 3.7C). This pathology was significantly attenuated in mice 
treated with XJB. Numerous apoptotic cells were also observed scattered throughout the 
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cerebellum of Ercc1-/Δ mice treated with vehicle only (Figure 3.7D). Fewer apoptotic cells were 
detected in the cerebellum of Ercc1-/Δ mice treated with XJB. 
 
 
 
 
Figure 3.7: Delayed loss of functional tissue in Ercc1-/Δ mice after treatment with XJB 
(A) Senescence-associated β-galactosidase (SA β-gal) staining of fixed-frozen liver sections from vehicle- or 
XJB-treated Ercc1-/Δ mice. Immunofluorescence detection of α-cleaved caspase-3 in (B) liver, (C) kidney and (D) 
cerebellum of Ercc1-/Δ mice treated with vehicle or XJB. 
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3.3 DISCUSSION 
In the mid 1950’s, Harman proposed the free radical theory of aging which posits that much of 
the “spontaneous” or endogenous damage that drives aging is a direct consequence of highly 
reactive free radicals generated during normal metabolism (Harman, 1956, 1992a, b). This was 
modified to include mitochondria when it was realized that these organelles are the major source 
of free radicals and ROS in most cells (Chance et al., 1979). Thus, decline of mitochondrial 
function, and a subsequent increase in ROS, is envisioned to be a chief contributor of oxidative 
stress associated with a broad spectrum of diseases associated with aging (Van Houten et al., 
2006). If mitochondrial dysfunction and ROS production is important for aging, then it might be 
expected that increasing or decreasing mitochondrial oxidant defenses should affect the 
healthspan and/or lifespan of an organism (Harper, 2008).  Despite clear evidence that disrupting 
the vicious cycle of mitochondrial dysfunction and increased ROS production in lower 
organisms extends healthspan and lifespan (Muller et al., 2007), the evidence for a similar effect 
in mammals remains equivocal (Jang and Remmen, 2009; Salmon et al., 2010). 
 To test the free radical theory of aging, we chronically treated Ercc1-/Δ mice with a 
mitochondrial-targeted radical scavenger XJB-5-131. Ercc1-/Δ mice are defective in nucleotide 
excision repair and interstrand crosslink repair (de Waard et al., 2010; Niedernhofer et al., 2006; 
Niedernhofer et al., 2004), both of which are implicated in protecting against DNA damage 
induced by oxidative stress (Niedernhofer et al., 2003; Wang, 2008).  Chronic XJB treatment led 
to significant reduction in the levels of cyclopurine adducts, DNA lesions caused by ROS, in the 
nuclear genome (Figure 3.6). These data support previous evidence that mitochondrial ROS 
promotes nuclear DNA damage (Van Remmen et al., 2003). The data also reveal a method by 
which to attenuate oxidative DNA damage in the nucleus. This is important because the 
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cyclopurine adducts measured were recently shown to accumulate in the liver, kidney and brain 
of wild-type mice as they age (Wang et al., 2012). These lesions may contribute to aging or be a 
biomarker of it as Ercc1-/Δ mice, which age rapidly, compared to wild-type littermates (Wang et 
al., 2012). 
 Chronic treatment of Ercc1-/Δ mice with XJB also reduced degenerative changes in the 
liver and kidney parenchyma (Figure 3.7). It also delayed the loss of insulin-producing cells in 
the pancreas, as well as histopathologic signs of neurodegeneration and osteoporosis. This was 
accompanied by a significant delay in the majority of progeroid symptoms in mice treated with 
XJB compared to mutant sibling animals treated with vehicle only (Table 3.1). This includes 
kyphosis (hunched posture), ataxia (unsteady gait), proximal muscle wasting, and reduced 
spontaneous activity. These changes are all characteristic of old age in humans as well (de Waard 
et al., 2010; Ding et al., 2010; Gregg et al., 2012a; Lackner et al., 2008; Silva, 2005). The fact 
that XJB treatment led to improvement in multiple tissues, delayed the onset of several aging-
related chronic degenerative diseases and improved organism function strongly argues that XJB 
delays aging per se in Ercc1-/Δ mice. The data therefore provide novel evidence to support the 
free radical theory of aging and the concept that mitochondrial ROS promote aging. 
 Numerous studies have examined the effect of other anti-oxidants for treating aging-
related diseases. Vitamin C is marketed as an oral and topical antioxidant. It was tested in several 
clinical trials for its ability to prevent cardiovascular disease, yielding no clear positive results 
(Wojcik et al., 2010). Importantly, Vitamin C, can also act as a pro-oxidant that promotes 
oxidative DNA damage (Podmore et al., 1998). Vitamin E appears to be efficacious in 
Alzheimer’s disease and for reducing risk of atherosclerosis, but only in a subset of patients at 
high risk (Behl, 1999; Robinson et al., 2006). However, meta-analyses of multiple clinical trials 
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reveal that both vitamins C and E can increase risk of mortality (Miller et al., 2005; 
Vivekananthan et al., 2003).  The lack of a clear beneficial effect may be due to the fact that in 
some tissues, cell types or subcellular domains these anti-oxidants become pro-oxidant. 
Alternatively, it may because without targeting them to sites of non-enzymatic production of 
deleterious ROS, ROS required for essential signaling pathways are also reduced (Bae et al., 
2011). XJB-5-131 bypasses both of these potential problems. 
 Coenzyme Q and vitamin E have both been targeted to the mitochondria by use of 
mitochrondrial membrane potential, i.e., MitoQ (mitochondrial-targeted coenzyme Q) and 
MitoVitE (mitochondrial-targeted vitamin E). When applied to mitochondria, MitoVitE 
decreases lipid peroxidation and protein damage (Smith et al., 1999), while MitoQ decreases 
lipid peroxidation and apoptosis when used to treat cells (Kelso et al., 2001). In a rodent model 
of Parkinson’s disease, MitoQ preserved motor function, but in clinical trials it had no effect on 
disease progression yet caused nausea and vomiting (Snow et al., 2010). MitoQ improved liver 
function in hepatitis C patients, suggesting it can attenuate tissue-specific inflammation (Gane et 
al., 2010). This has led to additional clinical trials for a variety of human pathologies, currently 
underway (Smith et al., 2011). Importantly, both MitoQ and MitoVitE are positively charged and 
can cause mitochondrial depolarization at high doses, which might cause poor long term 
tolerance (Kelso et al., 2001; Smith et al., 1999). In contrast, XJB is neutral. 
 TEMPOL, the reactive portion of XJB, attenuates damage in a number of aging-related 
pathologies in rodent models including hypertension, ischemia, neurodegeneration and chronic 
inflammation (Wilcox, 2010). In addition, chronic treatment with TEMPOL significantly extends 
the lifespan of Drosophila and mice (Wilcox, 2010). However, weight loss has been found as a 
consequence of long-term TEMPOL administration (Soule et al., 2007).  Additionally, its use in 
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rats induced systemic hypotension (Rashid et al., 2011). Therefore, clinical trials of TEMPOL 
have been limited to topical application to treat alopecia associated with radiotherapy for brain 
cancer (Metz et al., 2004).  We observed no side-effects as a consequence of chronic treatment 
with XJB, supported by the fact that the weight of mice treated with XJB, is identical to that of 
mice given vehicle only (Figure 3.3). 
 What may set XJB apart from previous anti-oxidants directed to the mitochondria is that 
it is targeted by a neutral gramicidin S analog, while other mitochondrial-targeted compounds 
rely on plasma membrane potential to drive uptake (Smith et al., 1999). Therefore, XJB has the 
unique ability to target damaged mitochondria, which have lost membrane potential and have the 
greatest likelihood of producing excess ROS. In addition, the nitroxide radical moiety of XJB 
can oscillate between different redox states and adapt itself to the local environment during the 
process of reducing oxidative stress (Fink et al., 2007). Finally, XJB recycles and therefore, can 
remain active while at the mitochondrial membrane (Figure 3.1), which is advantageous over 
stoichiometric anti-oxidants. Based on our results, XJB represents a lead agent in a novel class of 
anti-oxidants with apparent efficacy for delaying symptoms and pathologies associated with 
neurodegeneration, progeroid syndromes, and potentially the aging in the general population. 
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3.4 METHODS 
3.4.1 XJB-5-131 and BODIPY-FL-XJB-5-131 
XJB-5-131 was synthesized as described previously (Wipf et al., 2005). BODIPY-FL-XJB-5-
131 was prepared in an analogous fashion and purified by chromatography on SiO2 (ISCO, 4 g 
column, liquid load in CH2Cl2, MeOH/CH2Cl2 gradient) to give an impure, red oil. The material 
was then purified a second time by chromatography on SiO2 (ISCO, 4 g column, liquid load in 
CH2Cl2, MeOH/CH2Cl2 gradient) to give BODIPY-FL-XJB-5-131 as a reddish orange oil: Rf 
0.57 (10% MeOH/CH2Cl2); HRMS (ESI) m/z calcd for C62H86BN9O8F2 (M+H) 1133.6660, 
found 1133.6678. 
3.4.2 Mice 
Ercc1-/Δ mice were generated by breeding Ercc1+/- and Ercc1+/Δ mice in inbred C57Bl/6J and 
FVB/n backgrounds, respectively, to create a cohort of mice that were in an f1 hybrid 
background and genetically identical. The mice were genotyped by PCR as previously described 
(Ahmad et al., 2008). All experiments were reviewed and approved by the University of 
Pittsburgh (Pittsburgh, PA) Institutional Animal Care and Use Committee and in accordance 
with the National Institutes of Health guidelines for the humane care of animals. 
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3.4.3 Live cell imaging of XJB-treated cells 
Ercc1-/- mouse embryonic fibroblasts were grown on MatTek glass bottom culture dishes and 
allowed to adhere overnight. At 60% confluence, MitoTracker® was added to the media to label 
mitochondria, as well as 500 µM BODIPY-FL-XJB-5-131, and images of the cells were captured 
every 3 min for 3 h at 40X magnification using a Nikon Eclipse Ti microscope equipped with a 
Photometrics CoolSnap HQ2 camera. 
3.4.4 XJB treatment of mice 
The Ercc1-/Δ mice were given intraperitoneal injections of 2 mg/kg XJB dissolved in sunflower 
oil (S5007 Sigma-Aldrich, St. Louis, MO) or an equivolume of vehicle only (sunflower oil) three 
times per week, beginning at five weeks of age, by an investigator blinded to the treatment 
group. Whenever possible, littermate pairs of Ercc1-/Δ mice were used, with one mouse in each 
treatment group, to minimize variability. The mice were weighed twice a week and monitored 
for the onset of age-related symptoms, including dystonia, trembling, ataxia, priapism and 
urinary incontinence (neurodegenerative symptoms), hind-limb muscle wasting, lethargy 
(reduced spontaneous activity) and kyphosis (hunched posture). Data only from littermate pairs 
were evaluated to determine the fraction of symptoms delayed in the mouse treated with XJB vs. 
its sibling treated with vehicle only using a paired Student’s t-test. All mice were euthanized at 
20 weeks of age and their tissues were isolated for pathological analysis. 
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3.4.5 Immunofluorescence 
Tissues were fixed in 10% formalin for 2 h, cryoprotected in 30% sucrose overnight, frozen 
using chilled 2-methylbutane, and sectioned by standard procedures using a cryostat. Cleaved 
caspase-3 (9664 Cell Signaling Technology, Beverly, MA) was used at a dilution of 1:250 with a 
4°C overnight incubation. SA β-gal staining was done overnight at 37°C as previously described 
(Dimri et al., 1995) with one modification, the final solution was pH 5.8 for murine samples. 
3.4.6 Immunohistochemistry 
Tissues were fixed in 10% formalin overnight, embedded in paraffin and sectioned using a 
microtome by standard procedures. They were then deparaffinized using xylenes, rehydrated in 
ethanol baths and stained. Tissues were stained with H&E by standard procedure. Anti-GFAP 
(13-0300 Invitrogen, Carlsbad, CA) was used a dilution of 1:250 with a 4°C overnight 
incubation. 
3.4.7 Micro-computed tomography 
Imaging of spines isolated from Ercc1-/Δ mice treated with XJB or vehicle only were acquired 
using a VivaCT 40 (Scanco Medical) with 15 µm isotropic voxel size resolution, 55 kVp of 
energy and 145 µA of current. After the acquisition of transverse two-dimensional image slices, 
three-dimensional reconstruction of the lumbar vertebrae was performed using a constant 
threshold value of 235, which was selected manually for the bone voxels by visually matching 
the threshold areas to the gray-scale images. 
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3.4.8 Measurement of 8,5′-cyclopurine-2′-deoxynucleosides in nuclear DNA of mouse 
livers 
Nuclear DNA was isolated from mouse livers using a high-salt method (Miller et al., 1988a) and 
analyzed for DNA damage as described previously (Wang et al., 2011b). In brief, nuclear DNA 
was digested using a four-enzyme cocktail, and to the digestion mixture was added uniformly 
15N-labeled cdA and cdG. The resulting nucleoside mixture was subjected to off-line high 
performance liquid chromatography (HPLC) separation for the enrichment of the lesions under 
study, following previously described procedures (Wang et al., 2011b). The LC-MS/MS/MS 
experiments were conducted using an LTQ linear ion trap mass spectrometer using recently 
described conditions (Wang et al., 2011b). 
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4.1 INTRODUCTION 
The free radical theory of aging, first proposed by Denham Harman in 1956, states that aging and 
age-related disease are associated with the attack of free radicals on cellular components 
(Harman, 1956). Free radicals damage cell membranes by modification of the lipids in the 
phospholipid bilayer. Polyunsaturated fatty acids (PUFAs) are particularly vulnerable to 
hydrogen abstraction by free radicals because the methylene hydrogens at double bonds are 
highly reactive. The product of this abstraction is a carbon-based radical, which rapidly reacts 
with molecular oxygen to produce a lipid peroxyl radical. This can react with a second 
neighboring fatty acid in a chain reaction to produce one lipid hydroperoxide and a second lipid 
peroxy radical. Alternatively, an epoxide can form via intramolecular reaction of the peroxide 
with another methylene carbon. This can lead to scission and the release of products such as 
malondialdehyde and α-β-unsaturated aldehydes. These products are more stable than free 
radicals, yet still reactive. These lipid peroxidation-derived hydroperoxides and aldehydes react 
with DNA to produce a variety of DNA lesions, including DNA interstrand crosslinks (Buege 
and Aust, 1978; Niedernhofer et al., 2003; Stone et al., 2008). Therefore free radical damage to 
membrane lipids can be particularly damaging because the affect membranes, the nuclear and 
mitochondrial genomes, and can act at long distances via stable products. 
 Lipid peroxyl radicals have been proposed to play a role in the aging process (Rikans and 
Hornbrook, 1997).  Indeed the levels of lipid hydroperoxides are 2-fold greater in liver and 
kidney from old wild-type mice compared to young (Tokumaru et al., 1996). Furthermore, lipid 
peroxidation is a major source of lipofuscin (Yin, 1996), an aging-related pigment consisting of 
oxidized cellular debris that collects in cells. Finally, defects in the repair of DNA interstrand 
crosslinks leads to dramatically accelerated aging in humans and mice (Niedernhofer et al., 
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2006). This must arise from endogenous processes and has been attributed to DNA interstrand 
crosslinks caused by lipid peroxidation (Niedernhofer et al., 2006; Weeda et al., 1997a). This 
study was designed to directly test the hypothesis that lipid peroxidation promotes aging. 
 To test this, we challenged mice with two common environmental exposures that 
promote lipid peroxidation in vivo. The first is carbon tetrachloride (CCl4). CCl4 is a chemical 
solvent historically used in the production of refrigerants and building materials, in aerosol 
propellants (i.e., fire extinguishers), in the dry cleaning industry, and in cleaning fluids, as well 
as for the oral treatment of hookworm (Faroon et al., 2005; Pooranaperundevi et al., 2010).  Use 
of CCl4 diminished dramatically since 1990 as a result of toxicology studies indicating that CCl4 
is a carcinogen in rodents (2001a). However, CCl4 is used in building materials and cleaning 
supplies. Therefore, the primary source of exposure to CCl4 is inhalation during its manufacture 
and use (Faroon et al., 2005). High exposures to CCl4 can result in hepatic toxicitiy (1992; 
Kadiiska et al., 2000). This is because the liver is the primary target as a result of the metabolism 
that occurs there. Cytochrome P450 is required to reduce CCl4 to the trichloromethyl free radical, 
which in the presence of oxygen is converted into a peroxy radical (Kadiiska et al., 2000). Both 
of these radicals are capable of oxidizing lipids. Exposure is not limited to manufacturing. 
White-collar workers can be exposed to fumes from cleaning products used in the workplace 
(Faroon et al., 2005). Furthermore CCl4 is in our water supply at a background level of 
approximately 1 µg/liter in the United States (Fawell and Mascarenhas, 2004). 
 Another environmental exposure that promotes lipid peroxidation is dietary PUFAs. Cell 
membranes are made up of a mixture of saturated and unsaturated lipids acquired largely from 
the diet. PUFAs, harboring conjugated double bonds, are particularly prone to lipid peroxidation 
(Buege and Aust, 1978). A diet rich in PUFAs can promote endogenous lipid peroxidation 
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(Jump, 2002). Dietary PUFAs include linoleic, α-linolenic, arachidonic, eicosapentaenoic, 
docosahexaenoic and n-3 docosapentaenoic acids (2011b; Astorg et al., 2004). Major dietary 
sources of PUFAs include vegetable oils (i.e. poppyseed, safflower, sunflower and corn oils), 
nuts and animal fats (2011b; Astorg et al., 2004). Therefore, by feeding mice a diet enriched with 
PUFAs derived from safflower oil, it is possible to increase endogenous LPO. 
 To increase the sensitivity of our in vivo studies, we used Ercc1-/Δ mice, which have 
reduced expression of ERCC1-XPF DNA repair endonuclease (Weeda et al., 1997a). ERCC1-
XPF is required for interstrand crosslink repair, as well as other DNA repair mechanisms 
(Ahmad et al., 2008; Bhagwat et al., 2009; Niedernhofer et al., 2004; Sijbers et al., 1996a). As a 
consequence the mice show premature aging of the hepatobiliary, renal, neurological, 
hematopoietic, musculoskeletal, epidermal and endocrine systems (de Waard et al., 2010; Goss 
et al., 2011; Gregg et al., 2012a; Niedernhofer et al., 2006; Vo et al., 2010). These mice model a 
human progeroid syndrome caused by a mutation in XPF, affecting expression of ERCC1-XPF 
(Niedernhofer et al., 2006), demonstrating the relevance of this model to human health. Chronic 
exposure of Ercc1-/Δ mice with either a sub-lethal dose (Faroon et al., 2005) of CCl4 or a diet 
enriched for PUFAs promoted LPO, accelerated the onset aging-related pathologies and reduced 
lifespan. These data support the conclusion that LPO can promote aging and does so, at least in 
part, by inducing DNA damage. 
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4.2 RESULTS 
4.2.1 Chronic exposure to CCl4 causes LPO and reduced lifespan in Ercc1
-/Δ mice 
Ercc1-/Δ mice, which are defective in nucleotide excision repair of helix-distorting monoadducts 
and the repair of interstrand crosslinks, and their wild-type (WT) littermates were chronically 
exposed to CCl4 (80 mg/kg) biweekly via subcutaneous injection for five weeks, which is a 
cumulative dose of 800 mg/kg (Figure 4.1A). Xpa-/- mice, which are defective only in nucleotide 
excision repair, were also exposed to the same regiment in order to facilitate identifying the 
impact of LPO-induced DNA interstrand crosslinks. The mice were monitored three times a 
week and sacrificed when the Ercc1-/Δ mice were considered end-stage (reduced spontaneous 
activity). CCl4 treatment of the ERCC1-deficient mice resulted in a decreased median lifespan 
compared to untreated Ercc1-/Δ mice (p = 0.08, one-tailed Student’s t-test; Figure 4.1B). The 
same dose had no detrimental effects on WT or Xpa-/- mice, with the single Xpa-/- death being 
unrelated to the treatment. The lifespan data support the hypothesis that unrepaired LPO-induced 
ICLs have a negative health impact. 
To determine if CCl4 was inducing LPO, lipid hydroperoxides (LOOH) were measured in 
liver samples from untreated 20 week-old Ercc1-/Δ and WT mice (n = 3 per group)  using an 
LOOH assay (Gregg et al., 2012a). Surprisingly, untreated mutant animals had a 7-fold increase 
in LPO compared to their WT littermates (Figure 4.1C; p < 0.01, one-tailed Student’s t-test). 
Upon analysis of liver samples from 19-23 week old Ercc1-/Δ and WT mice 4-8 weeks after 
treatment with CCl4 ended (n = 3 per group), there was a significant increase in the mutant 
LOOH levels compared to their WT littermates (p < 0.05, one-tailed Student’s t-test). Treatment 
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Figure 4.1: Chronic exposure to CCl4 promotes lipid peroxidation and decreases lifespan of Ercc1
-/Δ mice 
(A) CCl4 was administered to WT, Xpa
-/- and Ercc1-/Δ mice by subcutaneous injection of 80mg/kg, twice a week for 
five weeks, beginning at 10 weeks of age. (B) Survival curve of the mice after treatment with CCl4. Graphed are 
wild-type (WT) mice + CCl4 (n=12; green), Xpa
-/- mice + CCl4 (n=8; red), untreated Ercc1
-/Δ mice (n=10; light 
purple), and Ercc1-/Δ mice + CCl4 (n=13; dark purple). (C) Lipid hydroperoxides (LOOH) measured by ELISA 
assay in liver tissue isolated from untreated WT (light green), untreated Ercc1-/Δ (light purple), CCl4-treated WT 
(dark green) and CCl4-treated Ercc1
-/Δ mice (dark purple). Values indicate the mean for 3 mice per group ± S.E.M. 
‘*’, p < 0.05; ‘**’ p < 0.01, one-tailed Student’s t-test. 
 
 
 
of Ercc1-/Δ mice with CCl4 conveyed a 1.5-fold induction in LOOH compared to untreated 
Ercc1-/Δ mice (Figure 4.1C). There was no significant increase in LPO in WT mice with this dose 
of CCl4. 
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4.2.2 CCl4 accelerates the onset of age-related histopathologic changes 
To determine to what extent CCl4-induced lipid peroxidation affected the liver of WT and DNA 
repair-deficient mice, tissue sections were analyzed for histopathologic changes in a blinded 
fashion. Hepatocytes from WT mice treated with CCl4 exhibited signs of increased nuclear size 
and focal necrosis, both changes associated with aging (Andrew, 1962; Chipchase et al., 2003; 
Gregg et al., 2012a). In addition, Ercc1-/Δ liver samples contained hepatocytes that were 
extremely enlarged with dense eosinophilic cytoplasm (Figure 4.2A). There was significantly 
more hepatocellular necrosis and degeneration, but no inflammatory response in the ERCC1-
deficient livers samples compared to CCl4-treated WT mice. There were also foci of nodular 
regeneration evident in the Ercc1-/Δ liver sections with frequent oval cell hyperplasia, often 
stemming from portal areas (Figure 4.2A). 
The liver sections from WT and Ercc1-/Δ littermate pairs treated with CCl4 were stained 
with Masson’s trichrome and periodic acid Schiff (PAS), to show fibrosis and glycogen 
deposition, respectively, which are both associated with advanced age (Gregg et al., 2012a; 
Guarente and Kenyon, 2000; Guttman and Kohn, 1960; Jiang et al., 2005; Lin et al., 2001). 
Increased portal fibrosis was evident in the treated Ercc1-/Δ mice compared to treated WT 
littermates by the dark blue staining with Masson’s trichrome (Figure 4.2B). In addition, the 
CCl4-treated Ercc1
-/Δ liver samples showed high levels of glycogen deposition (Figure 4.2C). 
These results indicate an increase in aging-related degeneration of the liver of mice treated with 
CCl4. 
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Figure 4.2: CCl4 accelerates the onset of age-related histopathologic changes 
(A) H&E stained liver sections from WT and Ercc1-/Δ mice treated with CCl4 (10x objective, top; 40x objective, 
bottom). Black arrows indicate areas of nodular regeneration, green arrows illustrates areas of necrosis. (B) 
Masson’s trichrome stained liver sections from WT and Ercc1-/Δ mice treated with CCl4 (20x objective). Blue 
indicates areas of fibrosis. (C) Periodic acid Schiff (PAS) stained liver sections from WT and Ercc1-/Δ mice (20x 
objective). The dark purple indicates areas of polysaccharide deposition. 
4.2.3 Dietary PUFAs decrease lifespan of Ercc1-/Δ mice 
Mice were fed either a diet high in PUFAs (safflower oil) or an isocaloric, control diet, in which 
the PUFAs were replaced with saturated fats, starting at 21 days of age (at weaning) and 
continued throughout their entire lifespan. Mice were sacrificed when they were terminal, 
showing decreased spontaneous movement. Maximum lifespan was significantly reduced in 
PUFA-fed Ercc1-/Δ mice compared to mice fed the control diet (Figure 4.3A & B; p < 0.05, 
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two-tailed Student’s t-test). In addition, Ercc1-/Δ mice that were fed the diet high in PUFAs 
exhibited increased aging-associated symptoms, including hind-limb muscle wasting, decreased 
grooming and increased osteoporotic changes (Figure 4.3C). Importantly, there was no 
difference in the weights of mice on the special diets compared to those fed normal mouse chow, 
indicating that the difference in lifespan could not be attributed to caloric restriction (Figure 4.4). 
 
Figure 4.3: Dietary PUFAs decrease the lifespan of Ercc1-/Δ mice 
(A) The average maximum lifespan was calculated using the mean age of the oldest 20% of mice on each diet (Zhou 
et al., 2012) (n = 6 per group; p < 0.05, two-tailed Student’s t-test). (B) Photograph of control- or PUFA-fed Ercc1-/Δ 
mice at 20 weeks of age. The white arrow illustrates kyphosis and the red arrow indicates hind-limb muscle wasting. 
 
 
Figure 4.4: Weights of Ercc1-/Δ mice 
Weights in grams of untreated (light purple), control diet- (light blue), and PUFA diet-fed (dark blue) Ercc1-/Δ mice 
starting at three weeks of age, when the mice were weaned onto the appropriate diet, until death 
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4.2.4 Dietary LPO promotes aging-related pathology in Ercc1-/Δ mice 
A veterinary pathologist, blinded to the treatment group, examined the tissue sections for 
histopathologic changes and scored the severity. Hematoxylin and eosin stained liver sections 
revealed portal fibrosis, necrosis and pyknotic nuclei in liver sections from Ercc1-/Δ mice fed the 
PUFA diet compared to Ercc1-/Δ mice fed the control diet (Figure 4.5A). Portal fibrosis was also 
evident by staining Ercc1-/Δ livers with Masson’s trichrome (Figure 4.5B). The severity of portal 
fibrosis was scored on average 30% higher (more severe) in ERCC1-deficient mice fed the diet 
high in PUFAs compared to mutant mice fed the control diet (Figure 4.5D). Additionally, 
Ercc1-/Δ mice fed the diet high in PUFAs had an increase in the amount of PAS staining 
(glycogen storage) compared to Ercc1-/Δ mice on the control diet (Figure 4.5C). The liver 
sections were also scored for portal fibrosis and hepatocellular abnormalities. Hepatocellular 
abnormalities were more severe in mutant mice fed the high PUFA diet compared to the control 
diet (Figure 4.5D). Taken together, these data indicate that dietary PUFA can promote 
aging-associate degenerative changes in the liver. 
Kidneys from PUFA-fed Ercc1-/Δ mice showed a loss of renal epithelial tubular cells and 
increased glomerulosclerosis compared to control-fed Ercc1-/Δ mice (Figure 4.6A). However, 
Masson’s trichrome stain of kidney cortex did not show differences in fibrosis between animals 
on the two diets (Figure 4.6B). In contrast PAS stain revealed an increase in extra-cellular matrix 
accumulation around the glomeruli in mutant mice fed the high PUFA diet (Figure 4.6C). When 
the kidney sections were scored for histopathology, there was an increase in both glomerular 
lesions and tubular abnormalities in the Ercc1-/Δ mice fed a high PUFA diet compared to mice 
fed the control diet (Figure 4.6D). These data demonstrate that dietary PUFAs can promote 
aging-related degenerative changes in the kidney. 
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Figure 4.5: Dietary PUFAs accelerate the onset of aging-related histopathologic changes in the liver of Ercc1-/Δ 
mice 
(A) H&E stained liver sections from control- or PUFA-fed Ercc1-/Δ mice (20x objective). White arrow illustrates 
necrosis. (B) Masson’s trichrome stained liver sections from from control- or PUFA-fed Ercc1-/Δ mice (20x 
objective). Blue indicates areas of fibrosis. (C) Periodic acid Schiff (PAS) stained liver sections from control- or 
PUFA-fed Ercc1-/Δ mice (20x objective). Dark purple indicates areas of glycogen deposition. (D) Histogram 
indicating the average pathologic score assigned indicating the extent of portal fibrosis and hepatocellular changes in 
each group (n= 3 mice per group). The scores were assigned by a veterinary pathologist who was blinded as to the 
diet of the mice. 
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Figure 4.6: Dietary PUFAs accelerate the onset of aging-related histopathologic changes in the kidney of 
Ercc1
-/Δ mice 
(A) H&E stained kidney sections from control- or high PUFA-fed Ercc1-/Δ mice (20x objective). (B) Masson’s 
trichrome stained kidney sections from control- or high PUFA-fed Ercc1-/Δ mice (20x objective). (C) Periodic acid 
Schiff (PAS) stained kidney sections from control- or high PUFA-fed Ercc1-/Δ mice (20x objective). (D) Histogram 
indicating the average pathologic score assigned indicating the extent of glomerulosclerosis and changes in the renal 
tubular epithelium for each group (n= 3 mice per group). The scores were assigned by a veterinary pathologist who 
was blinded as to the diet of the mice. 
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4.3 DISCUSSION AND FUTURE DIRECTIONS 
Herein, we demonstrated that increased lipid peroxidation, whether through direct chemical 
induction or indirect dietary supplementation, can accelerate aging-associated histopathologies 
and affect the lifespan of mice. We used a cumulative dose of 800 mg/kg CCl4, 10-fold lower 
than the lethal dose in mice (Faroon et al., 2005), which resulted in extreme hepatotoxicity of 
Ercc1-/Δ mice (Figure 4.2). Interestingly, the effects seen in the liver of WT animals treated with 
CCl4, including increased nuclear size and focal necrosis (Figure 4.2A), have been shown to 
occur with normal age (Gregg et al., 2012a; Ohtsubo and Nomaguchi, 1986), indicating that lipid 
peroxidation can promote aging-related changes in Ercc1-/Δ and WT mice. Because CCl4 can also 
lead to renal and neurological (purkinje cell damage) toxicitiy (1992), both the kidney and 
cerebellum from CCl4-treated mice will also be evaluated for the effects of increased LPO in 
these tissues. 
The Biomarkers of Oxidative Stress Studies (BOSS) have attempted to validate multiple 
non-invasive approaches to measure levels of oxidative stress in the plasma and urine of 
CCl4-treated rats (Kadiiska et al., 2000; Kadiiska et al., 2005a; Kadiiska et al., 2005b). The lipid 
hydroperoxide assay, one type of analysis evaluated in the BOSS project, represents a snapshot 
of LPO at one specific time point within a tissue (Kadiiska et al., 2005a). This may account for 
the broad spectrum of measured lipid hydroperoxides in liver samples of Ercc1-/Δ mice treated 
with CCl4 (Figure 4.1C) as the samples were collected at end-of-life, which was, in itself, 
variable between treated mice. It would, therefore, be interesting in future studies to use more 
techniques (i.e. isoprostanes measured by immunoassay or GC-MS and malondialdehyde 
measured by GC-MS) developed in the BOSS projects to analyze LPO over time (Kadiiska et 
al., 2005a). Additionally, using mass spectrometry analysis to identify types of DNA lesions 
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would also be beneficial to identifying whether LPO-induced DNA interstrand crosslinks are the 
lesions promoting age-related decline. 
It is well-established that increased glycogen storage and lipofuscin deposition are 
biomarkers of aging in several organisms, including yeast, mouse, rat, and Chinese hamsters 
(Guarente and Kenyon, 2000; Guttman and Kohn, 1960; Jiang et al., 2005; Lin et al., 2001). 
PAS has been shown to stain not only glycogen, but also lipofuscin, the aging pigment, making 
PAS an indispensible tool for assessing aging in multiple tissues (Jung et al., 2010; Kishi et al., 
2008). Therefore, our results, showing increased PAS staining in the liver and kidneys of Ercc1-
/Δ mice from either CCl4 treatment, or a diet high in PUFAs, indicate an acceleration of aging 
compared to control animals (Figure 4.5 and Figure 4.6). 
While CCl4 resulted in exaggerated aging-associated pathologic phenotypes, similar 
changes, albeit to a much lesser extent, were observed in Ercc1-/Δ mice fed a diet high in PUFAs, 
indicating that dietary intake can impact lipid peroxidation and aging. This identifies 
environmental and dietary factors that promote aging, providing potential targets for prevention.  
Future studies should focus on measuring lipid peroxidation after various chemical and dietary 
interventions. Ideally, these data will help us to provide better prevention strategies to eliminate 
environmental and dietary hazards, in order to improve the healthspan of humans. 
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4.4 MATERIALS AND METHODS 
4.4.1 Mice 
Ercc1-/Δ mice were generated by breeding Ercc1+/- and Ercc1+/Δ mice in inbred C57Bl/6J and 
FVB/n backgrounds, respectively, to create a cohort of mice that were in an f1 hybrid 
background yet genetically identical. The mice were genotyped by PCR as previously described 
(Ahmad et al., 2008). All experiments were reviewed and approved by the University of 
Pittsburgh (Pittsburgh, PA) Institutional Animal Care and Use Committee and in accordance 
with the National Institutes of Health guidelines for the humane care of animals.  
4.4.2 CCl4 treatment of animals 
WT, Xpa-/- and Ercc1-/Δ mice were injected subcutaneously with 80 mg/kg CCl4 twice a week for 
five weeks. Treatment began when the mice were 10 weeks of age. Animals were monitored 
daily and weighed twice a week. Mice were sacrificed when they were considered terminal or 
experienced reduced spontaneous activity. Tissues were isolated for histopathologic analysis. 
4.4.3 Measuring lipid hydroperoxides 
Lipid hydroperoxides were measured in fresh tissue homogenates using the Hydroperoxide 
Assay kit (#705003, Cayman Chemicals, Ann Arbor, MI) according to the manufacturer’s 
instructions. Liver specimens were sonicated on ice in 1 mL of HPLC-grade water and used 
immediately after collection.  
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4.4.4 Food 
Special diets were ordered from Harlan-Teklad. The chow pellets contained a standard formula 
of macronutrients (20.6% protein, 1.7% crude fiber, 3.5 kcal/g energy density and necessary 
micronutrients. The only difference was that the fat component of the diet was substituted with 
12.4% polyunsaturated fats derived from safflower oil (PUFA diet). The control diet contained 
the same amount of saturated fat derived from coconut oil with a small component of 
polyunsaturated fat (<0.6% linoleic acid, which is essential for life). 
4.4.5 Histological staining 
Tissues were fixed in 10% formalin overnight, embedded in paraffin and sectioned using a 
microtome by standard procedures. Subsequently, sections were stained by standard procedures 
with hematoxylin and eosin (H&E), Masson’s trichrome and periodic acid Schiff (PAS). 
4.4.6 Scoring 
Slides of liver, kidney and pancreas sections were scored by a veterinary pathologist who was 
blinded to the genotype and treatment of the animals. The scoring was based on a three point 
system with 0 being unaffected or no pathology and 3 being the most severe pathology. 
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5.0    NF-ΚB  INHIBITION  DELAYS  DNA  DAMAGE-INDUCED  SENESCENCE 
                              AND AGING IN MICE
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5.1 INTRODUCTION 
Aging is characterized by the inability of tissues to maintain homeostasis (Kirkwood, 2005; 
Resnick and Marcantonio, 1997).  This leads to an impaired response to stress and, as a 
consequence, an increased risk of morbidity and mortality (Kirkwood, 2005). The incidence of 
numerous debilitating chronic diseases such as cardiovascular disease, neurodegeneration, 
diabetes, arthritis and osteoporosis increases almost exponentially with age (Chung et al., 2009). 
Aging is thought to be driven, at least in part, by the accumulation of stochastic damage in cells. 
This includes damage to proteins (Kirkwood, 2005), DNA, mitochondria (Green et al., 2011) and 
telomeres (Liu et al., 2002), which is driven by reactive oxygen species (Lee et al., 1999; Packer 
and Fuehr, 1977; Trifunovic et al., 2004) generated through chronic inflammation (Franceschi et 
al., 2007; Gosselin and Abbadie, 2003) or aerobic respiration in mitochondria (Green et al., 
2011). However, the mechanism by which cellular damage drives aging is not known. The 
simplest model is that damage causes attrition of functional cells. But this is inadequate in light 
of emerging evidence that aging-related degenerative changes in old and damaged organisms can 
be delayed or reversed by circulating factors (Brack et al., 2007; Conboy et al., 2005; Lavasani 
et al., 2012; Rando and Chang, 2012; Villeda et al., 2011). These observations point instead 
towards the cellular response to damage being the key driver of aging. 
The transcription factor NF-κB is a central component of the cellular response to damage, 
stress and inflammation (Hayden and Ghosh, 2008). In mammals, the NF-κB family consists of 
five subunits, p65/RelA, c-Rel, RelB, p50 and p52. NF-κB binds to DNA as a dimer, the most 
common being the p65p50 heterodimer (Hayden et al., 2006).  The p65p50 heterodimer is 
localized primarily in the cytoplasm, maintained in this inactive state via sequestration by IκB 
proteins (Hayden et al., 2006). NF-κB activation via the canonical pathway is mediated by the 
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upstream IκB kinase (IKK), a heterotrimer consisting of two catalytic subunits, IKKα and IKKß, 
and a regulatory subunit termed IKKγ or NEMO (NF-κB Essential Modulator) (Hayden et al., 
2006). In response to a variety of factors, including pro-inflammatory cytokines, pathogens, 
oxidative stress and growth factors, IKK is activated and phosphorylates IκB, leading to its 
polyubiquitination and subsequent proteasomal degradation (Bubici et al., 2006; Hayden and 
Ghosh, 2008; Ramana et al., 2004; Wullaert et al., 2006).  IκB degradation allows NF-κB to 
translocate to the nucleus where it binds to its cognate DNA sequence as well as co-activators 
such as CBP/p300, to regulate gene expression (Furia et al., 2002). 
Numerous studies report increased NF-κB activity with aging.  Human fibroblasts from 
aged individuals and Hutchinson-Gilford progeria syndrome (HGPS) patients have increased 
NF-κB activation (Adler, 2007; Kriete et al., 2008). NF-κB DNA binding is increased in skin, 
liver, kidney, cerebellum, cardiac muscle, and gastric mucosa of old rodents compared to young 
(Bregegere et al., 2006; Giardina and Hubbard, 2002; Helenius et al., 1996; Korhonen et al., 
1997; Xiao and Majumdar, 2000). In addition, NF-κB was identified as the transcription factor 
most associated with mammalian aging, based on patterns of gene expression (Adler, 2007). 
Furthermore, chronic activation of NF-κB is observed in numerous age-related diseases (Tilstra 
et al., 2011) including muscle atrophy (Cai et al., 2004; Li et al., 2008), multiple sclerosis 
(Ghosh et al., 2007a), atherosclerosis (Cuaz-Perolin et al., 2008), heart disease (Valen, 2004), 
both type I and II diabetes (Tilstra et al., 2007), osteoarthritis (Berenbaum, 2004), dementia 
(Yamamoto and Gaynor, 2001), osteoporosis (Kim et al., 2006), and cancer (Karin, 2006). 
However, these studies do not demonstrate a causal relationship between NF-κB activation and 
aging. 
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Genetic depletion of NF-κB in the skin of transgenic mice reversed age-related gene 
expression and histologic changes (Adler, 2007), providing support for NF-κB activation playing 
a causal role in skin aging. Similarly, haploinsufficiency of p65 leads to improved growth and 
extended lifespan of Sirt6-/- mice (Kawahara et al., 2009). However, Sirt6-/- mice manifest severe 
colitis, suggesting that chronic inflammation may drive their degenerative phenotypes and that 
attenuating this inflammation through genetic depletion of NF-κB accounts for their improved 
lifespan (Mostoslavsky et al., 2006; Natoli, 2009). Thus, it remains to be determined if NF-κB 
activation drives systemic aging and if NF-κB is a therapeutic target for attenuating and/or 
delaying aging-related degenerative changes. 
To address these gaps in knowledge, we used a mouse model of XFE progeroid 
syndrome, a disease of accelerated aging caused by mutations in XPF, which encodes the 
catalytic subunit of the XPF-ERCC1 DNA repair endonuclease.  The syndrome is characterized 
by accelerated aging of virtually all organ systems, all driven by failure to repair stochastic 
endogenous DNA damage. A murine model for XFE progeroid syndrome, Ercc1-/∆ mice, which 
have about 10% of the normal amount of ERCC1 protein model, this disease and spontaneously 
develop progressive, degenerative changes that correlate strongly with natural aging (Goss et al., 
2011; Gregg et al., 2012a; Niedernhofer et al., 2006; Schumacher et al., 2008; Vo et al., 2010). 
Thus, the Ercc1-/- mice, which have a complete absence of ERCC1 protein, and Ercc1-/∆ mice 
offer a unique opportunity to investigate the mechanism by which one type of cellular damage 
promotes aging and whether NF-κB plays a pivotal role. 
We found that NF-κB is stochastically activated in a variety of cell types with normal and 
accelerated aging, and that genetic or pharmacologic inhibition of NF-κB activation delays the 
onset of numerous aging-related symptoms and pathologies.  Inhibition of IKK/NF-κB activity 
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reduced cellular senescence and oxidative damage, including DNA and protein damage, 
revealing that cellular stress responses promote further cellular damage.  Our findings strongly 
suggest that inhibitors of the IKK/NF-κB pathway may delay damage and extend healthspan in 
patients with accelerated aging and chronic degenerative diseases of old age. 
5.2 RESULTS 
5.2.1 NF-B is activated during normal and accelerated aging 
To examine the extent of NF-κB activation associated with aging, NF-κBEGFP knock-in mice 
with the EGFP reporter under the control of NF-κB regulatory elements (NF-κBEGFP) were used 
(Magness et al., 2004).  Kidney specimens from 3 month-old and 2 year-old NF-κBEGFP reporter 
mice were compared (Figure 5.1A).  The older wild-type (WT) mice had more cells expressing 
EGFP compared to young WT mice, indicative of increased NF-κB activation.  EGFP expression 
was observed primarily in the glomeruli and was stochastic, with many cells showing strong 
expression while neighboring cells showed none.  To determine if NF-κB  is also upregulated in 
the progeroid mouse models, kidney specimens from Ercc1-/ΔNF-κBEGFP mice (lifespan 7 months 
(Dollé et al., 2011)) and WT NF-κBEGFP littermates were isolated at 3 months of age (Figure 
5.1B)  and from Ercc1-/-NF-κBEGFP mice (lifespan 28 days (Niedernhofer et al., 2006)) and WT 
NF-κBEGFP littermates at 21 days (Figure 5.1C) to measure EGFP expression. Similar to natural 
aging, NF-B activity was greater in the kidneys of ERCC1-deficient mice, particularly in the 
glomeruli, compared to WT littermates.  In addition, EGFP+ cells were detected in the liver, 
pancreas, spleen and muscle of Ercc1-/-NF-κBEGFP mice (Figure 5.2). Amongst six littermate 
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pairs, we detected a significant increase in the fraction of EGFP+ cells in the progeroid mice: 
kidney (2.5-fold increase relative to WT littermates), pancreas (2.5-fold), muscle (1.7-fold), and 
liver (4-fold) (Figure 5.1D).  In contrast, the percent of EGFP+ cells was 35% lower in the 
spleens of Ercc1-/-NF-κBEGFP mice than WT NF-κBEGFP littermates, indicating that NF-B 
activation is not exclusively driven by inflammation.  These data support earlier reports (Adler, 
2007; Kriete et al., 2008) that there is increased NF-B activation with mammalian aging, and 
extends this to include a murine model of XFE progeroid syndrome, which is driven by a DNA 
repair defect. 
To confirm that NF-κB activity is increased in cells from progeroid Ercc1-/- mice, the 
levels of phosphorylated p65/RelA (p-p65) and IκB were measured by immunoblot in nuclear 
and cytoplasmic extracts from passage 5, congenic Ercc1-/- and WT primary MEFs.  There was a 
>2-fold increase in nuclear p-p65 in Ercc1-/- MEFs compared to WT (Figure 5.1E), which 
correlated with an increase in the level of phosphorylated IκB (p-IκB) in the cytoplasm. 
Increased NF-κB binding activity was also detected in nuclear extracts from Ercc1-/- MEFs by 
electrophoretic mobility shift assay (EMSA, Figure 5.1F).  Pretreatment of the nuclear lysates 
with anti-p50 and, in particular, anti-p65 antibodies reduced this DNA binding activity (Figure 
5.3). These data establish increased NF-κB activity in DNA repair-deficient Ercc1-/- cells from 
progeroid mice and suggest that p65 is the predominant subunit contributing to this increased 
activity. 
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Figure 5.1: NF-κB activation is increased in tissues of old wild-type (WT) and progeroid, DNA repair-
deficient mice 
Kidney sections from NF-κBEGFP mice were imaged using fluorescent microscopy to detect EGFP expression 
(green). Nuclei were counter-stained with Hoechst dye (blue; 20x objective). Comparisons include (A) Young adult 
(3 month-old) and old WT NF-κBEGFP (2 year-old) mice,  (B) Ercc1-/∆NF-κBEGFP and WT NF-κBEGFP mice at 3 
months of age, and (C) Ercc1-/-NF-κBEGFP and WT NF-κBEGFP mice at 21 days of age. (D) Quantification of EGFP 
expression. The number of EGFP+ cells was counted in five random fields of tissue per mouse (n = 6 mice per 
group). Reported is the fold difference in the number of EGFP+ cells relative to the mean value (black bar) of the 
group. Diamond symbols represent individual mice (control in green and Ercc1-/-NF-κBEGFP in yellow). P-values 
were calculated using a Student's t-test. (E) Ercc1-/- and WT primary MEFs were passaged five times at 20% O2 to 
promote the onset of senescence (Parrinello et al., 2003a).  The levels of p-p65, IκBα and p-IκBα in nuclear and 
cytoplasmic extracts were measured by immunoblot. (F) NF-κB EMSA was performed with a radiolabeled 
oligonucleotide containing an NF-κB binding site using nuclear extracts from Ercc1-/- and WT primary MEFs. 
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Figure 5.2: NF-κB is activated in DNA repair-deficient, progeroid Ercc1-/Δ mice 
Representative images of EGFP expression in tissue sections from 21 day-old progeroid Ercc1-/- mice and their 
normal littermates harboring the NF-κBEGFP reporter knock-in contruct. Kidney, skeletal muscle, pancreas, liver, and 
spleen sections from Ercc1-/-NF-κBEGFP and WT NF-κBEGFP mice were imaged using fluorescent microscopy to 
detect EGFP expression (green). Nuclei were counter-stained with Hoechst dye (blue; 20x objective). 
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Figure 5.3: EMSA of NF-κB activity 
EMSA was performed using nuclear extracts from WT and Ercc1-/- primary MEFs, passage 5 and a 5'-32P 
end-labeled duplex oligonucleotide containing a centrally located NF-κB binding sequence. Some extracts were 
pre-incubated with antibodies against p65 and p50 to determine which NF-κB subunits are mediating NF-κB 
binding activity. 
5.2.2 Genetic reduction of NF-κB delays the onset of progeroid symptoms in Ercc1-/Δ mice 
To determine if NF-κB activation drives age-related pathologies, Ercc1-/∆ mice were bred to have 
a deletion of one allele of the NF-κB subunit, p65/RelA (Ercc1-/∆p65+/-).  To determine if genetic 
depletion of p65 indeed resulted in reduced NF-κB DNA binding activity, EMSAs were 
performed using extracts from WT, Ercc1-/-, Ercc1-/-p65+/-, and Ercc1-/-p65-/- primary MEFs 
(Figure 5.4A).  Heterozygosity of p65 resulted in a reduction in NF-κB binding activity, whereas 
homozygous deletion of p65 reduced NF-κB binding activity even further. 
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To examine the role of NF-κB/p65 in the aging process, Ercc1-/∆ and Ercc1-/∆p65+/- 
littermates were monitored biweekly for the onset of age-related symptoms.  The onset of the 
majority of symptoms characteristic of Ercc1-/∆ mice was delayed in Ercc1-/∆p65+/- mice, 
including trembling, kyphosis, sarcopenia and urinary incontinence, all signs of 
neurodegeneration (Table 5.1). The aging score, representing the fraction of all aging-related 
symptoms that were delayed in Ercc1-/∆p65+/- mice compared to littermate Ercc1-/∆ mice, 
revealed a trend towards a delay in onset of aging pathologies (Figure 5.4B). Additionally, the 
overall physical appearance of the Ercc1-/∆p65+/- mice was dramatically improved (Figure 5.4C). 
At 15 weeks of age, Ercc1-/∆ mice exhibited ocular impairment, a wide-base stance (ataxia), 
sarcopenia, kyphosis and frailty, all of which were dramatically attenuated in Ercc1-/∆p65+/- 
mice. 
Table 5.1: Genetic depletion of the p65 subunit of NF-κB delays aging symptoms of progeroid 
Ercc1
-/Δ mice 
Symptoms 
Age at onset (weeks) 
Change of onset 
(weeks) 
Number of 
Ercc1-/Δ mice 
(WT, p65+/-) 
Ercc1-/Δ Ercc1-/Δ p65+/- 
Dystonia 7.3 7.0 -0.3 7, 7 
Trembling 7.0 7.1 0.1 7, 7 
Kyphosis 9.8 11.1 1.3 7, 7 
Ataxia 12.1 11.3 -0.8 7, 7 
Sarcopenia 13.3 13.8 0.5 7, 7 
Spontaneous 
activity 
19.4 17.2 -2.2 5, 5 
Urinary 
incontinence 
15.9 19.3 3.4 4, 2 
Ercc1-/Δ and Ercc1-/Δ p65+/- mice were evaluated biweekly for the onset of spontaneous symptoms associated with 
aging.  Shown is the average age at onset of each symptom for each group and the difference between the group 
averages.  Yellow shaded cells indicate symptoms delayed in the p65 heterozygous mice. 
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In addition to assessing outward signs of aging, histologic analysis was performed.  Mice 
were euthanized at 10 and 15 weeks of age and tissues collected for analysis of several hallmarks 
of age-related degeneration. Compared to Ercc1-/∆ mice, Ercc1-/∆p65+/- mice exhibited a marked 
reduction of steatosis (Figure 5.4D), a marker of aged liver (Farrell and Larter, 2006).  Kidneys 
from Ercc1-/∆ mice had increased proteinaceous renal tubular hyaline casts and 
glomerulosclerosis (Figure 5.4D), typical of aged kidneys (Remuzzi et al., 2002; Rodriguez-
Puyol, 1998), that was reduced in Ercc1-/∆p65+/- mice. There also was a reduction in glial 
fibrillary acidic protein (GFAP) staining, a marker of neurodegeneration (Nichols et al., 1993), 
in the cerebella of Ercc1-/∆p65+/- mice compared to Ercc1-/∆ littermates (Figure 5.4D).  Finally, 
osteoporosis was significantly reduced in Ercc1-/∆p65+/- mice (Figure 5.4D; Figure 5.5).  Taken 
together, these results demonstrate that reducing NF-κB activity delays the onset of numerous 
age-related pathologies and extends healthspan. 
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Figure 5.4: Genetic depletion of the p65 subunit of NF-κB delays aging symptoms and chronic diseases in 
progeroid Ercc1-/∆ mice 
(A) EMSA on nuclear extracts from passage 5 WT, Ercc1-/-, Ercc1-/-p65+/-, Ercc1-/-p65-/- MEFs grown at 20% O2 to 
measure NF-κB activity after depletion of p65. (B) Ercc1-/∆ and Ercc1-/∆p65+/- mice were evaluated biweekly for the 
onset of spontaneous symptoms associated with aging. The aging score, which represents the fraction of aging 
symptoms delayed in a particular mouse compared to its sibling, for littermate pairs of Ercc1-/∆ (red) and 
Ercc1-/∆p65+/- (orange) mice and is a measure of healthspan (11). The mean aging score for each genotype is 
represented by a black bar. (C) Representative images of Ercc1-/∆ and Ercc1-/∆p65+/- sex-matched littermates at 15 
weeks of age. (D) Histopathologic changes in Ercc1-/∆p65+/- and Ercc1-/∆ mice.  Liver sections were stained with oil 
red O to detect neutral lipids in 10 week-old mice (hepatic steatosis; 100x objective).  Kidney specimens from 15 
week-old mice were stained with haematoxylin and eosin (H&E) to detect proteinaceous renal tubular hyaline casts 
and glomerulosclerosis (20x objective).  Cerebellar sections were immunostained for glial fibrillary acidic protein 
(GFAP, red), a marker of neurodegeneration, in 10 week-old mice.  Nuclei were counter-stained with DAPI (blue; 
40x objective).  Micro-computed tomography (μCT) of the vertebrae to assess bone porosity (quantification, Figure 
5.5A). 
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Figure 5.5: Quantitation of bone porosity (osteoporosis) in Ercc1-/∆ mice following genetic or pharmacologic 
inhibition of NF-κB 
Micro-computed tomography of spines isolated from mice using a VivaCT 40 (Scanco Medical) with 15 µm 
isotropic voxel size resolution, 55 kVp of energy and 145 µA of current. (A) The percent change in porosity in 
Ercc1-/∆ and Ercc1-/∆p65+/- mice compared to age-matched WT mice. '*', p < 0.05, Tukey-Kramer test. The values 
denote the mean ± S.D. of 9 mice per group. (B) The percent change in porosity in Ercc1-/∆ mice treated with 
8K-NBD or 8K-mNBD compared to age-matched WT mice. '*', p < 0.05, Tukey-Kramer test. The values denote the 
mean ± S.D. of 3 mice per group. 
5.2.3 Pharmacologic inhibition of NF-B delays the onset of progeroid symptoms in 
Ercc1
-/∆ mice 
To determine if pharmacologic suppression of IKK/NF-B signaling also results in an extension 
of healthspan, a peptide inhibitor of IKK, termed NBD, was used.  The 11 amino acid NBD 
peptide, when fused to a protein transduction domain such as Antp or 8K, is efficacious for 
treating muscular dystrophy (Acharyya et al., 2007), inflammatory bowel disease (Dave et al., 
2007), arthritis (Dai et al., 2004), and Parkinson’s disease (Ghosh et al., 2007b) in mice.  The 
activity of the peptide was tested in vitro by treating Ercc1-/- primary MEFs with 200 µM 8K-
NBD. This led to a reduction in nuclear p-p65 (Figure 5.6A). Ercc1-/∆ mice were chronically 
treated with 8K-NBD (10 mg/kg intraperitoneal, 3X per week) beginning at 5 wks of age, which 
is prior to the onset of their aging symptoms. Littermate mutant animals were treated with an 
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equivalent dose of an inactive, mutant peptide (8K-mNBD) used as a negative control. 
Investigators conducting the experiment were blinded as to the treatment group. Mice treated 
with 8K-NBD showed a delay in the onset of the majority of symptoms compared to siblings  
 
 
Figure 5.6: Pharmacologic inhibition of IKK/NF-κB activation delays aging symptoms and chronic 
diseases in progeroid Ercc1-/∆ mice 
Pharmacologic inhibition of IKK/NF-κB activation delays aging symptoms and chronic diseases in progeroid 
Ercc1-/∆ mice. (A) Immunodetection of p-p65 in nuclear extracts of WT or Ercc1-/- primary MEFs treated with 
200µM NBD or untreated (UT); Lamin A/C loading control.  Histogram indicating the level of p-p65 normalized to 
untreated WT cells and corrected for loading.  Values denote mean ± S.D. from three experiments. (B) Sibling, 
sex-matched pairs of Ercc1-/∆ mice were treated with 8K-NBD or 8K-mNBD, 10mg/kg, i.p., 3X per week, beginning 
at 5 weeks of age. The aging score was calculated between Ercc1-/∆ littermate pairs treated with 8K-mNBD (blue) or 
8K-NBD (green). Mean aging score is represented by a black bar (p = 0.003, Student's t-test). (C) Representative 
images of Ercc1-/∆ mice treated with 8K-NBD or 8K-mNBD peptide at 15 and 19 weeks of age.  (D) Histopathologic 
changes analyzed in tissue sections from 18 week-old Ercc1-/∆ mice treated with 8K-NBD or 8K-mNBD. Liver 
sections were stained with oil red O to detect neutral lipids (hepatic steatosis; 100x objective).  Kidney specimens 
were stained with H&E to detect hyaline casts and glomerulosclerosis (20x objective).  Cerebellar sections were 
immunostained for GFAP (red), a marker of neurodegeneration.  Nuclei were counter-stained with DAPI (blue; 40x 
objective).  µCT of vertebrae to measure bone porosity (quantification, Figure 5.5B). 
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treated with the mutant peptide (Table 5.2). Ataxia, sarcopenia and weight loss were significantly 
delayed (Table 5.2 and Table 5.3). In addition, the aging score revealed a highly significant 
difference between treatment groups (p = 0.003; Figure 5.6B).  There also was a visible 
difference in the appearance of the mice treated with 8K-NBD compared to their siblings treated 
with the mutant peptide at 15 and 19 weeks of age (Figure 5.6C), including improved reflexes, 
gait, muscle and eyes. 
 
 
Table 5.2: Pharmacologic suppression of IKK/NF-κB activation attenuates progeroid symptoms and 
pathologies of progeroid Ercc1-/Δ mice 
Symptoms 
Age at onset (weeks) 
Change of 
onset (weeks) 
Number of 
Ercc1-/Δ mice 
(mNBD, NBD) 
mNBD NBD 
Dystonia 9.2 9.1 -0.1 12, 17 
Trembling 10.7 9.8 -0.9 12, 17 
Kyphosis 12.9 12.2 -0.7 11, 15 
Ataxia* 14.5 16.2 1.7 10, 13 
Sarcopenia* 15.1 17.2 2.1 8, 12 
Spontaneous 
activity 
20.4 10.7 0.3 3, 2 
Urinary 
incontinence 
17.5 19.7 2.2 5, 3 
Sibling, sex-matched pairs of Ercc1-/Δ mice were treated with 8K-NBD or 8K-mNBD, 10 mg/kg, i.p., 3X per week, 
beginning at 5 weeks of age and continuing throughout their lifespan. Shown is the average age at onset of 
characteristic progeroid symptoms in treated Ercc1-/Δ mice and the difference between the group averages. Yellow 
shaded cells indicate symptoms delayed in mice treated with the NF-κB inhibitor 8K-NBD compared to 8K-mNBD. 
The asterisks indicate a significant delay (p < 0.05; Student’s t-test). 
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Histologic analysis was performed on tissues of 19 week-old mice to determine if 
treatment with 8K-NBD reduced age-related pathology. Similar to the Ercc1-/∆p65+/- mice, 
8K-NBD treatment resulted in reduced liver steatosis and renal hyaline casts compared to control 
mice (Figure 5.6D). GFAP staining was also reduced, consistent with the delay in onset of 
symptoms caused by neurodegeneration (Figure 5.6D). µCT analysis revealed a significant 
reduction in bone porosity (osteoporosis) in mice treated with 8K-NBD compared to untreated 
Ercc1-/∆ mice (Figure 5.6D and Figure 5.5B). Collectively these data demonstrate that 
pharmacological inhibition of IKK/NF-κB activation leads to attenuation of age-related 
pathologies. 
 
Table 5.3: Chronic treatment of Ercc1-/Δ mice with the NF-κB inhibitor 8K-NBD significantly delayed 
progeroid symptoms and pathologies 
Symptoms 
Age at onset (weeks) 
Change of onset 
(weeks) 
Number of 
Ercc1-/Δ mice 
(Vehicle, NBD) 
Vehicle NBD 
Dystonia 8.0 9.1 1.1 17, 17 
Trembling* 7.8 9.8 2.0 17, 17 
Kyphosis 11.3 12.1 0.8 17, 15 
Ataxia** 13.9 16.4 2.5 17, 13 
Sarcopenia*** 14.0 16.9 2.9 16, 11 
Spontaneous 
activity 
17.8 18.4 0.6 8, 2 
Urinary 
incontinence 
13.6 18.5 4.9 5, 2 
Ercc1-/Δ mice were treated with 8KNBD,10 mg/kg, i.p., 3X per week, beginning at 5 weeks of age and continuing 
throughout their lifespan. Shown are the average age-at-onset of each symptom for mice treated with the peptide 
inhibitor or vehicle only (phosphate buffered saline) and the differences between the group averages. Yellow shaded 
cells indicate symptoms delayed in mice treated with the NF-κB inhibitor, 8K-NBD, versus vehicle-treated mice. 
P-values were determined using Student’s t-test. ‘*’, p < 0.05; ‘**’, p < 0.01; ‘***’, p < 0.001. 
 
 108 
Unexpectedly, the age-at-onset of progeroid symptoms was delayed slightly in mutant 
animals treated with the mutant NBD peptide compared to untreated mutant animals (Table 5.2 
vs. Table 5.1), suggesting that the mutant peptide has residual activity, which was confirmed in 
cell culture assays (data not shown). Therefore, we also compared the age-at-onset of symptoms 
in Ercc1-/∆ mice treated with 8K-NBD to Ercc1-/∆ mice treated with vehicle only (phosphate 
buffered saline) (Table 5.3). This comparison revealed a significant delay in the onset of even 
more symptoms in mice treated with 8K-NBD (trembling, ataxia, sarcopenia) and a more 
significant delay of all symptoms assessed. At 15 weeks of age Ercc1-/∆ mice exhibited dystonia 
and cachexia, and by 19 weeks of age incontinence, ocular defects and sarcopenia were obvious 
(Figure 5.7). These symptoms were largely spared in Ercc1-/∆ mice treated with 8K-NBD. These 
data demonstrate that pharmacologic inhibition of NF-κB activation can be used to 
simultaneously delay the onset of symptoms associated with multiple, common age-related 
chronic degenerative diseases. 
 
Figure 5.7: Chronic treatment of Ercc1-/∆ mice with the NF-κB inhibitor, 8K-NBD, significantly delayed 
aging-related symptoms and chronic degenerative diseases 
Ercc1-/∆ mice were treated with 8K-NBD, 10 mg/kg, i.p., 3X per week, beginning at 5 weeks of age and continuing 
throughout their lifespan.  Representative images of Ercc1-/∆ mice treated with 8K-NBD or PBS at 15 and 19 weeks 
of age. Aging-related phenotypes are labeled with arrows. 
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5.2.4 8K-NBD alters NF-B signaling in vivo 
To determine if 8K-NBD indeed affects NF-κB-regulated gene expression in vivo, the gene 
expression profile from liver of 19 week-old Ercc1-/Δ mice chronically exposed to 8K-NBD was 
compared to littermate mutant animals treated with the mutant peptide (8K-mNBD). A full 
mouse genome array revealed 1,269 genes (~5% of all genes) with significantly changed 
expression patterns between 8K-NBD-treated versus 8K-mNBD-treated mice (p ≤ 0.05, 1.2-fold 
change up- or down-regulated). Of the 29 genes with known NF-κB regulatory elements that 
significantly differed between treatment groups, 26 were significantly down-regulated in mice 
treated with 8K-NBD (Table 5.4), demonstrating that 8K-NBD treatment reduces NF-κB activity 
in vivo. 
All genes with significantly altered expression were grouped according to their known or 
predicted biological function into gene ontology (GO) categories. Significantly altered biological 
processes were identified as those with a disproportionate number of genes having altered 
expression relative to those printed on the Affymetrix chip. Five major biological processes were 
significantly suppressed in response to inhibition of NF-κB. These processes, ranked by their 
relative enrichment score, included immune responses, cell cycle regulation, apoptosis, stress 
and DNA damage responses, and growth hormone signaling (Figure 5.8A).   Of note, NF-B is 
known to regulate many of these processes and NF-B activation was one of the GO categories 
identified as suppressed in tissues from mice chronically treated with 8K-NBD (Figure 5.8A).  
To validate the microarray data, the expression of a number of NF-κB target genes was measured 
using qRT-PCR, including Apod, Gadd45b, Bcl2, Lamb2, Icam1, Plcd1 and Sod1 (Figure 5.8B).  
Expression of the majority of these genes was confirmed to be reduced in mice treated with  
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Table 5.4: 8K-NBD inhibits NF-κB in vivo and corrects gene expression changes associated with aging 
Gene symbol Fold change p 
Csf3 1.8 0.001 
Agt 1.2 0.02 
Sod1 1.1 0.04 
Ctsb -1.1 0.02 
Eng -1.2 0.05 
Il15ra -1.2 0.001 
Scarb1 -1.2 0.02 
Prkcd -1.2 0.01 
Icam1 -1.3 0.01 
Nfkbia -1.3 0.02 
Ccnd3 -1.3 0.03 
Ccl19 -1.4 0.04 
Tcrg -1.4 0.01 
App -1.5 0.03 
Bcl2 -1.5 0.007 
Plcd1 -1.6 0.03 
Ccnd2 -1.7 0.02 
Cd48 -1.7 0.03 
Sdc4 1.5 0.006 
Abcb1a -1.8 0.04 
Cd80 -1.9 0.03 
Upk1b -1.9 0.03 
Oas3 -2.0 0.03 
Penk -2.1 0.009 
Ighg1 -2.4 0.03 
Ptx3 -2.4 0.01 
Lamb2 -2.5 0.009 
Gadd45b -3.5 0.02 
Apod -4.4 0.01 
RNA was isolated from the liver of 18-19 week old Ercc1-/Δ mice chronically treated with 8K-NBD or 8K-mNBD (n 
= 4 per group). Differences in gene expression were analyzed using total genome Affymetrix arrays. Shown are 
genes with known NF-κB regulatory elements that were significantly altered in Ercc1-/Δ mice treated with 8K-NBD 
compared to 8K-mNBD. Green indicates genes implicated in inflammation; blue indicates genes implicated in cell 
survival and cell cycle control. 
 
 
8K-NBD relative to littermates treated with the control peptide (n = 4 mice per group; Figure 
5.8B). 
The expression of key genes known to be altered in old WT mice was also evaluated by 
qRT-PCR (Schumacher et al., 2008). The growth hormone/insulin-like growth factor 1 axis is  
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Figure 5.8: 8K-NBD inhibits NF-κB in vivo and corrects gene expression changes associated with aging 
RNA was isolated from liver of 18-19 week-old Ercc1-/∆ mice chronically treated with 8K-NBD or 8K-mNBD (n = 
4 per group). Differences in gene expression were analyzed using total genome Affymetrix arrays. (A) Gene 
ontology enrichment analysis of the networks and pathways regulated by 8K-NBD. The biological processes most 
significantly affected by chronic inhibition of IKK/NF-κB are ranked by their relative enrichment score. (B) qRT-
PCR of genes identified by microarray analysis to be significantly differentially expressed in Ercc1-/∆ mice 
chronically treated with 8K-NBD relative to sibling mutant animals treated with 8K-mNBD. The dashed red line 
indicates mean expression in mice treated with the mutant peptide. The bars indicate the mean expression in mice 
treated with the NF-κB inhibitor 8K-NBD (n = 4 per treatment group) ± S.D. For the NF-κB regulated genes, green 
coloring indicates genes implicated in inflammation; blue indicates genes implicated in cell survival. In black is 
expression of Cdkn2a (the gene encoding p16INK4a), a marker of cellular senescence. 
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downregulated in aged mice and progeroid ERCC1-deficient mice  (Niedernhofer et al., 2006). 
Interestingly, chronic treatment with 8K-NBD led to an increase in expression of many of these 
genes involved in these pathways including Ghr, Prlr and Dio2 (Figure 5.8B). 
5.2.5 Inhibition of NF-kB reduces senescence in vitro and in vivo 
To examine the mechanism through which NF-κB inhibition extends healthspan, we examined 
the role of NF-κB in regulating cellular senescence in vitro.  Primary mouse embryonic 
fibroblasts (MEFs) grown at atmospheric oxygen senesce prematurely due to oxidative stress 
(Parrinello et al., 2003b). DNA repair-deficient Ercc1-/- MEFs senesce even earlier than congenic 
WT cells (Figure 5.9A).  This corresponded with increased γH2AX foci (Figure 5.9B), a marker 
of cellular senescence  (Rodier et al., 2011).  Deletion (p65-/-) or p65 heterozygosity (p65+/-) 
rescued proliferation and senescence to a large extent (Figure 5.9A and Figure 5.9B).  
Hepatocytes of Ercc1-/∆ mice show profound cellular senescence (Gregg et al., 2012a).  Reduced 
expression of p65 resulted in a significant reduction in the number of senescent hepatocytes in 
Ercc1-/∆ mice (Figure 5.9C). In addition, p16INK4a expression was dramatically reduced in the 
livers of Ercc1-/∆ mice chronically treated with 8K-NBD compared to untreated animals (Figure 
5.9D), consistent with the qRT-PCR results (Figure 5.8B).  Taken together, these results 
demonstrate that reducing NF-κB/p65 activity attenuates celluar senescence, at least under 
conditions of stress. 
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Figure 5.9: Inhibition of NF-κB reduces cellular senescence in vitro and in vivo 
(A) Proliferation of WT (black; n = 4), Ercc1-/- (red; n = 3), Ercc1-/-p65+/- (purple; n = 1) and Ercc1-/-p65-/- (orange; 
n = 3) congenic primary MEFs grown at 20% O2 for several passages. Ercc1
-/- MEFs grew slower than WT MEFs, 
while Ercc1-/-p65-/- MEFs showed better growth compared to Ercc1-/- MEFs.   (B) γH2AX staining (red) of passage 
5 WT, Ercc1-/- and Ercc1-/-p65-/- primary MEFs grown at 20% O2. Nuclei were counter-stained with DAPI (blue; 
20x objective). Histogram indicating the percent of cells positive for γH2AX foci. (C) SA β-gal staining of liver 
sections from 10 week-old control, Ercc1-/∆ and Ercc1-/Δp65+/- mice (40x objective). Histogram indicating the 
percent of SA β-gal positive cells from five images from at least nine mice per genotype. Values denote the mean ± 
S.E.M.  '*', p < 0.05, Tukey-Kramer test. (D) Immunodetection of p16 in liver extracts of 19 week-old untreated 
Ercc1-/∆ and NBD-treated Ercc1-/∆  mice. 
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5.2.6 Inhibition of NF-κB reduces oxidative stress and damage in vitro and in vivo 
A key driver of cellular senescence is genotoxic stress (Rodier and Campisi, 2011). Hence, we 
next asked if NF-κB activation in ERCC1-deficient cells regulates oxidative stress.  Ercc1-/- and 
Ercc1-/-p65-/- primary MEFs grown at 20% O2 were stained with DiOC6 (green) to identify 
mitochondria and MitoSOX (red) to measure superoxide anion in mitochondria. Ercc1-/-p65-/- 
MEFs had reduced mitochondrial ROS compared to Ercc1-/- MEFs (Figure 5.10A).  This was 
supported by the observation that Ercc1-/∆p65+/- mice have less lipofuscin in their liver than 
Ercc1-/∆ mice (Figure 5.10B). Lipofuscin is an accumulation of oxidized fatty acids associated 
with aging (Fletcher et al., 1973; Siakotos and Koppang, 1973; Tappel, 1973; Taubold, 1975). 
We also examined the levels of a unique type of oxidatively induced DNA lesions, 
8,5’-cyclopurine-2’-deoxynucleosides (cPu), which include 8,5’-cyclo-2’-deoxyadenosine (cdA) 
and 8,5’-cyclo-2’-deoxyguanosine (cdG).  These lesions may serve as reliable biomarkers of 
oxidative DNA damage because they are rather stable and O2 inhibits their formation, thus 
minimizing their artificial generation during DNA extraction and enzymatic digestion (Jaruga 
and Dizdaroglu, 2008). Levels of all four cPu lesions, i.e., R- and S-diastereomers of cdG and 
cdA, were significantly decreased in Ercc1-/∆p65+/- mice compared to Ercc1-/∆ littermates (Figure 
5.10C). This was also true in Ercc1-/∆ mice chronically treated with 8K-NBD compared to 
untreated mutant animals (Figure 5.10D) These data provide multiple lines of evidence 
supporting the conclusion that reduction in NF-κB activity leads to an attenuation of oxidative 
stress and damage. 
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Figure 5.10: Inhibition of NF-κB reduces oxidative stress and damage in vitro and in vivo 
(A) Ercc1-/- and Ercc1-/-p65-/- passage 6 primary MEFs grown at 20% O2 were stained with DiOC6 (green) to mark 
mitochondria and MitoSOX (red) to detect mitochondrial superoxide anion (40x objective). (B) Liver sections from 
10 week-old Ercc1-/∆ and Ercc1-/Δp65+/- mice imaged for lipofuscin fluorescence (20x objective). Histogram 
indicating the total fluorescent area for five images from three different mice per genotype calculated using 
MetaMorph software. (C) The levels of the (5’R) and (5’S)  diastereomers of 8,5’-cyclo-2’-deoxyguanosine (cdG) 
and 8,5’-cyclo-2’-deoxyadenosine (cdA) in nuclear DNA isolated from the livers of 10 week-old control, p65+/-, 
Ercc1-/∆ and Ercc1-/∆p65+/- mice. (D) The levels of cdG and cdA in nuclear DNA isolated from the livers of 19 
week-old control, untreated Ercc1-/∆and 8K-NBD-treated Ercc1-/∆ mice. '*', p < 0.05, Tukey-Kramer test. Values 
denote the mean ± S.E.M. (n = 3 per group). 
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5.3 DISCUSSION 
Time-dependent accumulation of damage to cells and macromolecules is thought to drive aging 
(Kirkwood, 2005). DNA damage is one type of damage implicated in aging based on the fact that 
mutations affecting a diverse array of DNA repair mechanisms lead to accelerated aging of one 
or more tissues (Hasty et al., 2003a). However, what is not known is the mechanism by which, 
for instance, damage to the nuclear genome drives aging. The mechanism could be via loss of 
functional cells once a threshold of damage is reached. Alternatively, activation of conserved 
stress response pathways may promote aging. Herein, we used a well-defined murine system to 
decipher how damage drives aging: mice that spontaneously age rapidly as a consequence of 
failure to repair endogenous DNA damage (Dollé et al., 2011; Gregg et al., 2012a; Gregg et al., 
2011). 
NF-κB is a family of transcription factors activated in response to a diverse array of 
cellular stressors (Miyamoto, 2011). NF-κB activity increases with chronologic age in a variety 
of tissues of mammals (Bregegere et al., 2006; Giardina and Hubbard, 2002; Helenius et al., 
1996; Korhonen et al., 1997; Xiao and Majumdar, 2000). Thus NF-κB activation could drive 
aging in response to time-dependent accumulation of cell damage. However, prior studies do not 
demonstrate a causal relationship between NF-κB activation and aging. Nor do they reveal what 
drives NF-κB activation with aging. 
Using a knock-in NF-κBEGFP reporter system, we discovered a significant increase in the 
percent of cells in which NF-κB is activated in old and DNA repair-deficient, progeroid mice 
relative to young WT mice. The progeroid mice had increased EGFP expression in kidney, 
skeletal muscle, pancreas and liver (Figure 5.1 and Figure 5.2). There was not significantly 
greater NF-κB activation in the spleen, suggesting that inflammatory cells are not the primary 
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driver of NF-κB activation. These data strongly support the conclusion that spontaneous, 
endogenous DNA damage is sufficient to drive NF-κB activation in vivo.  The resolution 
afforded by the reporter construct revealed that age-related activation of NF-κB is stochastic, 
meaning that there is activation in one cell while none is detected in adjacent cells, rather than 
pan-activation throughout a tissue.  This is consistent with the stochastic theory of aging, which 
posits that cellular damage occurs randomly in a fraction of cells (Kirkwood, 2005). 
We also demonstrate a key causal role for NF-κB in driving multiple age-related 
pathologies. Inhibition of the IKK/NF-κB pathway, genetically through deletion of one copy of 
p65 or pharmacologically using an IKK inhibitory peptide, delayed the onset and severity of 
aging-related pathologies in the musculoskeletal, hepatobiliary, renal, and nervous systems 
(Figure 5.4D and Figure 5.6D). Aging-related symptoms caused by these pathologies were also 
delayed or attenuated (Table 5.1 and Table 5.2). This provides strong experimental evidence that 
an increase of IKK/NF-κB activity plays a causal role in aging. 
We further demonstrate that genetic reduction of NF-κB reduces the amount of 
mitochondrial-derived reactive oxygen species (Figure 5.10A). This could be mediated through 
upregulation of antioxidants. Expression of catalase and targets of NRF2 are significantly 
increased in mice chronically treated with the IKK inhibitor 8K-NBD (Figure 5.8) compared to 
an inactive mutant peptide. In further support of this, oxidative damage to lipids (lipofuscin; 
Figure 5.10B) and DNA (Figure 5.10C and Figure 5.10D) are significantly reduced in 
Ercc1-/Δp65+/- mice and Ercc1-/Δ mice chronically treated with the IKK inhibitor, 8K-NBD. This 
corresponded with a reduction in multiple markers of cellular senescence including reduced 
proliferation of primary cells, increased γH2AX foci and SA β-gal activity.  These data support a 
mechanism by which accumulated cellular damage (in particular DNA damage) with aging leads 
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to activation of NF-κB. This in turn drives increased ROS production and even more cellular 
damage. Inhibiting NF-κB activation in response to stress is sufficient to attenuate damage and 
extend health a murine model of accelerated aging. 
Interestingly, our data indicate that treating Ercc1-/∆ mice with 8K-NBD beginning at five 
weeks of age has a greater beneficial effect than genetic depletion of p65 from conception.  The 
delay in aging symptoms, the attenuation of osteoporosis, and the maintenance of weight were 
greater in mice in which NF-B activity was inhibited pharmacologically compared to 
genetically. This could be because p65/NF-κB has a positive role during development and/or 
early in life. Also, p65 was heterozygous in our mice, and therefore it is possible that the 
remaining copy of p65 is sufficient to initiate a stress response. Alternatively, 8K-NBD may be 
more effective at inhibiting NF-κB in response to stress, possibly because inhibition of IKK 
would act upstream of p65 and could lead to the cytoplasmic sequestration of more than just the 
p65 subunit of NF-κB.  Targeting IKK also may affect other pathways in addition to NF-κB.  For 
example, IKK phosphorylates BCL10, CTNNB1, CCND1, FOXO3, TP53, ESR1, MTOR and 
HIF1A in addition to NF-κB (Li et al., 2007; Lim et al., 2009; Scheidereit, 2006; Shtutman et 
al., 1999). 
The magnitude of the effect on healthspan elicited by NF-κB inhibition has only been 
observed in outbred mice treated with rapamycin (Harrison et al., 2009), which targets the 
mTOR pathway, or by genetic deletion of S6K1, a downstream target of mTOR (Selman et al., 
2009).  Interestingly, mTOR has been shown to activate NF-κB via interaction with IKK (Dan et 
al., 2008).  In contrast to the results with rapamycin and our results with NBD, treatment with 
resveratrol and other SIRT agonists appear only able to extend healthspan and lifespan in mice 
on high fat diets (Baur et al., 2006). 
 119 
Interestingly, chronic inhibition of NF-κB with the 8K-NBD peptide caused a dramatic 
change in gene expression compared to Ercc1-/∆ littermates treated with a less active control 
peptide. Expression of 5% of all genes was significantly altered. Based on ontology analysis of 
these genes, the biological process most significantly affected by NF-κB inhibition was the 
immune response, which was not surprisingly down-regulated. In addition, many processes 
previously demonstrated to be altered in progeroid or old WT mice, including suppression of the 
growth hormone/IGF-1 axis, inhibition of cell cycle progression, activation of pro-apoptotic 
mechanisms and DNA damage/stress response (Niedernhofer et al., 2006), were at least partially 
corrected by NF-κB inhibition. This provides experimental evidence that NF-κB is indeed a 
master regulator of aging-related transcriptional reprogramming. 
Gene expression analysis also confirmed the efficacy of inhibition of IKK/NF-κB by 
8K-NBD, demonstrating decreased expression of numerous genes with known NF-κB promoter 
sequences including Gadd45b, Ccnd2, Ccnd3, Bcl2, Apod and Prkcd (Gilmore, 2009).  The NF-
κB regulated genes that were most down-regulated by 8K-NBD were Apod and Gadd45, both of 
which have been shown to have roles in cellular senescence and age-related disease (Jackson and 
Pereira-Smith, 2006; Provost et al., 1991). Similarly, a number of cytokines and other pro-
inflammatory genes, expressed by senescent cells (Coppe et al., 2008a), are down-regulated in 
Ercc1-/∆ mice chronically treated with 8K-NBD, notably Il16, Il17ra, Il20, Il1r, Il15r, Il28ra, 
Ildr1 and Il6st. 8K-NBD treatment also reduced liver expression of p16 at both mRNA and 
protein level.  Moreover, chronic 8K-NBD treatment significantly upregulated catalase, genes 
regulated by NRF2, and genes involved in mitochondrial respiration, all important in regulating 
ROS levels.  These observations are consistent with the recent demonstration of a key role for 
p16-expressing, senescent cells in driving aging, suggesting that 8K-NBD treatment can reduce 
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senescence (Baker et al., 2011). 8K-NBD treatment also suppressed expression of chemokines 
known to regulate the trafficking of immune cells during inflammation. Overall, the expression 
data demonstrate that inhibition of IKK/NF-κB leads to suppression of numerous processes that 
are known to modulate healthspan including inflammation and cellular senescence. 
In conclusion, these studies demonstrate that spontaneous, endogenous DNA damage can 
activate NF-κB. Activation of NF-κB is stochastic, occurring only in a subset of cells. Chronic 
inhibition of IKK/NF-κB activation is sufficient to delay the onset of aging symptoms and 
chronic aging-related diseases that arise spontaneously in DNA repair–deficient Ercc1-/Δ mice 
that model a human progeroid syndrome.  Moreover, inhibiting NF-κB activation reduces ROS 
production and oxidative damage to lipids and DNA.  This demonstrates a direct causal role for 
NF-κB in driving aging-related changes in response to cellular damage by promoting continued 
damage. Inhibition of NF-κB offers a novel strategy for simultaneously delaying and/or 
attenuating multiple chronic degenerative diseases in progeroid patients and potentially in old 
age. 
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5.4 MATERIALS AND METHODS 
5.4.1 Mice 
Ercc1-/- and Ercc1-/Δ mice were generated in an f1 hybrid background by crossing heterozygous 
Ercc1+/- and Ercc1+/∆ mice from two different inbred C57Bl/6J and FVB/n backgrounds, to 
obtain genetically identical mice without strain-specific pathology. The mice were genotyped 
using PCR as previously described (Ahmad et al., 2008). Ercc1-/-NF-κBEGFP mice were 
generated by crossing Ercc1+/- C57Bl/6J mice with NF-κBEGFP mice (provided by Christian 
Jobin, UNC Chapel Hill) (Karrasch et al., 2007).  These mice were then bred with Ercc1+/- 
FVB/n to generate Ercc1-/-NF-κBEGFP mice. p65+/- mice were bred with Ercc1+/- C57Bl/6J mice.  
These were then bred with Ercc1+/Δ FVB/n to generate Ercc1-/Δp65+/- mice. 
5.4.2 Isolation and treatment of mouse embryonic fibroblasts 
Double heterozygous mice were bred to yield WT, Ercc1-/-, Ercc1-/-p65+/- and Ercc1-/-p65-/- pups 
for isolation of primary mouse embryonic fibroblasts (MEFs) as previously described 
(Niedernhofer et al., 2006). The cells were grown in 1:1 DMEM:Ham’s F10 supplemented with 
10% FBS, 1%, penicillin and streptomycin and 1% non-essential amino acids. They were 
passaged 5 times at 20% oxygen prior to fractionation using the NE-PER Cytoplasmic and 
Nuclear Extraction Reagent Kit (ThermoFisher Scientific, Rockford, IL) for Western blot 
analysis or EMSA. For 8K-NBD treatment, cells were incubated with 200µM 8K-NBD for 3 
hours prior to collection and immunoblotting for p-p65. 
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5.4.3 Nuclear extracts and Western blotting 
Immunodetection of activated NF-κB and IκB in nuclear and cytoplasmic cell fractions was 
performed as previously described (Xiong et al., 2004) using anti-p-p65 (93H1), anti-p-IκBα 
(5A5) (Cell Signaling, Danvers, MA) and anti-IκBα (sc371; Santa Cruz Biotechnology, Santa 
Cruz, CA). Anti-lamin A/C (sc20681; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-β-
actin (Abcam, Cambridge, MA) antibodies were used as loading controls for the nuclear and 
cytoplasmic fractions, respectively. Immunodetection of p16INK4a from liver extracts was 
performed using anti-p16INK4a antibody (sc1207; Santa Cruz Biotechnology, Santa Cruz, CA) 
with anti-tubulin (ab4074, Abcam, Cambridge, MA) as a loading control. All primary antibodies 
were used at a 1:1000 dilution and an overnight incubation at 4°C. 
5.4.4 Electrophoretic mobility shift assay (EMSA) 
EMSA was completed based on a modified protocol described in  (Reay et al., 2011). Briefly, 
nuclear cellular fractions were extracted from MEFs using NE-PER Cytoplasmic and Nuclear 
Extraction Reagent Kit (ThermoFisher Scientific, Rockford, IL).  5 μg of each extract was mixed 
with 2 μL of 5X Gel Shift Binding Buffer (Promega, Madison, WI) and nuclease-free distilled 
water in a 9 μL final volume. This was followed by incubation with  an α-32P-deoxycytodine 
triphosphate radiolabeled DNA probe containing the NF-κB binding domain (MP Biomedicals, 
Solon, OH). The design of the NF-B probe was described previously (Guttridge et al., 1999).  
The oligonucleotide sequences are as follows, with the DNA binding sequence underlined: NF-
κB template: 5′-CAGGGCTGGGGATTCCCCATCTCCACAGTTTCACTTC-3′; NF-κB 
annealing: 5′-GAAGTGAAACTGTGG-3′ (Integrated DNA Technologies, Inc., Coralville, IA).  
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dNTPs used to fill the overhangs were added using  DNA Polymerase I, Large (Klenow) 
Fragment (Invitrogen, Carlsbad, CA) and the reaction was purified using illustra MicroSpin G50 
columns (GE Healthcare, Piscataway, NJ).  Probes were added at a count per minute (cpm) of 
~150,000 in 1 μL, followed by separation on a 6% non-denaturing polyacrylamide gel.  For 
competition assays 2 μl of 100 μg/ml antibodies against p65/RelA and p50 were added to nuclear 
extracts and incubated for 20 minutes, prior to the addition of the duplex oligonucleotide. 
5.4.5 Fluorescence microscopy 
To quantify NF-κB activity, EGFP expression was measured in tissues, using Metamorph 
software (MDS Analytical Technologies, Sunnyvale, CA).  Five 20X images were taken of each 
tissue analyzed for each mouse (n=6 per genotype, age) and the percent of cells expressing EGFP 
was quantified based on tissue area. This was reported as the fold increase in the number of 
EGFP+ cells above the average value for controls. Anti-GFAP (13-0300; Invitrogen, Carlsbad, 
CA) was used at a 1:250 dilution and incubated overnight at 4°C. Anti-p-H2AX (05-636 
Millipore, Billerica, MA) was used at a 1:500 dilution and incubated overnight at 4˚C. For 
lipofuscin analysis, five 40X images were taken of liver sections from control, Ercc1-/Δ and 
Ercc1-/Δp65+/- mice sacrificed at 10 weeks of age (n=3 per genotype). To quantify lipofuscin, the 
total green fluorescent area was quantified using Metamorph software. This was then reported as 
the average total area between the mice in the group. 
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5.4.6 Cell proliferation measurement 
Proliferation was assessed as previously described (Ahmad et al., 2008). Briefly, WT and mutant 
MEFs were plated at a density of 0.25 x 106 per 6cm dish. Cells were trypsinized at confluence, 
counted, and replated at the same density until mutant cells stopped growing. The total number 
of cells at each passage was calculated as follows: [(no. of cells at previous passage/no. of cells 
plated) x no. of cells at current passage]. The total cell number was plotted as the log cell 
number. 
5.4.7 Senescence-associated β-galactosidase 
Fixed liver sections from control, Ercc1-/Δ and Ercc1-/Δp65+/- mice sacrificed at 10 weeks of age 
(n>9 per genotype) were stained for senescence-associated β-galactosidase as described 
previously (Debacq-Chainiaux et al., 2009). Five 40X images per mouse were taken on 
brightfield (SA β-gal) and DAPI staining was use to count total cell number per section. The 
percent of cells that were senescent for each animal was averaged and plotted using standard 
error of the mean for error calculation. 
5.4.8 Measurement of reactive oxygen species in vitro 
To measure superoxide anion levels, Ercc1-/-p65-/- and Ercc1-/- MEFs were grown to 80-90% 
confluency and rinsed with PBS. Media was replaced with serum-free media containing 5µM 
MitoSOX™ reagent (M36008, Invitrogen, Carlsbad, CA) and 2.5µM DiOC6 (D273, Invitrogen, 
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Carlsbad, CA). Cells were incubated for 25 minutes at 37°C. They were then washed twice with 
PBS, replaced with media containing serum, and imaged immediately. 
5.4.9 Measurement of 8,5’-cyclopurine-2’-deoxynucleosides in nuclear DNA of mouse 
livers 
Nuclear DNA was isolated from mouse livers using a high-salt method (Miller et al., 1988b) and 
analyzed for DNA damage as described previously (Wang et al., 2011a).  In brief, nuclear DNA 
was digested using a four-enzyme cocktail, and to the digestion mixture was added uniformly 
15N-labeled cdA and cdG.  The resulting nucleoside mixture was subjected to off-line high 
performance liquid chromatography (HPLC) separation for the enrichment of the lesions under 
study, following previously described procedures (Wang et al., 2011a). The LC-MS/MS/MS 
experiments were conducted using an LTQ linear ion trap mass spectrometer using recently 
described conditions  (Wang et al., 2011a). 
5.4.10 Peptides 
8K-NBD (KKKKKKKKGGTALDWSWLQTE) and inactive 8K-mutant NBD (8K-mNBD) 
(KKKKKKKKGGTALDASALQTE) were synthesized at the University of Pittsburgh Peptide 
facility. Peptides were dissolved in DMSO at 40μM and stored at -80°C until dilution in PBS 
directly before use. 
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5.4.11 NBD treatment of animals 
Sibling pairs of Ercc1-/∆ mice housed in a single cage were treated with 8K-NBD or 8K-mNBD 
10mg/kg three times per week intraperitoneally by an investigator blinded as to the treatment 
group. Treatment began at 5 weeks of age before the animals were symptomatic and continued 
throughout their lifespan. Mice were euthanized via CO2 inhalation at 12 or 18-20 weeks of age 
and tissues isolated for histopathological analysis. 
5.4.12 Phenotype and weight measurements 
Mice were weighed biweekly and assessed for the onset of characteristic progeroid symptoms 
including kyphosis, dystonia, trembling, ataxia, and urinary incontinence due to 
neurodegeneration, muscle wasting and reduced spontaneous activity due to frailty. The aging 
score is an overall measurement of the quality of life or healthspan and reflects the fraction of 
symptoms that occurred later in mice with reduced IKK/NF-κB activity. The aging score was 
determined as follows. For each symptom, the mouse in which the symptom was delayed 
received a score of +1 and the control littermate a score of 0. If the symptoms occurred 
simultaneously in both mice, both mice received score of 0. The sum of score for each animal 
was divided by the number of symptoms measured to determine the fraction of symptoms 
delayed. This number was plotted for each animal as well as average determined for each 
treatment group to give an overall aging score. 
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5.4.13 Immunohistochemistry 
Tissues were fixed in 10% formalin overnight, embedded in paraffin and sectioned using a 
microtome by standard procedures. Haematoxylin and eosin staining was done according to 
standard procedures. Fixed frozen sections of liver were stained for oil red O by the following 
procedure.  Slides were rinsed in running tap water for 10 min, rinsed with 60% isopropanol, 
stained with oil red O for 15 min, rinsed with 60% isopropanol, counterstained by dipping 15 
times in haematoxylin, rinsed with distilled water and mounted with gelvatol. 
5.4.14 Micro-computed tomography 
Micro-computed tomography of the spines isolated from WT and Ercc1-/∆ mice littermates were 
acquired using a VivaCT 40 (Scanco USA, Inc, Wayne, PA) with 15 µm isotropic voxel size 
resolution, 55 kVp of energy and 145 µA of current. After the acquisition of transverse 
two-dimensional image slices, three-dimensional reconstruction of the lumbar vertebrae was 
performed using a constant threshold value of 235, which was selected manually for the bone 
voxels by visually matching the threshold areas to the gray-scale images. 
5.4.15 Microarray 
Genome-wide expression was measured in mice treated with 8K-NBD or 8K-mNBD, as 
previously described (Niedernhofer et al., 2006). All significant gene entries were subjected to 
GO classification (http://www.geneontology.org). Significant overrepresentation of pathways 
and gene networks was determined by DAVID (http://david.abcc.ncifcrf.gov/summary.jsp; 
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through BBID, BIOCARTA and KEGG annotations), as well as by means of the ingenuity 
pathway analysis software (IPA) (www.ingenuity.com). Microarray data is available on 
ArrayExpress (E-MEXP-3615). 
5.4.16 Statistics overview 
To determine significance a two-tailed Student’s t-test was used with p-values of less than 0.05 
considered significant. In addition, higher levels of significance (p < 0.01; p < 0.001) are 
indicated in a Table 5.3. For analysis of experiments involving more than two groups, ANOVA 
with a post-hoc Tukey-Kramer test was performed to determine significance (McDonald, 2009; 
Schumacher et al., 2008). For the microarray data, significant overrepresentation of pathways 
and gene networks was determined by DAVID (http://david.abcc.ncifcrf.gov/summary.jsp; 
through BBID, BIOCARTA and KEGG annotations), as well as by means of the ingenuity 
pathway analysis software (IPA) (www.ingenuity.com). 
5.4.17 Study approval 
Experiments involving mice were reviewed and approved by the University of Pittsburgh 
(Pittsburgh, PA) Institutional Animal Care and Use Committee and in accord with the National 
Institutes of Health guidelines for the humane care of animals. 
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6.0  OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
The overarching goal of my dissertation was to address the contribution that DNA interstrand 
crosslinks have on aging. In order to address this problem, I took a genetic approach using a 
mouse model deficient in the DNA repair endonuclease, ERCC1-XPF. Mutations in this protein 
complex result in premature aging of mice and men (de Waard et al., 2010; Goss et al., 2011; 
Gregg et al., 2012a; Jaspers et al., 2007; Niedernhofer et al., 2006; Vo et al., 2010). One 
advantage to using this mouse model was the elimination of genetic and environmental variables 
that can complicate analyses and produce confounding results. The only difference between the 
mice used in these studies was the mutation in the alleles of Ercc1. Therefore, differences that 
were observed can be directly attributed to the effects of DNA damage. 
ERCC1-deficient mice have been shown to mimic natural aging in multiple organ 
systems (de Waard et al., 2010; Goss et al., 2011; Gregg et al., 2012a; Vo et al., 2010). 
Therefore, because they rapidly, but predictably, age over the course of seven months (de Waard 
et al., 2010), rather than the normal murine lifespan of three years, ERCC1-deficient mice 
present a valuable tool to study the acceleration or delay of aging symptoms in a shortened 
timeframe.  
Data presented herein demonstrate that DNA interstrand crosslinks can promote age-
related degeneration and that amelioration of endogenous sources of DNA damage can result in 
improved healthspan. Chapter 2.0  addressed whether DNA interstrand crosslinks could promote 
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age-related degeneration in vitro and in vivo. This demonstrates for the first time that cytostasis 
(senescence), rather than cytotoxicity (cell death), promotes age-related decline in the liver, 
kidney and brain, and presents a mechanism by which cancer survivors experience symptoms of 
accelerated aging years after chemotherapeutic treatment. The results show that increased DNA 
damage and senescence can be induced by a crosslinking agent, while a monoadducting, 
structurally similar compound, promotes cell death through apoptosis. Additionally, age-related 
symptoms of ERCC1-deficient mice can be accelerated by treatment with a crosslinking agent. 
Taken together, these data indicate that long-term side effects of premature aging can occur as a 
result of cytostasis induced by the crosslinking compound. 
This study on the cytostatic nature of crosslinking agents raises an important issue of 
whether cancer treatment could be applied with the goal of inducing cytostasis, rather than 
cytotoxicity. Recent studies have shown that senescent cells secrete cytokines, chemokines, 
growth factors, cell surface molecules, and survival factors that promote senescence in 
surrounding cells (Coppe et al., 2008b). Human tumor cells are able to senesce, in vitro and in 
vivo, in response to genotoxic chemotherapeutic agents (Coppe et al., 2008b). A study of prostate 
cancer biopsies before and after treatment with the DNA crosslinking agent, mitoxantrone, 
confirmed that the senescence-associated secretory phenotype (SASP) can be induced by 
crosslinking chemotherapy (Coppe et al., 2008b). Therefore, the SASP could be promoting the 
accelerated aging symptoms that result from treatment with crosslinking agents.  An interesting 
study would be to cross ERCC1-deficient mice with INK-ATTAC mice (mice that clear p16INK4a 
expressing cells) (Baker et al., 2011). P16INK4a is a tumor suppressor involved in cell cycle 
regulation. Increased expression of p16INK4a results in reduced proliferative capacity and 
senescence (Kim and Sharpless, 2006). Crossing INK-ATTAC mice to ERCC1-deficient mice 
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would eliminate p16INK4a-positive senescent cells and is proposed to slow the progression of the 
accelerated aging of these mice. In addition, the combined mutant mice could then be treated 
with crosslinking agents and the progression of their aging symptoms could be monitored. It is 
proposed that the elimination of the p16INK4a-positive cells would considerably slow the 
premature aging of Ercc1-/Δ mice. 
Chapter 3.0 addressed whether mitochondrial-produced reactive oxygen species (ROS) 
are an endogenous source of DNA ICLs. The amount of DNA damage and resulting genetic 
mutations found in the nuclear genome increases with age in a variety of tissues in aged 
organisms (Dolle et al., 2002; Hamilton et al., 2001; Mecocci et al., 1999; Wang et al., 2012). In 
addition, mitochondria are the main source of ROS, due to normal cellular respiration (Doig et 
al., 2006; Tronche et al., 2002), some of which can diffuse throughout the cell damaging lipids, 
DNA, RNA and proteins (Chakravarti and Chakravarti, 2007; Cooke et al., 2003; Cui et al., 
2012; Mandavilli et al., 2002). We found that targeting a radical scavenger directly to the 
mitochondria reduced the amount of nuclear oxidative DNA damage. In fact, we found that not 
only was DNA damage reduced by treatment with XJB, but aging-associated symptoms and 
pathologies in Ercc1-/Δ mice were also delayed supporting the hypothesis that ROS-induced 
crosslinks are a potential source of endogenous DNA damage that drives aging. 
Future plans should include directly measuring ROS through spin trap assays and 
2’,7’-dichlorofluorescein diacetate (DCFDA) fresh tissue assays. Preliminary DCFDA data show 
that there is a significant increase of ROS in liver extracts of Ercc1-/Δ mice. Measuring ROS in 
tissues from mice treated with XJB would directly show that the radical scavenger can deplete 
harmful ROS in various tissues throughout the organism. In addition, ERCC1-deficient mice 
could be crossed with mice that overexpress superoxide dismutase to genetically deplete ROS. 
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As we found a delay of neurodegenerative phenotypes in the ERCC1-deficient mice treated with 
XJB, previous studies have indicated that superoxide dismutase overexpressing mice can rescue 
neurodegenerative phenotypes (Massaad et al., 2009).  
Chapter 4.0 of my dissertation investigated lipid peroxidation (LPO) as a potential 
endogenous source of DNA ICLs. To induce LPO, mice were treated with a sub-lethal dose of 
CCl4 or a diet high in polyunsaturated fatty acids (PUFAs). Lipid hydroperoxides, one byproduct 
of LPO, are increased in both normally and prematurely aged mice (Tokumaru et al., 1996). In 
fact, CCl4 treatment of Ercc1
-/Δ mice resulted in a further increase of lipid hydroperoxide. This 
coincided with extreme exaggeration of aging-associated liver pathologies. Similar changes, 
though to a much lesser extent were observed in the liver of Ercc1-/Δ mice fed a diet high in 
PUFAs. Analysis of kidneys from the ERCC1-deficient mice fed the high PUFA diet also 
showed aging-related histopathological changes. 
As previously discussed, future studies will include analyzing additional tissues from 
these mice. Furthermore, tissues should also be analyzed for the mechanism that leads to the 
acceleration of the Ercc1-/Δ aging phenotype. TUNEL and cleaved caspase-3 staining can be 
completed to identify whether apoptosis plays a role. However, based on data from the 
mechlorethamine study, cellular senescence is likely the cause. Unfortunately, senescence 
markers require either fixed frozen or snap frozen tissues, which are unavailable from these 
mice. Therefore, repeating CCl4 treatment of the mice would be beneficial, not only to obtain 
samples for senescence analyses, but this would also allow for LPO to be measured overtime to 
determine if there is a critical level of lipid peroxidation that the mice must pass before they 
exhibit increased pathologies and symptoms associated with aging. If this is the case, additional 
interventional studies could be completed, to investigate whether treating mice at later 
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timepoints, before the threshold is hit, would rescue or delay the acceleration of age-associated 
symptoms and pathologies. 
Finally, chapter 5.0 in my dissertation investigated the role in NF-κB and aging. We 
found that NF-κB is increased in both normal and prematurely aged mice. In addition, DNA 
damage activates NF-κB, which promotes aging. Futhermore, by both genetic and pharmacologic 
inhibition of NF-κB, we were able to delay symptoms and pathologies associated with advanced 
age in the Ercc1-/Δ mice.  
Because NF-κB was found to only be activated in a subset of cells in a stochastic manner 
within various tissues, additional studies are underway to pinpoint the individual cell types in 
which NF-κB is activated. Future studies should focus on treating NF-κBEGFP reporter mice with 
XJB to determine if a reduction in ROS can also attenuate NF-κB activation. This would help to 
reveal the order of events during the process of senescence. 
My studies have revealed a cytostatic mechanism of premature aging in relation to 
increased DNA damage. In addition, we have shown that viable therapeutic approaches exist that 
could present novel methods to delay and attenuate the symptoms of aging, thereby increasing 
the quality of life in old age. 
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7.0  PUBLIC HEALTH PERSPECTIVE 
Between 2000 and 2030, as a result of the aging “baby boom” generation, the number of older 
Americans (age 65 and over) is expected to double and comprise nearly 20% of the total 
population (Greenberg, 2011; Gregg et al., 2012a). In addition, the biggest risk factor for a 
number of diseases including cancer, heart disease, arthritis, and dementia is advanced age 
(Resnick and Dosa, 2004).  In light of the projected increase in the population of older 
Americans, the cost of healthcare will skyrocket and is projected to reach $4.6 trillion by 2020, a 
two-fold increase since 2008 (2012b). Consequently, identifying the causes of aging and 
strategies to ameliorate aging-related diseases, while preserving tissue homeostasis, is a pressing 
public health issue.  
Furthermore, because early clinical chemotherapy trials were started in the late 1970s and 
early 1980s, only now has long-term toxicity become evident in cancer survivors (Maccormick, 
2006). Patients have suffered from a number of health problems that are typically associated with 
advanced age, including neurodegenerative, musculoskeletal and osteoporotic symptoms, as well 
as skin changes and fatigue. Therefore, chemotherapies have been identified as a possible source 
of premature aging in long-term cancer survivors (Grillari et al., 2007; Maccormick, 2006). Our 
studies, utilizing DNA-repair deficient mice that age rapidly address both of these needs, 
enabling us to test hypotheses about the causes of aging, how DNA damage contributes to aging, 
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and also to identify things in our environment (exposures and diets) that lead to DNA damage, 
which if avoided could promote improved health in old age.  
 
 136 
  APPENDIX 
PUBLICATIONS 
Robinson, A.R.*, Tilstra, J.S.*, Wang, J.*, Gregg, S.Q.*, Clauson, C.L.*, Reay, D., Nasto, L.A., 
St. Croix, C.,  Usas, A., Vo, N., Huard, J. Clemens, P., Stoltz, D.B., Gutteridge, D.C., 
Watkins, S.C., Garinis, G.A., Wang, Y., Niedernhofer, L.J., and P.D. Robbins, P.D. 
(2012) Inhibition of NF-κB transcriptional activation delays the onset of age-related 
degenerative disease. Journal of Clinical Investigation (accepted).  
Nasto, L.A., Seo, H.Y., Robinson, A.R., Tilstra, J.S., Clauson, C.L., Sowa, G.A., Ngo, K., 
Dong, Q., Pola, E., Lee, J.Y., Niedernhofer, L.J., Kang, J.D., Robbins, P.D., and N. Vo. 
(2012) Inhibition of NF-κB activity ameliorates age-associated disc degeneration in a 
mouse model of accelerated aging. Spine (accepted). PMID: 22343279 
Smith, S.C., Robinson, A.R., Niedernhofer, L.J. and M. Hetman (2012) Down-regulation of 
cholesterol biosynthesis in forebrains of ERCC1-deficient mice. Neurobiology of 
Disease. 45, 1136-1144. PMID: 22245387. 
Lavasani, M., Robinson, A.R., Lu, A., Song, M., Feduska, J.M., Ahani, B., Tilstra, J.S., 
Feldman, C.H., Robbins, P.D., Niedernhofer, L.J.*, J. Huard* (2012) Muscle-derived 
stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria 
model. Nature Communications. 3, 608. PMID: 22215083. 
Gregg, S.Q., Gutierrez, V., Robinson, A.R., Woodell, T., Nakao, A., Ross, M., Michalopolous, 
G., Rigatti, L., Rothermel, C.E., Stolz, D.B. and L.J. Niedernhofer. (2011). A mouse 
model of accelerated liver aging due to a defect in DNA repair. Hepatology 55, 609-621. 
PMID: 21953681. 
Gregg, S.Q., Robinson, A.R. and L.J. Niedernhofer. (2011). Physiological consequences of 
defects in ERCC1-XPF DNA repair endonuclease. DNA Repair (Amst) 10, 781-791. 
PMID: 21612988. 
 137 
Goss, J.R., Stolz, D.B., Robinson, A.R., Zhang, M., Arbujas, N., Robbins, P.D., Glorioso, J.C. 
and L.J. Niedernhofer. (2011). Premature aging –related peripheral neuropathy in a 
mouse model of progeria. Mechanisms of Ageing and Development. PMID: 21596054. 
Matoka, D.J., Yao, V., Harya, D.S., Gregg, J.L., Robinson, A.R., Niedernhofer, L.J., Parwani, 
A., Maier, C., and D.J. Bacich (2011) Deficiency of DNA repair nuclease ERCC1-XPF 
promotes prostate cancer progression in a tissue recombination model. The Prostate. 
PMID: 22212909. 
Vo, N., Seo, H.Y., Robinson, A., Sowa, G., Bentley, D., Taylor, L., Studer, R., Usas, A., Huard, 
J., Alber, S., Watkins, S.C., Lee, J., Coehlo, P., Wang, D., Loppini, M., Robbins, P.D., 
Niedernhofer, L.J. and J. Kang. (2010). Accelerated aging of intervertebral discs in a 
mouse model of progeria. Journal of Orthopaedic Research. 28, 1600-1607. PMID: 
20973062. 
Schumacher, B., van der Pluijm, I., Moorhouse, M.J., Kosteas, T., Robinson, A.R., Suh, Y., 
Breit, T.M., van Steeg, H., Niedernhofer, L.J., van Ijcken, W., Bartke, A., Spindler, S.R., 
Hoeijmakers, J.H., van der Horst, G.T. and G.A.Garinis. (2008). Delayed and accelerated 
aging share common longevity assurance mechanisms. PLoS Genetics. 4, e1000161. 
PMID: 18704162. 
Ahmad, A., Robinson, A.R., Duensing, A., van Drunen, E., Beverloo, H.B., Weisberg, D.B., 
Hasty, P., Hoeijmakers, J.H. and L.J. Niedernhofer. (2008). ERCC1-XPF endonuclease 
facilitates DNA double-strand break repair. Molecular and Cellular Biology. 28: 5082-
5092. PMID: 18541667. 
Jaspers, N.G.J., Raams, A., Silengo, M.C., Wijgers, N., Niedernhofer, L.J., Robinson, A.R., 
Giglia,-Mari, G., Hoogstraten, D., Hoeijmakers, J.H.J, and W. Vermeulen (2007) First 
case of human ERCC1 deficiency displays a mild defect in nucleotide excision repair but 
severe developmental failure. American Journal of Human Genetics. 80(3):457-66. 
PMID: 17273966. 
Niedernhofer, L.J., Garinis, G.A., Raams, A., Lalai, A.S., Robinson, A.R., Appeldoorn, E., 
Lalai, A., Odijk, H., Oostendorp, R., Ahmad, A., van Leeuwen, W., Theil, A.F., van der 
Horst, G.T.J., Vermeulen, W., Meinecke, P., Kleijer, W.J., Vijg, J., Jaspers, N.G.J., and 
J.H.J. Hoeijmakers (2006) A novel progeroid syndrome reveals that genotoxic stress 
suppresses the somatotroph axis. Nature. 444(7122):1038-43. PMID: 17183314. 
 138 
BIBLIOGRAPHY 
(1992). Carbon Tetrachloride. In Technology Transfer Network (U.S. Environmental Protection 
Agency). 
 
(2001a). Summary of the toxicity assessment of carbon tetrachloride, S.A.B.o.T.A. Pollutants, 
ed. (Raleigh, NC). 
 
(2001b). World Population Ageing: 1950-2050, D.o.E.a.S. Affairs, ed. (New York, NY)). 
 
(2009). Cadmium Compounds. Hazardous Substances Data Bank TOXNET, 
http://toxnet.nlm.nih.gov/. Accessed 5/4/2012. 
 
(2011a). Healthy Aging: Fact Sheet, N.C.o. Aging, ed. (Washington, D.C.). 
 
(2011b). USDA National Nutrient Database for Standard Reference (USDA, Agricultural 
Research Service)). 
 
(2012a). Melphalan. In MedlinePlus (Bethesda, MD, U.S. National Library of Medicine). 
 
(2012b). National Health Expenditure Projections 2010-2020, C.f.M.M. Services, ed. (Baltimore, 
MD, Office of the Actuary). 
 
Acharyya, S., Villalta, S.A., Bakkar, N., Bupha-Intr, T., Janssen, P.M., Carathers, M., Li, Z.W., 
Beg, A.A., Ghosh, S., Sahenk, Z., et al. (2007). Interplay of IKK/NF-kappaB signaling in 
macrophages and myofibers promotes muscle degeneration in Duchenne muscular 
dystrophy. J Clin Invest 117, 889-901. 
 
Adair, G.M., Rolig, R.L., Moore-Faver, D., Zabelshansky, M., Wilson, J.H., and Nairn, R.S. 
(2000). Role of ERCC1 in removal of long non-homologous tails during targeted 
homologous recombination. EMBO J 19, 5552-5561. 
 
Adler, A., Sinha, S., Kawahara, TLA., Zhang, JY., Segal, E., Chang, HY. (2007). Motif module 
map reveals enforcement of aging by continual NF-kB activity. Genes Dev 21. 
 
Ahmad, A., Enzlin, J.H., Bhagwat, N.R., Wijgers, N., Raams, A., Appledoorn, E., Theil, A.F., 
JH, J.H., Vermeulen, W., NG, J.J., et al. (2010). Mislocalization of XPF-ERCC1 
nuclease contributes to reduced DNA repair in XP-F patients. PLoS Genet 6, e1000871. 
 
 139 
Ahmad, A., Robinson, A.R., Duensing, A., van Drunen, E., Beverloo, H.B., Weisberg, D.B., 
Hasty, P., Hoeijmakers, J.H., and Niedernhofer, L.J. (2008). ERCC1-XPF endonuclease 
facilitates DNA double-strand break repair. Mol Cell Biol 28, 5082-5092. 
 
Al-Minawi, A.Z., Saleh-Gohari, N., and Helleday, T. (2008). The ERCC1/XPF endonuclease is 
required for efficient single-strand annealing and gene conversion in mammalian cells. 
Nucleic Acids Res 36, 1-9. 
 
Ames, B.N. (1989). Endogenous DNA damage as related to cancer and aging. Mutat Res 214, 
41-46. 
 
Andersen, S.L., Bergstralh, D.T., Kohl, K.P., LaRocque, J.R., Moore, C.B., and Sekelsky, J. 
(2009). Drosophila MUS312 and the vertebrate ortholog BTBD12 interact with DNA 
structure-specific endonucleases in DNA repair and recombination. Mol Cell 35, 128-
135. 
 
Anderson, S.K., and Walker, E.B. Medicinal Chemistry. In Anticancer Drugs. 
 
Andrew, W. (1962). An electron microscope study of age changes in the liver of the mouse. Am 
J Anat 110, 1-18. 
 
Arase, S., Kozuka, T., Tanaka, K., Ikenaga, M., and Takebe, H. (1979). A sixth complementation 
group in xeroderma pigmentosum. Mutat Res 59, 143-146. 
 
Astorg, P., Arnault, N., Czernichow, S., Noisette, N., Galan, P., and Hercberg, S. (2004). Dietary 
intakes and food sources of n-6 and n-3 PUFA in French adult men and women. Lipids 
39, 527-535. 
 
Auerbach, A.D. (2009). Fanconi anemia and its diagnosis. Mutat Res 668, 4-10. 
 
Axelrad, J.E., Louis, E.D., Honig, L.S., Flores, I., Ross, G.W., Pahwa, R., Lyons, K.E., Faust, 
P.L., and Vonsattel, J.P. (2008). Reduced Purkinje cell number in essential tremor: a 
postmortem study. Arch Neurol 65, 101-107. 
 
Bae, Y.S., Oh, H., Rhee, S.G., and Yoo, Y.D. (2011). Regulation of reactive oxygen species 
generation in cell signaling. Mol Cells 32, 491-509. 
 
Baker, B.S., Carpenter, A.T., and Ripoll, P. (1978). The Utilization during Mitotic Cell Division 
of Loci Controlling Meiotic Recombination and Disjunction in DROSOPHILA 
MELANOGASTER. Genetics 90, 531-578. 
 
Baker, D.J., Wijshake, T., Tchkonia, T., LeBrasseur, N.K., Childs, B.G., van de Sluis, B., 
Kirkland, J.L., and van Deursen, J.M. (2011). Clearance of p16Ink4a-positive senescent 
cells delays ageing-associated disorders. Nature 479, 232-236. 
 
 140 
Balaban, R.S., Nemoto, S., and Finkel, T. (2005). Mitochondria, oxidants, and aging. Cell 120, 
483-495. 
 
Bardwell, A.J., Bardwell, L., Tomkinson, A.E., and Friedberg, E.C. (1994). Specific cleavage of 
model recombination and repair intermediates by the yeast Rad1-Rad10 DNA 
endonuclease. Science 265, 2082-2085. 
 
Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A., Prabhu, V.V., Allard, 
J.S., Lopez-Lluch, G., Lewis, K., et al. (2006). Resveratrol improves health and survival 
of mice on a high-calorie diet. Nature 444, 337-342. 
 
Behl, C. (1999). Alzheimer's disease and oxidative stress: implications for novel therapeutic 
approaches. Prog Neurobiol 57, 301-323. 
 
Berenbaum, F. (2004). Signaling transduction: target in osteoarthritis. Curr Opin Rheumatol 16, 
616-622. 
 
Berger, F., Paulmurugan, R., Bhaumik, S., and Gambhir, S.S. (2008). Uptake kinetics and 
biodistribution of 14C-D-luciferin--a radiolabeled substrate for the firefly luciferase 
catalyzed bioluminescence reaction: impact on bioluminescence based reporter gene 
imaging. Eur J Nucl Med Mol Imaging 35, 2275-2285. 
 
Berneburg, M., Clingen, P.H., Harcourt, S.A., Lowe, J.E., Taylor, E.M., Green, M.H., Krutmann, 
J., Arlett, C.F., and Lehmann, A.R. (2000). The cancer-free phenotype in 
trichothiodystrophy is unrelated to its repair defect. Cancer Res 60, 431-438. 
 
Bhagwat, N., Olsen, A.L., Wang, A.T., Hanada, K., Stuckert, P., Kanaar, R., D'Andrea, A., 
Niedernhofer, L.J., and McHugh, P.J. (2009). XPF-ERCC1 participates in the Fanconi 
anemia pathway of cross-link repair. Mol Cell Biol 29, 6427-6437. 
 
Bosma, P.T., van Eert, S.J., Jaspers, N.G., Stoter, G., and Nooter, K. (2003). Functional cloning 
of drug resistance genes from retroviral cDNA libraries. Biochem Biophys Res Commun 
309, 605-611. 
 
Brack, A.S., Conboy, M.J., Roy, S., Lee, M., Kuo, C.J., Keller, C., and Rando, T.A. (2007). 
Increased Wnt Signaling During Aging Alters Muscle Stem Cell Fate and Increases 
Fibrosis. Science 317, 807-810. 
 
Bregegere, F., Milner, Y., and Friguet, B. (2006). The ubiquitin-proteasome system at the 
crossroads of stress-response and ageing pathways: a handle for skin care? Ageing Res 
Rev 5, 60-90. 
 
Brookman, K.W., Lamerdin, J.E., Thelen, M.P., Hwang, M., Reardon, J.T., Sancar, A., Zhou, 
Z.Q., Walter, C.A., Parris, C.N., and Thompson, L.H. (1996). ERCC4 (XPF) encodes a 
human nucleotide excision repair protein with eukaryotic recombination homologs. Mol 
Cell Biol 16, 6553-6562. 
 141 
 
Brooks, P.J. (2007). The case for 8,5'-cyclopurine-2'-deoxynucleosides as endogenous DNA 
lesions that cause neurodegeneration in xeroderma pigmentosum. Neuroscience 145, 
1407-1417. 
 
Brooks, P.J., Wise, D.S., Berry, D.A., Kosmoski, J.V., Smerdon, M.J., Somers, R.L., Mackie, H., 
Spoonde, A.Y., Ackerman, E.J., Coleman, K., et al. (2000). The oxidative DNA lesion 
8,5'-(S)-cyclo-2'-deoxyadenosine is repaired by the nucleotide excision repair pathway 
and blocks gene expression in mammalian cells. J Biol Chem 275, 22355-22362. 
 
Bubici, C., Papa, S., Dean, K., and Franzoso, G. (2006). Mutual cross-talk between reactive 
oxygen species and nuclear factor-kappa B: molecular basis and biological significance. 
Oncogene 25, 6731-6748. 
 
Buege, J.A., and Aust, S.D. (1978). Microsomal lipid peroxidation. Methods Enzymol 52, 302-
310. 
 
Busch, D.B., van Vuuren, H., de Wit, J., Collins, A., Zdzienicka, M.Z., Mitchell, D.L., 
Brookman, K.W., Stefanini, M., Riboni, R., Thompson, L.H., et al. (1997). Phenotypic 
heterogeneity in nucleotide excision repair mutants of rodent complementation groups 1 
and 4. Mutat Res 383, 91-106. 
 
Cai, D., Frantz, J.D., Tawa, N.E., Jr., Melendez, P.A., Oh, B.C., Lidov, H.G., Hasselgren, P.O., 
Frontera, W.R., Lee, J., Glass, D.J., et al. (2004). IKKbeta/NF-kappaB activation causes 
severe muscle wasting in mice. Cell 119, 285-298. 
 
Carlsen, H., Moskaug, J.O., Fromm, S.H., and Blomhoff, R. (2002). In vivo imaging of NF-
kappa B activity. J Immunol 168, 1441-1446. 
 
Caruso, L.B., and Silliman, R.A. (2006). Geriatric Medicine, 17 edn (New York, McGraw Hill). 
 
Chakravarti, B., and Chakravarti, D.N. (2007). Oxidative modification of proteins: age-related 
changes. Gerontology 53, 128-139. 
 
Chance, B., Sies, H., and Boveris, A. (1979). Hydroperoxide metabolism in mammalian organs. 
Physiol Rev 59, 527-605. 
 
Charloux, C., Paul, M., Loisance, D., and Astier, A. (1995). Inhibition of hydroxyl radical 
production by lactobionate, adenine, and tempol. Free Radic Biol Med 19, 699-704. 
 
Chipchase, M.D., O'Neill, M., and Melton, D.W. (2003). Characterization of premature liver 
polyploidy in DNA repair (Ercc1)-deficient mice. Hepatology 38, 958-966. 
 
Christakis, P. (2011). The birth of chemotherapy at Yale. Bicentennial lecture series: Surgery 
Grand Round. Yale J Biol Med 84, 169-172. 
 
 142 
Chung, H.Y., Cesari, M., Anton, S., Marzetti, E., Giovannini, S., Seo, A.Y., Carter, C., Yu, B.P., 
and Leeuwenburgh, C. (2009). Molecular inflammation: underpinnings of aging and age-
related diseases. Ageing Res Rev 8, 18-30. 
 
Conboy, I.M., Conboy, M.J., Wagers, A.J., Girma, E.R., Weissman, I.L., and Rando, T.A. 
(2005). Rejuvenation of aged progenitor cells by exposure to a young systemic 
environment. Nature 433, 760-764. 
 
Cooke, M.S., Evans, M.D., Dizdaroglu, M., and Lunec, J. (2003). Oxidative DNA damage: 
mechanisms, mutation, and disease. FASEB J 17, 1195-1214. 
 
Coppe, J.P., Patil, C.K., Rodier, F., Sun, Y., Munoz, D.P., Goldstein, J., Nelson, P.S., Desprez, 
P.Y., and Campisi, J. (2008a). Senescence-associated secretory phenotypes reveal cell-
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 
2853-2868. 
 
Coppe, J.P., Patil, C.K., Rodier, F., Sun, Y., Munoz, D.P., Goldstein, J., Nelson, P.S., Desprez, 
P.Y., and Campisi, J. (2008b). Senescence-associated secretory phenotypes reveal cell-
nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6, 
2853-2868. 
 
Crossan, G.P., van der Weyden, L., Rosado, I.V., Langevin, F., Gaillard, P.H., McIntyre, R.E., 
Gallagher, F., Kettunen, M.I., Lewis, D.Y., Brindle, K., et al. (2011). Disruption of 
mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat 
Genet 43, 147-152. 
 
Cuaz-Perolin, C., Billiet, L., Bauge, E., Copin, C., Scott-Algara, D., Genze, F., Buchele, B., 
Syrovets, T., Simmet, T., and Rouis, M. (2008). Antiinflammatory and antiatherogenic 
effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged 
ApoE-/- mice. Arterioscler Thromb Vasc Biol 28, 272-277. 
 
Cui, H., Kong, Y., and Zhang, H. (2012). Oxidative stress, mitochondrial dysfunction, and aging. 
J Signal Transduct 2012, 646354. 
 
Dai, S., Hirayama, T., Abbas, S., and Abu-Amer, Y. (2004). The IkappaB kinase (IKK) inhibitor, 
NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in 
inflammatory arthritis. J Biol Chem 279, 37219-37222. 
 
Dan, H.C., Cooper, M.J., Cogswell, P.C., Duncan, J.A., Ting, J.P., and Baldwin, A.S. (2008). 
Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in 
association with IKK. Genes Dev 22, 1490-1500. 
 
Dave, S.H., Tilstra, J.S., Matsuoka, K., Li, F., Karrasch, T., Uno, J.K., Sepulveda, A.R., Jobin, 
C., Baldwin, A.S., Robbins, P.D., et al. (2007). Amelioration of chronic murine colitis by 
peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain 
peptide. J Immunol 179, 7852-7859. 
 143 
 
de Boer, J., Andressoo, J.O., de Wit, J., Huijmans, J., Beems, R.B., van Steeg, H., Weeda, G., 
van der Horst, G.T., van Leeuwen, W., Themmen, A.P., et al. (2002). Premature aging in 
mice deficient in DNA repair and transcription. Science 296, 1276-1279. 
 
de Laat, W.L., Jaspers, N.G., and Hoeijmakers, J.H. (1999). Molecular mechanism of nucleotide 
excision repair. Genes Dev 13, 768-785. 
 
de Laat, W.L., Sijbers, A.M., Odijk, H., Jaspers, N.G., and Hoeijmakers, J.H. (1998). Mapping 
of interaction domains between human repair proteins ERCC1 and XPF. Nucleic Acids 
Res 26, 4146-4152. 
 
De Silva, I.U., McHugh, P.J., Clingen, P.H., and Hartley, J.A. (2000). Defining the roles of 
nucleotide excision repair and recombination in the repair of DNA interstrand cross-links 
in mammalian cells. Mol Cell Biol 20, 7980-7990. 
 
de Vries, A., van Oostrom, C.T., Hofhuis, F.M., Dortant, P.M., Berg, R.J., de Gruijl, F.R., 
Wester, P.W., van Kreijl, C.F., Capel, P.J., van Steeg, H., et al. (1995). Increased 
susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair 
gene XPA. Nature 377, 169-173. 
 
de Waard, M.C., van der Pluijm, I., Zuiderveen Borgesius, N., Comley, L.H., Haasdijk, E.D., 
Rijksen, Y., Ridwan, Y., Zondag, G., Hoeijmakers, J.H., Elgersma, Y., et al. (2010). 
Age-related motor neuron degeneration in DNA repair-deficient Ercc1 mice. Acta 
Neuropathol 120, 461-475. 
 
Debacq-Chainiaux, F., Erusalimsky, J.D., Campisi, J., and Toussaint, O. (2009). Protocols to 
detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of 
senescent cells in culture and in vivo. Nat Protoc 4, 1798-1806. 
 
Diderich, K., Alanazi, M., and Hoeijmakers, J.H. (2011). Premature aging and cancer in 
nucleotide excision repair-disorders. DNA Repair (Amst) 10, 772-780. 
 
Dimri, G.P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E.E., Linskens, 
M., Rubelj, I., Pereira-Smith, O., et al. (1995). A biomarker that identifies senescent 
human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92, 9363-
9367. 
 
Ding, L., Kuhne, W.W., Hinton, D.E., Song, J., and Dynan, W.S. (2010). Quantifiable 
biomarkers of normal aging in the Japanese medaka fish (Oryzias latipes). PLoS One 5, 
e13287. 
 
Doig, J., Anderson, C., Lawrence, N.J., Selfridge, J., Brownstein, D.G., and Melton, D.W. 
(2006). Mice with skin-specific DNA repair gene (Ercc1) inactivation are hypersensitive 
to ultraviolet irradiation-induced skin cancer and show more rapid actinic progression. 
Oncogene 25, 6229-6238. 
 144 
 
Dollé, M., Kuiper, R., Roodbergen, M., Robinson, J., Vlugt, S., Wijnhoven, S., Beems, R., 
Fonteyne, L., With, P., Pluijm, I., et al. (2011). Broad segmental progeroid changes in 
short-lived Ercc1-/ 7 mice. In Pathobiology of Aging & Age-related Diseases. 
 
Dolle, M.E., Busuttil, R.A., Garcia, A.M., Wijnhoven, S., van Drunen, E., Niedernhofer, L.J., 
van der Horst, G., Hoeijmakers, J.H., van Steeg, H., and Vijg, J. (2006). Increased 
genomic instability is not a prerequisite for shortened lifespan in DNA repair deficient 
mice. Mutat Res 596, 22-35. 
 
Dolle, M.E., Snyder, W.K., Dunson, D.B., and Vijg, J. (2002). Mutational fingerprints of aging. 
Nucleic Acids Res 30, 545-549. 
 
Dronkert, M.L., and Kanaar, R. (2001). Repair of DNA interstrand cross-links. Mutat Res 486, 
217-247. 
 
Ellis, N.A., Ciocci, S., and German, J. (2001). Back mutation can produce phenotype reversion 
in Bloom syndrome somatic cells. Hum Genet 108, 167-173. 
 
Enzlin, J.H., and Scharer, O.D. (2002). The active site of the DNA repair endonuclease XPF-
ERCC1 forms a highly conserved nuclease motif. EMBO J 21, 2045-2053. 
 
Fagbemi, A.F., Orelli, B., and Scharer, O.D. (2011). Regulation of endonuclease activity in 
human nucleotide excision repair. DNA Repair (Amst) 10, 722-729. 
 
Fan, L., Fuss, J.O., Cheng, Q.J., Arvai, A.S., Hammel, M., Roberts, V.A., Cooper, P.K., and 
Tainer, J.A. (2008). XPD helicase structures and activities: insights into the cancer and 
aging phenotypes from XPD mutations. Cell 133, 789-800. 
 
Faroon, O., Taylor, J., Roney, N., Fransen, M.E., Bogaczyk, S., and Diamond, G. (2005). 
Toxicological profile for carbon tetrachloride, U.S.D.o.H.a.H. Services, ed. (Atlanta, GA, 
Agency for Toxic Substances and Disease Registry). 
 
Farrell, G.C., and Larter, C.Z. (2006). Nonalcoholic fatty liver disease: from steatosis to 
cirrhosis. Hepatology 43, S99-S112. 
 
Fawell, J.K., and Mascarenhas, R. (2004). Carbon tetrachloride in drinking-water, W. Water 
Sanitation and Health Programme, ed. (World Health Organization). 
 
Fekairi, S., Scaglione, S., Chahwan, C., Taylor, E.R., Tissier, A., Coulon, S., Dong, M.Q., Ruse, 
C., Yates, J.R., 3rd, Russell, P., et al. (2009). Human SLX4 is a Holliday junction 
resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell 138, 
78-89. 
 
 145 
Fink, M.P., Macias, C.A., Xiao, J., Tyurina, Y.Y., Jiang, J., Belikova, N., Delude, R.L., 
Greenberger, J.S., Kagan, V.E., and Wipf, P. (2007). Hemigramicidin-TEMPO 
conjugates: novel mitochondria-targeted anti-oxidants. Biochem Pharmacol 74, 801-809. 
 
Fishman-Lobell, J., and Haber, J.E. (1992). Removal of nonhomologous DNA ends in double-
strand break recombination: the role of the yeast ultraviolet repair gene RAD1. Science 
258, 480-484. 
 
Fletcher, B.L., Dillard, C.J., and Tappel, A.L. (1973). Measurement of fluorescent lipid 
peroxidation products in biological systems and tissues. Anal Biochem 52, 1-9. 
 
Franceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M.P., Invidia, 
L., Celani, L., Scurti, M., et al. (2007). Inflammaging and anti-inflammaging: a systemic 
perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 
128, 92-105. 
 
Frantz, M.C., and Wipf, P. (2010). Mitochondria as a target in treatment. Environ Mol Mutagen 
51, 462-475. 
 
Friedberg, E.C., Walker, G.C., Siede, W., Wood, R.D., Schultz, R.A., and Ellenberger, T. 
(2006). DNA Repair and Mutagenesis, 2nd ed. edn (Washington, D.C., ASM Press). 
 
Fujiwara, Y., Ichihashi, M., Uehara, Y., Matsumoto, A., Yamamoto, Y., Kano, Y., and Tanakura, 
Y. (1985a). Xeroderma pigmentosum groups C and F: additional assignments and a 
review of the subjects in Japan. J Radiat Res 26, 443-449. 
 
Fujiwara, Y., Uehara, Y., Ichihashi, M., and Nishioka, K. (1985b). Xeroderma pigmentosum 
complementation group F: more assignments and repair characteristics. Photochem 
Photobiol 41, 629-634. 
 
Furia, B., Deng, L., Wu, K., Baylor, S., Kehn, K., Li, H., Donnelly, R., Coleman, T., and 
Kashanchi, F. (2002). Enhancement of nuclear factor-kappa B acetylation by coactivator 
p300 and HIV-1 Tat proteins. J Biol Chem 277, 4973-4980. 
 
Gane, E.J., Weilert, F., Orr, D.W., Keogh, G.F., Gibson, M., Lockhart, M.M., Frampton, C.M., 
Taylor, K.M., Smith, R.A., and Murphy, M.P. (2010). The mitochondria-targeted anti-
oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. 
Liver Int 30, 1019-1026. 
 
Geleziunas, R., McQuillan, A., Malapetsa, A., Hutchinson, M., Kopriva, D., Wainberg, M.A., 
Hiscott, J., Bramson, J., and Panasci, L. (1991). Increased DNA synthesis and repair-
enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia 
resistant to nitrogen mustards. J Natl Cancer Inst 83, 557-564. 
 
Ghosh, A., Roy, A., Liu, X., Kordower, J.H., Mufson, E.J., Hartley, D.M., Ghosh, S., Mosley, 
R.L., Gendelman, H.E., and Pahan, K. (2007a). Selective inhibition of NF-kappaB 
 146 
activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. 
Proc Natl Acad Sci U S A 104, 18754-18759. 
 
Ghosh, A., Roy, A., Liu, X., Kordower, J.H., Mufson, E.J., Hartley, D.M., Ghosh, S., Mosley, 
R.L., Gendelman, H.E., and Pahan, K. (2007b). Selective inhibition of NF-kappaB 
activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. 
Proc Natl Acad Sci U S A 104, 18754-18759. 
 
Giardina, C., and Hubbard, A.K. (2002). Growing old with nuclear factor-kappaB. Cell Stress 
Chaperones 7, 207-212. 
 
Gilman, A. (1963). The initial clinical trial of nitrogen mustard. Am J Surg 105, 574-578. 
 
Gilmore, T. (2009). Rel/NF-kB Transcription Factors. In wwwnf-kborg. 
 
Goldstein, S., Merenyi, G., Russo, A., and Samuni, A. (2003). The role of oxoammonium cation 
in the SOD-mimic activity of cyclic nitroxides. J Am Chem Soc 125, 789-795. 
 
Goss, J.R., Stolz, D.B., Robinson, A.R., Zhang, M., Arbujas, N., Robbins, P.D., Glorioso, J.C., 
and Niedernhofer, L.J. (2011). Premature aging-related peripheral neuropathy in a mouse 
model of progeria. Mech Ageing Dev 132, 437-442. 
 
Gosselin, K., and Abbadie, C. (2003). Involvement of Rel/NF-kappa B transcription factors in 
senescence. Exp Gerontol 38, 1271-1283. 
 
Graham, J.M., Jr., Anyane-Yeboa, K., Raams, A., Appeldoorn, E., Kleijer, W.J., Garritsen, V.H., 
Busch, D., Edersheim, T.G., and Jaspers, N.G. (2001). Cerebro-oculo-facio-skeletal 
syndrome with a nucleotide excision-repair defect and a mutated XPD gene, with 
prenatal diagnosis in a triplet pregnancy. Am J Hum Genet 69, 291-300. 
 
Green, D.R., Galluzzi, L., and Kroemer, G. (2011). Mitochondria and the autophagy-
inflammation-cell death axis in organismal aging. Science 333, 1109-1112. 
 
Greenberg, S. (2011). A Profile of Older Americans: 2011, U.S.D.o.H.a.H. Services, ed. 
(Washington, D.C., Administration on Aging)). 
 
Gregg, S.Q., Gutierrez, V., Robinson, A.R., Woodell, T., Nakao, A., Ross, M.A., Michalopoulos, 
G.K., Rigatti, L., Rothermel, C.E., Kamileri, I., et al. (2012a). A mouse model of 
accelerated liver aging caused by a defect in DNA repair. Hepatology 55, 609-621. 
 
Gregg, S.Q., Robinson, A.R., and Niedernhofer, L.J. (2011). Physiological consequences of 
defects in ERCC1-XPF DNA repair endonuclease. DNA Repair 10, 781-791. 
 
Gregg, S.Q., Wang, J., Frantz, M.C., Maniar, S., Guerrero, C., Skoda, E.M., St. Croix, C.M., 
Stolz, D.B., Robbins, P.D., Wang, Y., et al. (2012b). Endogenous oxidative DNA lesions 
drive cellular senescence. submitted. 
 147 
 
Grillari, J., Katinger, H., and Voglauer, R. (2007). Contributions of DNA interstrand cross-links 
to aging of cells and organisms. Nucleic Acids Res 35, 7566-7576. 
 
Guarente, L., and Kenyon, C. (2000). Genetic pathways that regulate ageing in model organisms. 
Nature 408, 255-262. 
 
Guttman, P.H., and Kohn, H.I. (1960). Progressive intercapillary glomerulosclerosis in the 
mouse, rat, and Chinese hamster, associated with aging and x-ray exposure. Am J Pathol 
37, 293-307. 
 
Guttridge, D.C., Albanese, C., Reuther, J.Y., Pestell, R.G., and Baldwin, A.S., Jr. (1999). NF-
kappaB controls cell growth and differentiation through transcriptional regulation of 
cyclin D1. Mol Cell Biol 19, 5785-5799. 
 
Hagelstrom, R.T., Blagoev, K.B., Niedernhofer, L.J., Goodwin, E.H., and Bailey, S.M. (2010). 
Hyper telomere recombination accelerates replicative senescence and may promote 
premature aging. Proc Natl Acad Sci U S A 107, 15768-15773. 
 
Hamel, B.C., Raams, A., Schuitema-Dijkstra, A.R., Simons, P., van der Burgt, I., Jaspers, N.G., 
and Kleijer, W.J. (1996). Xeroderma pigmentosum--Cockayne syndrome complex: a 
further case. J Med Genet 33, 607-610. 
 
Hamilton, M.L., Van Remmen, H., Drake, J.A., Yang, H., Guo, Z.M., Kewitt, K., Walter, C.A., 
and Richardson, A. (2001). Does oxidative damage to DNA increase with age? Proc Natl 
Acad Sci U S A 98, 10469-10474. 
 
Hansson, J., Lewensohn, R., Ringborg, U., and Nilsson, B. (1987). Formation and removal of 
DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced 
cytotoxicity in human melanoma cells. Cancer Res 47, 2631-2637. 
 
Harman, D. (1956). Aging: a theory based on free radical and radiation chemistry. J Gerontol 11, 
298-300. 
 
Harman, D. (1992a). Free radical theory of aging. Mutat Res 275, 257-266. 
 
Harman, D. (1992b). Free radical theory of aging: history. EXS 62, 1-10. 
 
Harper, J.M. (2008). Wild-derived mouse stocks: an underappreciated tool for aging research. 
Age (Dordr) 30, 135-145. 
 
Harrison, D.E., Strong, R., Sharp, Z.D., Nelson, J.F., Astle, C.M., Flurkey, K., Nadon, N.L., 
Wilkinson, J.E., Frenkel, K., Carter, C.S., et al. (2009). Rapamycin fed late in life 
extends lifespan in genetically heterogeneous mice. Nature 460, 392-395. 
 
 148 
Hartley, J.A., Berardini, M.D., and Souhami, R.L. (1991). An agarose gel method for the 
determination of DNA interstrand crosslinking applicable to the measurement of the rate 
of total and "second-arm" crosslink reactions. Anal Biochem 193, 131-134. 
 
Hasty, P., Campisi, J., Hoeijmakers, J., van Steeg, H., and Vijg, J. (2003a). Aging and Genome 
Maintenance: Lessons from the Mouse? Science 299, 1355-1359. 
 
Hasty, P., Campisi, J., Hoeijmakers, J., van Steeg, H., and Vijg, J. (2003b). Aging and genome 
maintenance: lessons from the mouse? Science 299, 1355-1359. 
 
Hayden, M.S., and Ghosh, S. (2008). Shared principles in NF-kappaB signaling. Cell 132, 344-
362. 
 
Hayden, M.S., West, A.P., and Ghosh, S. (2006). NF-kappaB and the immune response. 
Oncogene 25, 6758-6780. 
 
Hefner, E., Preuss, S.B., and Britt, A.B. (2003). Arabidopsis mutants sensitive to gamma 
radiation include the homologue of the human repair gene ERCC1. J Exp Bot 54, 669-
680. 
 
Helenius, M., Hanninen, M., Lehtinen, S.K., and Salminen, A. (1996). Changes associated with 
aging and replicative senescence in the regulation of transcription factor nuclear factor-
kappa B. Biochem J 318 ( Pt 2), 603-608. 
 
Heston, W.E. (1950). Carcinogenic action of the mustards. J Natl Cancer Inst 11, 415-423. 
 
Hirschhorn, R. (2003). In vivo reversion to normal of inherited mutations in humans. J Med 
Genet 40, 721-728. 
 
Hoeijmakers, J.H. (2001). Genome maintenance mechanisms for preventing cancer. Nature 411, 
366-374. 
 
Hoffman, C., and Rice, D.P. (1996). Chronic Care in America: A 21st Century Challenge (San 
Francisco, CA). 
 
Hoy, C.A., Thompson, L.H., Mooney, C.L., and Salazar, E.P. (1985). Defective DNA cross-link 
removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. 
Cancer Res 45, 1737-1743. 
 
Hsia, K.T., Millar, M.R., King, S., Selfridge, J., Redhead, N.J., Melton, D.W., and Saunders, 
P.T. (2003). DNA repair gene Ercc1 is essential for normal spermatogenesis and 
oogenesis and for functional integrity of germ cell DNA in the mouse. Development  130, 
369-378. 
 
Imoto, K., Boyle, J., Oh, K., Khan, S., Ueda, T., Nadem, C., Slor, H., Orgal, S., Gadoth, N., 
Busch, D., et al. (2007). Patients with defects in the interacting nucleotide excision repair 
 149 
proteins ERCC1 or XPF show xeroderma pigmentosum with late onset severe 
neurological degeneration. J Invest Dermatol 127. 
 
Itoh, T., Linn, S., Ono, T., and Yamaizumi, M. (2000). Reinvestigation of the classification of 
five cell strains of xeroderma pigmentosum group E with reclassification of three of 
them. J Invest Dermatol 114, 1022-1029. 
 
Ivanov, E.L., and Haber, J.E. (1995). RAD1 and RAD10, but not other excision repair genes, are 
required for double-strand break-induced recombination in Saccharomyces cerevisiae. 
Mol Cell Biol 15, 2245-2251. 
 
Jackson, J.G., and Pereira-Smith, O.M. (2006). p53 is preferentially recruited to the promoters of 
growth arrest genes p21 and GADD45 during replicative senescence of normal human 
fibroblasts. Cancer Res 66, 8356-8360. 
 
Jang, Y.C., and Remmen, V.H. (2009). The mitochondrial theory of aging: insight from 
transgenic and knockout mouse models. Exp Gerontol 44, 256-260. 
 
Jaruga, P., and Dizdaroglu, M. (2008). 8,5'-Cyclopurine-2'-deoxynucleosides in DNA: 
Mechanisms of formation, measurement, repair and biological effects. DNA Repair 7, 
1413-1425. 
 
Jaspers, N.G., Raams, A., Silengo, M.C., Wijgers, N., Niedernhofer, L.J., Robinson, A.R., 
Giglia-Mari, G., Hoogstraten, D., Kleijer, W.J., Hoeijmakers, J.H., et al. (2007). First 
reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal 
syndrome with a mild defect in nucleotide excision repair and severe developmental 
failure. Am J Hum Genet 80, 457-466. 
 
Jendrach, M., Pohl, S., Voth, M., Kowald, A., Hammerstein, P., and Bereiter-Hahn, J. (2005). 
Morpho-dynamic changes of mitochondria during ageing of human endothelial cells. 
Mech Ageing Dev 126, 813-821. 
 
Jiang, J., Kurnikov, I., Belikova, N.A., Xiao, J., Zhao, Q., Amoscato, A.A., Braslau, R., Studer, 
A., Fink, M.P., Greenberger, J.S., et al. (2007). Structural requirements for optimized 
delivery, inhibition of oxidative stress, and antiapoptotic activity of targeted nitroxides. J 
Pharmacol Exp Ther 320, 1050-1060. 
 
Jiang, T., Liebman, S.E., Lucia, M.S., Li, J., and Levi, M. (2005). Role of altered renal lipid 
metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-
related renal disease. Kidney Int 68, 2608-2620. 
 
Jump, D.B. (2002). The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277, 8755-
8758. 
 
 150 
Jung, T., Hohn, A., and Grune, T. (2010). Lipofuscin: Detection and Quantification by 
Microscopic Techniques. In Advanced Protocols in Oxidative Stress II, Methods in 
Molecular Biology, D. Armstrong, ed. (Humana Press). 
 
Kadiiska, M.B., Gladen, B.C., Baird, D.D., Dikalova, A.E., Sohal, R.S., Hatch, G.E., Jones, D.P., 
Mason, R.P., and Barrett, J.C. (2000). Biomarkers of oxidative stress study: are plasma 
antioxidants markers of CCl(4) poisoning? Free Radic Biol Med 28, 838-845. 
 
Kadiiska, M.B., Gladen, B.C., Baird, D.D., Germolec, D., Graham, L.B., Parker, C.E., Nyska, 
A., Wachsman, J.T., Ames, B.N., Basu, S., et al. (2005a). Biomarkers of oxidative stress 
study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? 
Free Radic Biol Med 38, 698-710. 
 
Kadiiska, M.B., Gladen, B.C., Baird, D.D., Graham, L.B., Parker, C.E., Ames, B.N., Basu, S., 
Fitzgerald, G.A., Lawson, J.A., Marnett, L.J., et al. (2005b). Biomarkers of oxidative 
stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and 
meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. 
Free Radic Biol Med 38, 711-718. 
 
Kagan, V.E., Wipf, P., Stoyanovsky, D., Greenberger, J.S., Borisenko, G., Belikova, N.A., 
Yanamala, N., Samhan Arias, A.K., Tungekar, M.A., Jiang, J., et al. (2009). 
Mitochondrial targeting of electron scavenging antioxidants: Regulation of selective 
oxidation vs random chain reactions. Adv Drug Deliv Rev 61, 1375-1385. 
 
Karin, M. (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441, 
431-436. 
 
Karrasch, T., Kim, J.S., Muhlbauer, M., Magness, S.T., and Jobin, C. (2007). Gnotobiotic IL-10-
/-;NF-kappa B(EGFP) mice reveal the critical role of TLR/NF-kappa B signaling in 
commensal bacteria-induced colitis. J Immunol 178, 6522-6532. 
 
Kawahara, T.L., Michishita, E., Adler, A.S., Damian, M., Berber, E., Lin, M., McCord, R.A., 
Ongaigui, K.C., Boxer, L.D., Chang, H.Y., et al. (2009). SIRT6 links histone H3 lysine 9 
deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 
136, 62-74. 
 
Kelso, G.F., Porteous, C.M., Coulter, C.V., Hughes, G., Porteous, W.K., Ledgerwood, E.C., 
Smith, R.A., and Murphy, M.P. (2001). Selective targeting of a redox-active ubiquinone 
to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 276, 
4588-4596. 
 
Kim, H.J., Chang, E.J., Kim, H.M., Lee, S.B., Kim, H.D., Su Kim, G., and Kim, H.H. (2006). 
Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear 
factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor 
activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Free Radic 
Biol Med 40, 1483-1493. 
 151 
 
Kim, W.Y., and Sharpless, N.E. (2006). The regulation of INK4/ARF in cancer and aging. Cell 
127, 265-275. 
 
Kim, Y., Lach, F.P., Desetty, R., Hanenberg, H., Auerbach, A.D., and Smogorzewska, A. (2011). 
Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 43, 142-146. 
 
Kirkwood, T.B. (2005). Understanding the odd science of aging. Cell 120, 437-447. 
 
Kishi, S., Bayliss, P.E., Uchiyama, J., Koshimizu, E., Qi, J., Nanjappa, P., Imamura, S., Islam, 
A., Neuberg, D., Amsterdam, A., et al. (2008). The identification of zebrafish mutants 
showing alterations in senescence-associated biomarkers. PLoS Genet 4, e1000152. 
 
Klein, H.L. (1988). Different types of recombination events are controlled by the RAD1 and 
RAD52 genes of Saccharomyces cerevisiae. Genetics 120, 367-377. 
 
Knipscheer, P., Raschle, M., Smogorzewska, A., Enoiu, M., Ho, T.V., Scharer, O.D., Elledge, 
S.J., and Walter, J.C. (2009). The Fanconi anemia pathway promotes replication-
dependent DNA interstrand cross-link repair. Science 326, 1698-1701. 
 
Kondo, S., Mamada, A., Miyamoto, C., Keong, C.H., Satoh, Y., and Fujiwara, Y. (1989). Late 
onset of skin cancers in 2 xeroderma pigmentosum group F siblings and a review of 30 
Japanese xeroderma pigmentosum patients in groups D, E and F. Photodermatol 6, 89-95. 
 
Korhonen, P., Helenius, M., and Salminen, A. (1997). Age-related changes in the regulation of 
transcription factor NF-kappa B in rat brain. Neurosci Lett 225, 61-64. 
 
Kotnis, A., Du, L., Liu, C., Popov, S.W., and Pan-Hammarstrom, Q. (2009). Non-homologous 
end joining in class switch recombination: the beginning of the end. Philos Trans R Soc 
Lond B Biol Sci 364, 653-665. 
 
Kraemer, K.H., Lee, M.M., and Scotto, J. (1987). Xeroderma pigmentosum. Cutaneous, ocular, 
and neurologic abnormalities in 830 published cases. Arch Dermatol 123, 241-250. 
 
Kraemer, K.H., Levy, D.D., Parris, C.N., Gozukara, E.M., Moriwaki, S., Adelberg, S., and 
Seidman, M.M. (1994). Xeroderma pigmentosum and related disorders: examining the 
linkage between defective DNA repair and cancer. J Invest Dermatol 103, 96S-101S. 
 
Kriete, A., Mayo, K.L., Yalamanchili, N., Beggs, W., Bender, P., Kari, C., and Rodeck, U. 
(2008). Cell autonomous expression of inflammatory genes in biologically aged 
fibroblasts associated with elevated NF-kappaB activity. Immun Ageing 5, 5. 
 
Krishna, M.C., Samuni, A., Taira, J., Goldstein, S., Mitchell, J.B., and Russo, A. (1996). 
Stimulation by nitroxides of catalase-like activity of hemeproteins. Kinetics and 
mechanism. J Biol Chem 271, 26018-26025. 
 
 152 
Kuraoka, I., Kobertz, W.R., Ariza, R.R., Biggerstaff, M., Essigmann, J.M., and Wood, R.D. 
(2000). Repair of an interstrand DNA cross-link initiated by ERCC1-XPF 
repair/recombination nuclease. J Biol Chem 275, 26632-26636. 
 
Lackner, C., Gogg-Kamerer, M., Zatloukal, K., Stumptner, C., Brunt, E.M., and Denk, H. 
(2008). Ballooned hepatocytes in steatohepatitis: the value of keratin 
immunohistochemistry for diagnosis. J Hepatol 48, 821-828. 
 
Lavasani, M., Robinson, A.R., Lu, A., Song, M., Feduska, J.M., Ahani, B., Tilstra, J.S., 
Feldman, C.H., Robbins, P.D., Niedernhofer, L.J., et al. (2012). Muscle-derived 
stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria 
model. Nat Commun 3, 608. 
 
Lawrence, N.J., Sacco, J.J., Brownstein, D.G., Gillingwater, T.H., and Melton, D.W. (2008). A 
neurological phenotype in mice with DNA repair gene Ercc1 deficiency. DNA Repair 
(Amst) 7, 281-291. 
 
Lawrence, N.J., Song, L., Doig, J., Ritchie, A.M., Brownstein, D.G., and Melton, D.W. (2009). 
Topical thymidine dinucleotide application protects against UVB-induced skin cancer in 
mice with DNA repair gene (Ercc1)-deficient skin. DNA Repair (Amst) 8, 664-671. 
 
Le May, N., Mota-Fernandes, D., Velez-Cruz, R., Iltis, I., Biard, D., and Egly, J.M. (2010). NER 
factors are recruited to active promoters and facilitate chromatin modification for 
transcription in the absence of exogenous genotoxic attack. Mol Cell 38, 54-66. 
 
Lee, A.C., Fenster, B.E., Ito, H., Takeda, K., Bae, N.S., Hirai, T., Yu, Z.X., Ferrans, V.J., 
Howard, B.H., and Finkel, T. (1999). Ras proteins induce senescence by altering the 
intracellular levels of reactive oxygen species. J Biol Chem 274, 7936-7940. 
 
Li, H., Malhotra, S., and Kumar, A. (2008). Nuclear factor-kappa B signaling in skeletal muscle 
atrophy. J Mol Med (Berl) 86, 1113-1126. 
 
Li, L., Elledge, S.J., Peterson, C.A., Bales, E.S., and Legerski, R.J. (1994). Specific association 
between the human DNA repair proteins XPA and ERCC1. Proc Natl Acad Sci U S A 91, 
5012-5016. 
 
Li, X.L., Shen, S.R., Wang, S., Ouyang, H.H., and Li, G.C. (2002). Restoration of T cell-specific 
V(D)J recombination in DNA-PKcs(-/-) mice by ionizing radiation: The effects on 
survival, development, and tumorigenesis. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue 
Bao (Shanghai) 34, 149-157. 
 
Li, Y., Wang, Z., Kong, D., Murthy, S., Dou, Q.P., Sheng, S., Reddy, G.P., and Sarkar, F.H. 
(2007). Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-
diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis 
in prostate cancer cells. J Biol Chem 282, 21542-21550. 
 
 153 
Lim, W., Cho, J., Kwon, H.Y., Park, Y., Rhyu, M.R., and Lee, Y. (2009). Hypoxia-inducible 
factor 1 alpha activates and is inhibited by unoccupied estrogen receptor beta. FEBS Lett 
583, 1314-1318. 
 
Lin, S.S., Manchester, J.K., and Gordon, J.I. (2001). Enhanced gluconeogenesis and increased 
energy storage as hallmarks of aging in Saccharomyces cerevisiae. J Biol Chem 276, 
36000-36007. 
 
Lindahl, T., and Barnes, D.E. (2000). Repair of endogenous DNA damage. Cold Spring Harb 
Symp Quant Biol 65, 127-133. 
 
Liu, L., Trimarchi, J.R., Smith, P.J., and Keefe, D.L. (2002). Mitochondrial dysfunction leads to 
telomere attrition and genomic instability. Aging Cell 1, 40-46. 
 
Lowry, R.B., MacLean, R., McLean, D.M., and Tischler, B. (1971). Cataracts, microcephaly, 
kyphosis, and limited joint movement in two siblings: a new syndrome. J Pediatr 79, 282-
284. 
 
Ma, J.L., Kim, E.M., Haber, J.E., and Lee, S.E. (2003). Yeast Mre11 and Rad1 proteins define a 
Ku-independent mechanism to repair double-strand breaks lacking overlapping end 
sequences. Mol Cell Biol 23, 8820-8828. 
 
Maccormick, R.E. (2006). Possible acceleration of aging by adjuvant chemotherapy: a cause of 
early onset frailty? Med Hypotheses 67, 212-215. 
 
Macias, C.A., Chiao, J.W., Xiao, J., Arora, D.S., Tyurina, Y.Y., Delude, R.L., Wipf, P., Kagan, 
V.E., and Fink, M.P. (2007). Treatment with a novel hemigramicidin-TEMPO conjugate 
prolongs survival in a rat model of lethal hemorrhagic shock. Ann Surg 245, 305-314. 
 
Magness, S.T., Jijon, H., Van Houten Fisher, N., Sharpless, N.E., Brenner, D.A., and Jobin, C. 
(2004). In vivo pattern of lipopolysaccharide and anti-CD3-induced NF-kappa B 
activation using a novel gene-targeted enhanced GFP reporter gene mouse. J Immunol 
173, 1561-1570. 
 
Mandavilli, B.S., Santos, J.H., and Van Houten, B. (2002). Mitochondrial DNA repair and aging. 
Mutat Res 509, 127-151. 
 
Massaad, C.A., Washington, T.M., Pautler, R.G., and Klann, E. (2009). Overexpression of SOD-
2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of 
Alzheimer's disease. Proc Natl Acad Sci U S A 106, 13576-13581. 
 
Matsumura, Y., Nishigori, C., Yagi, T., Imamura, S., and Takebe, H. (1998). Characterization of 
molecular defects in xeroderma pigmentosum group F in relation to its clinically mild 
symptoms. Hum Mol Genet 7, 969-974. 
 
 154 
Maynard, S., Schurman, S.H., Harboe, C., de Souza-Pinto, N.C., and Bohr, V.A. (2009). Base 
excision repair of oxidative DNA damage and association with cancer and aging. 
Carcinogenesis 30, 2-10. 
 
Mayne, L.V., and Lehmann, A.R. (1982). Failure of RNA synthesis to recover after UV 
irradiation: an early defect in cells from individuals with Cockayne's syndrome and 
xeroderma pigmentosum. Cancer Res 42, 1473-1478. 
 
McDonald, J.H. (2009). Handbook of Biological Statistics, 2nd ed edn ((2nd ed.). Baltimore, 
Maryland, Sparky House Publishing). 
 
McHugh, P.J., Spanswick, V.J., and Hartley, J.A. (2001). Repair of DNA interstrand crosslinks: 
molecular mechanisms and clinical relevance. Lancet Oncol 2, 483-490. 
 
McVey, M., and Lee, S.E. (2008). MMEJ repair of double-strand breaks (director's cut): deleted 
sequences and alternative endings. Trends Genet 24, 529-538. 
 
McWhir, J., Selfridge, J., Harrison, D.J., Squires, S., and Melton, D.W. (1993). Mice with DNA 
repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities 
and die before weaning. Nat Genet 5, 217-224. 
 
Mecocci, P., Fano, G., Fulle, S., MacGarvey, U., Shinobu, L., Polidori, M.C., Cherubini, A., 
Vecchiet, J., Senin, U., and Beal, M.F. (1999). Age-dependent increases in oxidative 
damage to DNA, lipids, and proteins in human skeletal muscle. Free Radic Biol Med 26, 
303-308. 
 
Meira, L.B., Graham, J.M., Jr., Greenberg, C.R., Busch, D.B., Doughty, A.T., Ziffer, D.W., 
Coleman, D.M., Savre-Train, I., and Friedberg, E.C. (2000). Manitoba aboriginal kindred 
with original cerebro-oculo- facio-skeletal syndrome has a mutation in the Cockayne 
syndrome group B (CSB) gene. Am J Hum Genet 66, 1221-1228. 
 
Melis, J.P., Wijnhoven, S.W., Beems, R.B., Roodbergen, M., van den Berg, J., Moon, H., 
Friedberg, E., van der Horst, G.T., Hoeijmakers, J.H., Vijg, J., et al. (2008). Mouse 
models for xeroderma pigmentosum group A and group C show divergent cancer 
phenotypes. Cancer Res 68, 1347-1353. 
 
Metz, J.M., Smith, D., Mick, R., Lustig, R., Mitchell, J., Cherakuri, M., Glatstein, E., and Hahn, 
S.M. (2004). A phase I study of topical Tempol for the prevention of alopecia induced by 
whole brain radiotherapy. Clin Cancer Res 10, 6411-6417. 
 
Michaelson-Richie, E.D., Ming, X., Codreanu, S.G., Loeber, R.L., Liebler, D.C., Campbell, C., 
and Tretyakova, N.Y. (2011). Mechlorethamine-induced DNA-protein cross-linking in 
human fibrosarcoma (HT1080) cells. J Proteome Res 10, 2785-2796. 
 
 155 
Millard, J.T., Raucher, S., and Hopkins, P.B. (1990). Mechlorethamine cross-links 
deoxyguanosine residues at 5'-GNC sequences in duplex DNA fragments. J Am Chem 
Soc 112, 2459-2460. 
 
Miller, E.R., 3rd, Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., and Guallar, E. 
(2005). Meta-analysis: high-dosage vitamin E supplementation may increase all-cause 
mortality. Ann Intern Med 142, 37-46. 
 
Miller, S.A., Dykes, D.D., and Polesky, H.F. (1988a). A simple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids Res 16, 1215. 
 
Miller, S.A., Dykes, D.D., and Polesky, H.F. (1988b). A simple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids Research 16, 1215. 
 
Mitchell, J.B., Russo, A., Kuppusamy, P., and Krishna, M.C. (2000). Radiation, radicals, and 
images. Ann N Y Acad Sci 899, 28-43. 
 
Miyamoto, S. (2011). Nuclear initiated NF-[kappa]B signaling: NEMO and ATM take center 
stage. Cell Res 21, 116-130. 
 
Moriwaki, S., Nishigori, C., Imamura, S., Yagi, T., Takahashi, C., Fujimoto, N., and Takebe, H. 
(1993). A case of xeroderma pigmentosum complementation group F with neurological 
abnormalities. Br J Dermatol 128, 91-94. 
 
Mostoslavsky, R., Chua, K.F., Lombard, D.B., Pang, W.W., Fischer, M.R., Gellon, L., Liu, P., 
Mostoslavsky, G., Franco, S., Murphy, M.M., et al. (2006). Genomic instability and 
aging-like phenotype in the absence of mammalian SIRT6. Cell 124, 315-329. 
 
Muller, F.L., Lustgarten, M.S., Jang, Y., Richardson, A., and Van Remmen, H. (2007). Trends in 
oxidative aging theories. Free Radic Biol Med 43, 477-503. 
 
Munoz, I.M., Hain, K., Declais, A.C., Gardiner, M., Toh, G.W., Sanchez-Pulido, L., 
Heuckmann, J.M., Toth, R., Macartney, T., Eppink, B., et al. (2009a). Coordination of 
structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. Mol 
Cell 35, 116-127. 
 
Munoz, P., Blanco, R., de Carcer, G., Schoeftner, S., Benetti, R., Flores, J.M., Malumbres, M., 
and Blasco, M.A. (2009b). TRF1 controls telomere length and mitotic fidelity in 
epithelial homeostasis. Mol Cell Biol 29, 1608-1625. 
 
Munoz, P., Blanco, R., Flores, J.M., and Blasco, M.A. (2005). XPF nuclease-dependent telomere 
loss and increased DNA damage in mice overexpressing TRF2 result in premature aging 
and cancer. Nat Genet 37, 1063-1071. 
 
Murakami, S. (2006). Stress resistance in long-lived mouse models. Exp Gerontol 41, 1014-
1019. 
 156 
 
Nakane, H., Takeuchi, S., Yuba, S., Saijo, M., Nakatsu, Y., Murai, H., Nakatsuru, Y., Ishikawa, 
T., Hirota, S., Kitamura, Y., et al. (1995). High incidence of ultraviolet-B-or chemical-
carcinogen-induced skin tumours in mice lacking the xeroderma pigmentosum group A 
gene. Nature 377, 165-168. 
 
Natoli, G. (2009). When sirtuins and NF-kappaB collide. Cell 136, 19-21. 
 
Nevedomskaya, E., Meissner, A., Goraler, S., de Waard, M., Ridwan, Y., Zondag, G., van der 
Pluijm, I., Deelder, A.M., and Mayboroda, O.A. (2010). Metabolic profiling of 
accelerated aging ERCC1 d/- mice. J Proteome Res 9, 3680-3687. 
 
Nichols, N.R., Day, J.R., Laping, N.J., Johnson, S.A., and Finch, C.E. (1993). GFAP mRNA 
increases with age in rat and human brain. Neurobiol Aging 14, 421-429. 
 
Niedernhofer, L.J., Daniels, J.S., Rouzer, C.A., Greene, R.E., and Marnett, L.J. (2003). 
Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol 
Chem 278, 31426-31433. 
 
Niedernhofer, L.J., Essers, J., Weeda, G., Beverloo, B., de Wit, J., Muijtjens, M., Odijk, H., 
Hoeijmakers, J.H., and Kanaar, R. (2001). The structure-specific endonuclease Ercc1-Xpf 
is required for targeted gene replacement in embryonic stem cells. EMBO J 20, 6540-
6549. 
 
Niedernhofer, L.J., Garinis, G.A., Raams, A., Lalai, A.S., Robinson, A.R., Appeldoorn, E., 
Odijk, H., Oostendorp, R., Ahmad, A., van Leeuwen, W., et al. (2006). A new progeroid 
syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444, 
1038-1043. 
 
Niedernhofer, L.J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A.F., de Wit, J., 
Jaspers, N.G., Beverloo, H.B., Hoeijmakers, J.H., et al. (2004). The structure-specific 
endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced 
double-strand breaks. Mol Cell Biol 24, 5776-5787. 
 
Nishigori, C., Ishizaki, K., Takebe, H., Imamura, S., and Hayakawa, M. (1986). A case of 
xeroderma pigmentosum group F with late onset of clinical symptoms. Arch Dermatol 
122, 510-511. 
 
Norris, P.G., Hawk, J.L., Avery, J.A., and Giannelli, F. (1988). Xeroderma pigmentosum 
complementation group F in a non-Japanese patient. J Am Acad Dermatol 18, 1185-
1188. 
 
Nouspikel, T., Lalle, P., Leadon, S.A., Cooper, P.K., and Clarkson, S.G. (1997). A common 
mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group 
G: implications for a second XPG function. Proc Natl Acad Sci U S A 94, 3116-3121. 
 
 157 
Nunez, F., Chipchase, M.D., Clarke, A.R., and Melton, D.W. (2000). Nucleotide excision repair 
gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver 
binucleation: the role of p53 and p21. FASEB J 14, 1073-1082. 
 
Ohtsubo, K., and Nomaguchi, T.A. (1986). A flow cytofluorometric study on age-dependent 
ploidy class changes in mouse hepatocyte nuclei. Mech Ageing Dev 36, 125-131. 
 
Ojwang, J.O., Grueneberg, D.A., and Loechler, E.L. (1989). Synthesis of a duplex 
oligonucleotide containing a nitrogen mustard interstrand DNA-DNA cross-link. Cancer 
Res 49, 6529-6537. 
 
Osawa, T., Davies, D., and Hartley, J.A. (2011). Mechanism of cell death resulting from DNA 
interstrand cross-linking in mammalian cells. Cell Death Dis 2, e187. 
 
Packer, L., and Fuehr, K. (1977). Low oxygen concentration extends the lifespan of cultured 
human diploid cells. Nature 267, 423-425. 
 
Paques, F., and Haber, J.E. (1997). Two pathways for removal of nonhomologous DNA ends 
during double-strand break repair in Saccharomyces cerevisiae. Mol Cell Biol 17, 6765-
6771. 
 
Park, C.H., Bessho, T., Matsunaga, T., and Sancar, A. (1995). Purification and characterization 
of the XPF-ERCC1 complex of human DNA repair excision nuclease. J Biol Chem 270, 
22657-22660. 
 
Parmar, K., D'Andrea, A., and Niedernhofer, L.J. (2009). Mouse models of Fanconi anemia. 
Mutat Res 668, 133-140. 
 
Parrinello, S., Samper, E., Krtolica, A., Goldstein, J., Melov, S., and Campisi, J. (2003a). 
Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell 
Biol 5, 741-747. 
 
Parrinello, S., Samper, E., Krtolica, A., Goldstein, J., Melov, S., and Campisi, J. (2003b). 
Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell 
Biol 5, 741-747. 
 
Paul, C., Povey, J.E., Lawrence, N.J., Selfridge, J., Melton, D.W., and Saunders, P.T. (2007). 
Deletion of genes implicated in protecting the integrity of male germ cells has differential 
effects on the incidence of DNA breaks and germ cell loss. PLoS One 2, e989. 
 
Pena, S.D., and Shokeir, M.H. (1974). Autosomal recessive cerebro-oculo-facio-skeletal (COFS) 
syndrome. Clin Genet 5, 285-293. 
 
Petit, C., and Sancar, A. (1999). Nucleotide excision repair: from E. coli to man. Biochimie 81, 
15-25. 
 
 158 
Podmore, I.D., Griffiths, H.R., Herbert, K.E., Mistry, N., Mistry, P., and Lunec, J. (1998). 
Vitamin C exhibits pro-oxidant properties. Nature 392, 559. 
 
Pooranaperundevi, M., Sumiyabanu, M.S., Viswanathan, P., Sundarapandiyan, R., and 
Anuradha, C.V. (2010). Insulin resistance induced by high-fructose diet potentiates 
carbon tetrachloride hepatotoxicity. Toxicol Ind Health 26, 89-104. 
 
Prado, F., and Aguilera, A. (1995). Role of reciprocal exchange, one-ended invasion crossover 
and single-strand annealing on inverted and direct repeat recombination in yeast: 
different requirements for the RAD1, RAD10, and RAD52 genes. Genetics 139, 109-123. 
 
Prasher, J.M., Lalai, A.S., Heijmans-Antonissen, C., Ploemacher, R.E., Hoeijmakers, J.H., Touw, 
I.P., and Niedernhofer, L.J. (2005). Reduced hematopoietic reserves in DNA interstrand 
crosslink repair-deficient Ercc1-/- mice. EMBO J 24, 861-871. 
 
Provost, P.R., Marcel, Y.L., Milne, R.W., Weech, P.K., and Rassart, E. (1991). Apolipoprotein D 
transcription occurs specifically in nonproliferating quiescent and senescent fibroblast 
cultures. FEBS Lett 290, 139-141. 
 
Qin, L., and Crews, F.T. (2012). NADPH oxidase and reactive oxygen species contribute to 
alcohol-induced microglial activation and neurodegeneration. J Neuroinflammation 9, 5. 
 
Ramana, K.V., Friedrich, B., Srivastava, S., Bhatnagar, A., and Srivastava, S.K. (2004). 
Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is 
regulated by aldose reductase. Diabetes 53, 2910-2920. 
 
Rando, ThomasÂ A., and Chang, HowardÂ Y. (2012). Aging, Rejuvenation, and Epigenetic 
Reprogramming: Resetting the Aging Clock. Cell 148, 46-57. 
 
Raschle, M., Knipscheer, P., Enoiu, M., Angelov, T., Sun, J., Griffith, J.D., Ellenberger, T.E., 
Scharer, O.D., and Walter, J.C. (2008). Mechanism of replication-coupled DNA 
interstrand crosslink repair. Cell 134, 969-980. 
 
Rashid, M., Kotwani, A., and Fahim, M. (2011). Long-acting phosphodiesterase 5 inhibitor, 
tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-
induced pulmonary hypertension in rats. Hum Exp Toxicol. 
 
Reay, D.P., Yang, M., Watchko, J.F., Daood, M., O'Day, T.L., Rehman, K.K., Guttridge, D.C., 
Robbins, P.D., and Clemens, P.R. (2011). Systemic delivery of NEMO binding 
domain/IKKgamma inhibitory peptide to young mdx mice improves dystrophic skeletal 
muscle histopathology. Neurobiol Dis. 
 
Remuzzi, A., Gagliardini, E., Donadoni, C., Fassi, A., Sangalli, F., Lepre, M.S., Remuzzi, G., 
and Benigni, A. (2002). Effect of angiotensin II antagonism on the regression of kidney 
disease in the rat. Kidney Int 62, 885-894. 
 
 159 
Resnick, N.M., and Dosa, D. (2004). Harrison's Principles of Internal Medicine, 15 edn 
(Montreal, McGraw-Hill). 
 
Resnick, N.M., and Marcantonio, E.R. (1997). How should clinical care of the aged differ? 
Lancet 350, 1157-1158. 
 
Rikans, L.E., and Hornbrook, K.R. (1997). Lipid peroxidation, antioxidant protection and aging. 
Biochim Biophys Acta 1362, 116-127. 
 
Rink, S.M., Solomon, M.S., Taylor, M.J., Rajur, S.B.-N., McLaughlin, L.W., and Hopkins, P.B. 
(1993). Covalent structure of a nitrogen mustard-induced DNA interstrand cross-link: an 
N7-to-N7 linkage of deoxyguanosine residues at the duplex sequence 5'-d(GNC). J Am 
Chem Soc 115, 2551-2557. 
 
Robinson, I., de Serna, D.G., Gutierrez, A., and Schade, D.S. (2006). Vitamin E in humans: an 
explanation of clinical trial failure. Endocr Pract 12, 576-582. 
 
Rodier, F., and Campisi, J. (2011). Four faces of cellular senescence. J Cell Biol 192, 547-556. 
 
Rodier, F., Coppe, J.P., Patil, C.K., Hoeijmakers, W.A., Munoz, D.P., Raza, S.R., Freund, A., 
Campeau, E., Davalos, A.R., and Campisi, J. (2009). Persistent DNA damage signalling 
triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11, 973-
979. 
 
Rodier, F., Munoz, D.P., Teachenor, R., Chu, V., Le, O., Bhaumik, D., Coppe, J.P., Campeau, 
E., Beausejour, C.M., Kim, S.H., et al. (2011). DNA-SCARS: distinct nuclear structures 
that sustain damage-induced senescence growth arrest and inflammatory cytokine 
secretion. J Cell Sci 124, 68-81. 
 
Rodriguez-Puyol, D. (1998). The aging kidney. Kidney Int 54, 2247-2265. 
 
Romieu, A., Gasparutto, D., and Cadet, J. (1999). Synthesis and characterization of 
oligonucleotides containing 5',8-cyclopurine 2'-deoxyribonucleosides: (5'R)-5',8-cyclo-2'-
deoxyadenosine, (5'S)-5',8-cyclo-2'-deoxyguanosine, and (5'R)-5',8-cyclo-2'-
deoxyguanosine. Chem Res Toxicol 12, 412-421. 
 
Ross, W.E., Ewig, R.A., and Kohn, K.W. (1978). Differences between melphalan and nitrogen 
mustard in the formation and removal of DNA cross-links. Cancer Res 38, 1502-1506. 
 
Roughley, P.J. (2004). Biology of intervertebral disc aging and degeneration: involvement of the 
extracellular matrix. Spine (Phila Pa 1976) 29, 2691-2699. 
 
Roughley, P.J., Alini, M., and Antoniou, J. (2002). The role of proteoglycans in aging, 
degeneration and repair of the intervertebral disc. Biochem Soc Trans 30, 869-874. 
 
 160 
Salmon, A.B., Richardson, A., and Perez, V.I. (2010). Update on the oxidative stress theory of 
aging: does oxidative stress play a role in aging or healthy aging? Free Radic Biol Med 
48, 642-655. 
 
Sargent, R.G., Brenneman, M.A., and Wilson, J.H. (1997a). Repair of site-specific double-strand 
breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol 
Cell Biol 17, 267-277. 
 
Sargent, R.G., Meservy, J.L., Perkins, B.D., Kilburn, A.E., Intody, Z., Adair, G.M., Nairn, R.S., 
and Wilson, J.H. (2000). Role of the nucleotide excision repair gene ERCC1 in formation 
of recombination-dependent rearrangements in mammalian cells. Nucleic Acids Res 28, 
3771-3778. 
 
Sargent, R.G., Rolig, R.L., Kilburn, A.E., Adair, G.M., Wilson, J.H., and Nairn, R.S. (1997b). 
Recombination-dependent deletion formation in mammalian cells deficient in the 
nucleotide excision repair gene ERCC1. Proc Natl Acad Sci U S A 94, 13122-13127. 
 
Satoh, H., Hiyama, K., Takeda, M., Awaya, Y., Watanabe, K., Ihara, Y., Maeda, H., Ishioka, S., 
and Yamakido, M. (1996). Telomere shortening in peripheral blood cells was related with 
aging but not with white blood cell count. Jpn J Hum Genet 41, 413-417. 
 
Scheidereit, C. (2006). IkappaB kinase complexes: gateways to NF-kappaB activation and 
transcription. Oncogene 25, 6685-6705. 
 
Schiestl, R.H., and Prakash, S. (1990). RAD10, an excision repair gene of Saccharomyces 
cerevisiae, is involved in the RAD1 pathway of mitotic recombination. Mol Cell Biol 10, 
2485-2491. 
 
Schlake, C., Ostermann, K., Schmidt, H., and Gutz, H. (1993). Analysis of DNA repair pathways 
of Schizosaccharomyces pombe by means of swi-rad double mutants. Mutat Res 294, 59-
67. 
 
Schrader, C.E., Vardo, J., Linehan, E., Twarog, M.Z., Niedernhofer, L.J., Hoeijmakers, J.H., and 
Stavnezer, J. (2004). Deletion of the nucleotide excision repair gene Ercc1 reduces 
immunoglobulin class switching and alters mutations near switch recombination 
junctions. J Exp Med 200, 321-330. 
 
Schumacher, B., van der Pluijm, I., Moorhouse, M.J., Kosteas, T., Robinson, A.R., Suh, Y., 
Breit, T.M., van Steeg, H., Niedernhofer, L.J., van Ijcken, W., et al. (2008). Delayed and 
accelerated aging share common longevity assurance mechanisms. PloS Genet 4, 
e1000161. 
 
Sekelsky, J.J., McKim, K.S., Chin, G.M., and Hawley, R.S. (1995). The Drosophila meiotic 
recombination gene mei-9 encodes a homologue of the yeast excision repair protein 
Rad1. Genetics 141, 619-627. 
 
 161 
Selfridge, J., Hsia, K.T., Redhead, N.J., and Melton, D.W. (2001). Correction of liver 
dysfunction in DNA repair-deficient mice with an ERCC1 transgene. Nucleic Acids Res 
29, 4541-4550. 
 
Selfridge, J., Song, L., Brownstein, D.G., and Melton, D.W. (2010). Mice with DNA repair gene 
Ercc1 deficiency in a neural crest lineage are a model for late-onset Hirschsprung disease. 
DNA Repair (Amst) 9, 653-660. 
 
Selman, C., Tullet, J.M., Wieser, D., Irvine, E., Lingard, S.J., Choudhury, A.I., Claret, M., Al-
Qassab, H., Carmignac, D., Ramadani, F., et al. (2009). Ribosomal protein S6 kinase 1 
signaling regulates mammalian life span. Science 326, 140-144. 
 
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R., and Ben-Ze'ev, 
A. (1999). The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl 
Acad Sci U S A 96, 5522-5527. 
 
Siakotos, A.N., and Koppang, N. (1973). Procedures for the isolation of lipopigments from brain, 
heart and liver, and their properties: A review. Mech Ageing Dev 2, 177-200. 
 
Sijbers, A.M., de Laat, W.L., Ariza, R.R., Biggerstaff, M., Wei, Y.F., Moggs, J.G., Carter, K.C., 
Shell, B.K., Evans, E., de Jong, M.C., et al. (1996a). Xeroderma pigmentosum group F 
caused by a defect in a structure-specific DNA repair endonuclease. Cell 86, 811-822. 
 
Sijbers, A.M., van der Spek, P.J., Odijk, H., van den Berg, J., van Duin, M., Westerveld, A., 
Jaspers, N.G., Bootsma, D., and Hoeijmakers, J.H. (1996b). Mutational analysis of the 
human nucleotide excision repair gene ERCC1. Nucleic Acids Res 24, 3370-3380. 
 
Sijbers, A.M., van Voorst Vader, P.C., Snoek, J.W., Raams, A., Jaspers, N.G., and Kleijer, W.J. 
(1998). Homozygous R788W point mutation in the XPF gene of a patient with xeroderma 
pigmentosum and late-onset neurologic disease. J Invest Dermatol 110, 832-836. 
 
Silva, F.G. (2005). The aging kidney: a review -- part I. Int Urol Nephrol 37, 185-205. 
 
Smith, R.A., Hartley, R.C., and Murphy, M.P. (2011). Mitochondria-targeted small molecule 
therapeutics and probes. Antioxid Redox Signal 15, 3021-3038. 
 
Smith, R.A., Porteous, C.M., Coulter, C.V., and Murphy, M.P. (1999). Selective targeting of an 
antioxidant to mitochondria. Eur J Biochem 263, 709-716. 
 
Smogorzewska, A., van Steensel, B., Bianchi, A., Oelmann, S., Schaefer, M.R., Schnapp, G., and 
de Lange, T. (2000). Control of human telomere length by TRF1 and TRF2. Mol Cell 
Biol 20, 1659-1668. 
 
Snow, B.J., Rolfe, F.L., Lockhart, M.M., Frampton, C.M., O'Sullivan, J.D., Fung, V., Smith, 
R.A., Murphy, M.P., and Taylor, K.M. (2010). A double-blind, placebo-controlled study 
 162 
to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in 
Parkinson's disease. Mov Disord 25, 1670-1674. 
 
Sonoda, E., Sasaki, M.S., Morrison, C., Yamaguchi-Iwai, Y., Takata, M., and Takeda, S. (1999). 
Sister chromatid exchanges are mediated by homologous recombination in vertebrate 
cells. Mol Cell Biol 19, 5166-5169. 
 
Soule, B.P., Hyodo, F., Matsumoto, K., Simone, N.L., Cook, J.A., Krishna, M.C., and Mitchell, 
J.B. (2007). Therapeutic and clinical applications of nitroxide compounds. Antioxid 
Redox Signal 9, 1731-1743. 
 
Stoepker, C., Hain, K., Schuster, B., Hilhorst-Hofstee, Y., Rooimans, M.A., Steltenpool, J., 
Oostra, A.B., Eirich, K., Korthof, E.T., Nieuwint, A.W., et al. (2011). SLX4, a 
coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia 
subtype. Nat Genet 43, 138-141. 
 
Stone, M.P., Cho, Y.J., Huang, H., Kim, H.Y., Kozekov, I.D., Kozekova, A., Wang, H., Minko, 
I.G., Lloyd, R.S., Harris, T.M., et al. (2008). Interstrand DNA cross-links induced by 
alpha,beta-unsaturated aldehydes derived from lipid peroxidation and environmental 
sources. Acc Chem Res 41, 793-804. 
 
Svendsen, J.M., Smogorzewska, A., Sowa, M.E., O'Connell, B.C., Gygi, S.P., Elledge, S.J., and 
Harper, J.W. (2009). Mammalian BTBD12/SLX4 assembles a Holliday junction 
resolvase and is required for DNA repair. Cell 138, 63-77. 
 
Tapias, A., Auriol, J., Forget, D., Enzlin, J.H., Scharer, O.D., Coin, F., Coulombe, B., and Egly, 
J.M. (2004). Ordered conformational changes in damaged DNA induced by nucleotide 
excision repair factors. J Biol Chem 279, 19074-19083. 
 
Tappel, A.L. (1973). Lipid peroxidation damage to cell components. Federation proceedings 32, 
1870-1874. 
 
Taubold, R.D. (1975). Studies on chemical nature of lipofusion (age pigment) isolated from 
normal human brain. Lipids 10, 383-390. 
 
Thielmann, H.W., Popanda, O., Edler, L., and Jung, E.G. (1991). Clinical symptoms and DNA 
repair characteristics of xeroderma pigmentosum patients from Germany. Cancer Res 51, 
3456-3470. 
 
Thorel, F., Constantinou, A., Dunand-Sauthier, I., Nouspikel, T., Lalle, P., Raams, A., Jaspers, 
N.G., Vermeulen, W., Shivji, M.K., Wood, R.D., et al. (2004). Definition of a short 
region of XPG necessary for TFIIH interaction and stable recruitment to sites of UV 
damage. Mol Cell Biol 24, 10670-10680. 
 
 163 
Tian, M., Shinkura, R., Shinkura, N., and Alt, F.W. (2004). Growth retardation, early death, and 
DNA repair defects in mice deficient for the nucleotide excision repair enzyme XPF. Mol 
Cell Biol 24, 1200-1205. 
 
Tilstra, J., Rehman, K.K., Hennon, T., Plevy, S.E., Clemens, P., and Robbins, P.D. (2007). 
Protein transduction: identification, characterization and optimization. Biochem Soc 
Trans 35, 811-815. 
 
Tilstra, J.S., Clauson, C.L., Niedernhofer, L.J., and Robbins, P.D. (2011). NF-B in aging and 
disease. Aging and Disease 2, 449-465. 
 
Tokuda, K., and Bodell, W.J. (1987). Cytotoxicity and sister chromatid exchanges in 9L cells 
treated with monofunctional and bifunctional nitrogen mustards. Carcinogenesis 8, 1697-
1701. 
 
Tokumaru, S., Iguchi, H., and Kojo, S. (1996). Change of the lipid hydroperoxide level in mouse 
organs on ageing. Mech Ageing Dev 86, 67-74. 
 
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J.N., Rovio, A.T., Bruder, C.E., 
Bohlooly, Y.M., Gidlof, S., Oldfors, A., Wibom, R., et al. (2004). Premature ageing in 
mice expressing defective mitochondrial DNA polymerase. Nature 429, 417-423. 
 
Tripsianes, K., Folkers, G., Ab, E., Das, D., Odijk, H., Jaspers, N.G., Hoeijmakers, J.H., Kaptein, 
R., and Boelens, R. (2005). The structure of the human ERCC1/XPF interaction domains 
reveals a complementary role for the two proteins in nucleotide excision repair. Structure 
13, 1849-1858. 
 
Tronche, F., Casanova, E., Turiault, M., Sahly, I., and Kellendonk, C. (2002). When reverse 
genetics meets physiology: the use of site-specific recombinases in mice. FEBS Lett 529, 
116-121. 
 
Tsodikov, O.V., Enzlin, J.H., Scharer, O.D., and Ellenberger, T. (2005). Crystal structure and 
DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease 
XPF-ERCC1. Proc Natl Acad Sci U S A 102, 11236-11241. 
 
Tsodikov, O.V., Ivanov, D., Orelli, B., Staresincic, L., Shoshani, I., Oberman, R., Scharer, O.D., 
Wagner, G., and Ellenberger, T. (2007). Structural basis for the recruitment of ERCC1-
XPF to nucleotide excision repair complexes by XPA. EMBO J 26, 4768-4776. 
 
Valen, G. (2004). Signal transduction through nuclear factor kappa B in ischemia-reperfusion 
and heart failure. Basic Res Cardiol 99, 1-7. 
 
Van Houten, B., Woshner, V., and Santos, J.H. (2006). Role of mitochondrial DNA in toxic 
responses to oxidative stress. DNA Repair (Amst) 5, 145-152. 
 
 164 
Van Remmen, H., Ikeno, Y., Hamilton, M., Pahlavani, M., Wolf, N., Thorpe, S.R., Alderson, 
N.L., Baynes, J.W., Epstein, C.J., Huang, T.T., et al. (2003). Life-long reduction in 
MnSOD activity results in increased DNA damage and higher incidence of cancer but 
does not accelerate aging. Physiol Genomics 16, 29-37. 
 
Villeda, S.A., Luo, J., Mosher, K.I., Zou, B., Britschgi, M., Bieri, G., Stan, T.M., Fainberg, N., 
Ding, Z., Eggel, A., et al. (2011). The ageing systemic milieu negatively regulates 
neurogenesis and cognitive function. Nature 477, 90-94. 
 
Vivekananthan, D.P., Penn, M.S., Sapp, S.K., Hsu, A., and Topol, E.J. (2003). Use of 
antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of 
randomised trials. Lancet 361, 2017-2023. 
 
Vo, N., Seo, H.Y., Robinson, A., Sowa, G., Bentley, D., Taylor, L., Studer, R., Usas, A., Huard, 
J., Alber, S., et al. (2010). Accelerated aging of intervertebral discs in a mouse model of 
progeria. J Orthop Res 28, 1600-1607. 
 
Wang, J., Clauson, C.L., Robbins, P.D., Niedernhofer, L.J., and Wang, Y. (2012). The oxidative 
DNA lesions 8,5'-cyclopurines accumulate with aging in a tissue-specific manner. Aging 
Cell. 
 
Wang, J., Yuan, B., Guerrero, C., Bahde, R., Gupta, S., and Wang, Y. (2011a). Quantification of 
oxidative DNA lesions in tissues of Long-Evans Cinnamon rats by capillary high-
performance liquid chromatography-tandem mass spectrometry coupled with stable 
isotope-dilution method. Analytical Chemistry (Washington) 83, 2201-2209. 
 
Wang, J., Yuan, B., Guerrero, C., Bahde, R., Gupta, S., and Wang, Y. (2011b). Quantification of 
oxidative DNA lesions in tissues of Long-Evans Cinnamon rats by capillary high-
performance liquid chromatography-tandem mass spectrometry coupled with stable 
isotope-dilution method. Anal Chem 83, 2201-2209. 
 
Wang, Y. (2008). Bulky DNA lesions induced by reactive oxygen species. Chem Res Toxicol 
21, 276-281. 
 
Warner, H.R., and Sierra, F. (2003). Models of accelerated ageing can be informative about the 
molecular mechanisms of ageing and/or age-related pathology. Mech Ageing Dev 124, 
581-587. 
 
Weeda, G., Donker, I., de Wit, J., Morreau, H., Janssens, R., Vissers, C.J., Nigg, A., van Steeg, 
H., Bootsma, D., and Hoeijmakers, J.H. (1997a). Disruption of mouse ERCC1 results in a 
novel repair syndrome with growth failure, nuclear abnormalities and senescence. Curr 
Biol 7, 427-439. 
 
Weeda, G., Eveno, E., Donker, I., Vermeulen, W., Chevallier-Lagente, O., Taieb, A., Stary, A., 
Hoeijmakers, J.H., Mezzina, M., and Sarasin, A. (1997b). A mutation in the XPB/ERCC3 
 165 
DNA repair transcription gene, associated with trichothiodystrophy. Am J Hum Genet 60, 
320-329. 
 
Westerveld, A., Hoeijmakers, J.H., van Duin, M., de Wit, J., Odijk, H., Pastink, A., Wood, R.D., 
and Bootsma, D. (1984). Molecular cloning of a human DNA repair gene. Nature 310, 
425-429. 
 
Wijen, J.P., Nivard, M.J., and Vogel, E.W. (2000). The in vivo genetic activity profile of the 
monofunctional nitrogen mustard 2-chloroethylamine differs drastically from its 
bifunctional counterpart mechlorethamine. Carcinogenesis 21, 1859-1867. 
 
Wilcox, C.S. (2010). Effects of tempol and redox-cycling nitroxides in models of oxidative 
stress. Pharmacol Ther 126, 119-145. 
 
Winter, A.G., Samuel, K., Hsia, K.T., and Melton, D.W. (2003). The repair and recombination 
enzyme ERCC1 is not required for immunoglobulin class switching. DNA Repair (Amst) 
2, 561-569. 
 
Wipf, P., Xiao, J., Jiang, J., Belikova, N.A., Tyurin, V.A., Fink, M.P., and Kagan, V.E. (2005). 
Mitochondrial targeting of selective electron scavengers: synthesis and biological 
analysis of hemigramicidin-TEMPO conjugates. J Am Chem Soc 127, 12460-12461. 
 
Wojcik, M., Burzynska-Pedziwiatr, I., and Wozniak, L.A. (2010). A review of natural and 
synthetic antioxidants important for health and longevity. Curr Med Chem 17, 3262-
3288. 
 
Wu, Y., Mitchell, T.R., and Zhu, X.D. (2008). Human XPF controls TRF2 and telomere length 
maintenance through distinctive mechanisms. Mech Ageing Dev 129, 602-610. 
 
Wullaert, A., Heyninck, K., and Beyaert, R. (2006). Mechanisms of crosstalk between TNF-
induced NF-kappaB and JNK activation in hepatocytes. Biochem Pharmacol 72, 1090-
1101. 
 
Xiao, Z.Q., and Majumdar, A.P. (2000). Induction of transcriptional activity of AP-1 and NF-
kappaB in the gastric mucosa during aging. Am J Physiol Gastrointest Liver Physiol 278, 
G855-865. 
 
Xiong, H., Zhu, C., Li, F., Hegazi, R., He, K., Babyatsky, M., Bauer, A.J., and Plevy, S.E. 
(2004). Inhibition of interleukin-12 p40 transcription and NF-kappaB activation by nitric 
oxide in murine macrophages and dendritic cells. J Biol Chem 279, 10776-10783. 
 
Yamamoto, Y., and Gaynor, R.B. (2001). Role of the NF-kappaB pathway in the pathogenesis of 
human disease states. Curr Mol Med 1, 287-296. 
 
 166 
Yamamura, K., Ichihashi, M., Hiramoto, T., Ogoshi, M., Nishioka, K., and Fujiwara, Y. (1989). 
Clinical and photobiological characteristics of xeroderma pigmentosum complementation 
group F: a review of cases from Japan. Br J Dermatol 121, 471-480. 
 
Yin, D. (1996). Biochemical basis of lipofuscin, ceroid, and age pigment-like fluorophores. Free 
Radic Biol Med 21, 871-888. 
 
Zafeiriou, D.I., Thorel, F., Andreou, A., Kleijer, W.J., Raams, A., Garritsen, V.H., Gombakis, 
N., Jaspers, N.G., and Clarkson, S.G. (2001). Xeroderma pigmentosum group G with 
severe neurological involvement and features of Cockayne syndrome in infancy. Pediatr 
Res 49, 407-412. 
 
Zelle, B., Berends, F., and Lohman, P.H. (1980). Repair of damage by ultraviolet radiation in 
xeroderma pigmentosum cell strains of complementation groups E and F. Mutat Res 73, 
157-169. 
 
Zhou, B., Yang, L., Li, S., Huang, J., Chen, H., Hou, L., Wang, J., Green, C.D., Yan, Z., Huang, 
X., et al. (2012). Midlife gene expressions identify modulators of aging through dietary 
interventions. Proc Natl Acad Sci U S A. 
 
Zhu, X.D., Niedernhofer, L., Kuster, B., Mann, M., Hoeijmakers, J.H., and de Lange, T. (2003). 
ERCC1/XPF removes the 3' overhang from uncapped telomeres and represses formation 
of telomeric DNA-containing double minute chromosomes. Mol Cell 12, 1489-1498. 
 
 
 
